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Zusammenfassung 
Brustkrebs ist die häufigste Krebserkrankung bei Frauen weltweit und führt, trotz guter 
Therapien, noch oft zum Tode. Obwohl Brustkrebs im frühen Stadium gut therapierbar ist, 
gibt es bei fortgeschrittener und metastasierter Krankheit nur eingeschränkte 
Therapiemöglichkeiten.  
Das Brustkrebs-assoziierte Antigen NY-BR-1 wurde durch ein serologisches Screening-
verfahren (SEREX) entdeckt. NY-BR-1 wird in der Mehrheit der Brusttumoren (>70 %) 
sowie in Metastasen, in gesundem Brustgewebe, im Hoden und gelegentlich in der Prostata 
exprimiert. Aufgrund seines begrenzten Expressionsmusters, seiner Immunogenität und seiner 
Lokalisation im Zytoplamsa und an der Plasmamembran, eignet sich NY-BR-1 als 
vielversprechendes Target für immuntherapeutische Anwendungen bei Brustkrebspatienten. 
Das Ziel dieser Doktorarbeit war die molekulare und funktionelle Charakterisierung von NY-
BR-1, um die biologische Funktion im normalen sowie im tumorgenen Brustgewebe heraus 
zu finden. 
Um den Effekt der Überexpremierung von NY-BR-1 in zellulären Prozessen, wie 
Proliferation, Apoptose und Zellzyklus zu untersuchen, wurden HEK293, HEK293T, MCF-
10A und MCF-7 mit NY-BR-1 transient transfiziert. Die Ergebnisse im Vergleich mit den 
Kontrollzellen zeigen, dass NY-BR-1
+
 Zellen nicht proliferieren, nicht vermehrt apoptotisch 
sind und in der G1 akkumulieren. Diese Erkenntnisse werden durch IHC Färbungen in 
normalen Brustgewebeschnitten für NY-BR-1 und Ki-67 (Proliferationsmarker) unterstützt, 
da die Zellen das Expressionsmuster NY-BR-1
+
/Ki-67
-
 aufweisen. 
Eine andere Methode für die Analyse der biologische Funktion von NY-BR-1 war die 
Identifikation von spezifischen Proteininteraktionspartnern mittels Co-Immunoprezipitation 
mit NY-BR-1 transfizierten Zelllysaten (HEK293, MCF-10A, MCF-7) mit anschließender 
Massenspektrometrie. In allen drei Zelllinien konnte das Protein Tubulin 4B-chain 
identifiziert werden, welches unter anderem in der Mitose eine wichtige Funktion übernimmt. 
Damit wird verdeutlicht, dass NY-BR-1 eine entscheidende Rolle während des Zellzyklus 
spielt. 
Um die transkriptionelle Regulation vom NY-BR-1 Gen zu untersuchen, wurde eine in silico 
Vorhersage für potentielle Transkriptionsfaktoren Bindungsstellen in der NY-BR-1 
Promoterregion mit dem Alibaba 2.0 Algorithmus durchgeführt. Gewebestücke sowie 
isolierte Epithelzellen aus gesundem Brustgewebe und Tumorzellen aus Pleuralergüssen 
wurden mit verschiedenen Hormonen, einem Demthylierungsreagenz und Histon-
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Deacethylasen Inhibitoren behandelt. Die NY-BR-1 Expression wurde mittels qPCR 
analysiert. Verschiedene Östrogenrezeptor-Bindungsstellen wurden in der NY-BR-1 
Promoterregion und innerhalb des Gens (bis Intron 21) mittels Chip-Seq zugeordnet. Mittles 
IHC Färbungen konnte verdeutlicht werden, dass das NY-BR-1 Protein und der 
Östrogenrezeptor hauptsächlich co-exprimiert in normalem Brustgewebe sind. In silico 
Analysen von RNA-Seq Daten konnten zeigen, dass NY-BR-1 vorwiegend in ER
+
 Luminal A 
und B Brustkrebsarten exprimiert wird. Die Stimulation von normalen Brust- sowie 
Tumorzellen aus Pleuralergüssen mit Östrogen, Tamoxifen oder Progesteron konnte keinen 
einheitlichen Hoch- oder Herunterregulierungseffekt aufweisen. Auf der anderen Seite konnte 
eine kurze Stimulation von Tumorzellen aus Pleuralergüssen mit Progesteron, Östrogen, 
Vitamin D3 und Retinsäure eine Hochregulierung von der NY-BR-1 Expression (8 fach) im 
Vergleich mit den unbehandelten Kontrollen gezeigt werden. NY-BR-1 Expression konnte 
auch durch eine VPA Behandlung induziert werden. Es ist erwähnenswert, dass die 
Kombination von VPA im Vergleich zu den Kontrollen mit den oben beschriebenen 
Hormonen nur eine schwache Hochregulierung der NY-BR-1 Expression (bis zu 3 fach) 
zeigen konnte. Diese Resultate legen nahe, dass NY-BR-1 Expression auf Histonlevel 
und/oder durch Nicht-histon Proteine, wie z.B. Transkriptionsfaktoren, die durch 
Acetylierung modifiziert werden können, reguliert wird. Die Behandlung der Zellen mit dem 
Demethylierungsreagens 5´Aza-deoxycytidine konnte keine deutliche Induzierung oder 
Hochregulierung der NY-BR-1 Expression hervorrufen. Des Weiteren wurde der 
Methylierungsstatus von ausgewählten Promoterregionen, welche die vorhergesagten CpG 
Inseln beinhalteten, in bestimmten stimulierten Proben analysiert. Es konnte allerdings keine 
Assoziation zwischen einem Methylierungsmuster und NY-BR-1 Expression beobachtet 
werden. Diese Erkenntnis konnte durch eine in silico Analyse von Proben aus der TCGA 
Datenbank bestätigt werden. Auffallend ist, dass eine verringerte NY-BR-1 Expression in 
kultivierten normalen Brustgewebestücken und isolierten Epithelzellen im Vergleich zu 
schockgefrorenen Zellen beobachtet werden konnte. Der gegenteilige Effekt war in 
Brusttumorzellen aus Pleuralergüssen, die in konditioniertem Medium kultiviert wurden, zu 
beobachten. Eine detaillierte Analyse des konditionierten Mediums wird zeigen, welche 
Faktoren z.B. Cyotkine, Chemokine, Hormone oder Wachstumsfaktoren, zu einer anhaltenden 
NY-BR-1 Expression führen. 
Unter Beachtung, dass NY-BR-1 Genexpression einem komplexen Regulationsmechanismus 
unterliegt, dass die Proteinexpression in normalen Brustgewebe mosaikartig ist und dass die 
Überexpremierung von NY-BR-1 inhibierend in Zelllinien auf Proliferation und G1 Phase im 
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Zellzyklus wirkt, wurde die Hypothese aufgestellt, dass NY-BR-1 in spezifischen 
Brustvorläuferzellpopulationen exprimiert wird. Daher wurden Mammosphäroide aus 
isolierten normalen Brustepithelzellen generiert und analysiert mittels 
Immunfluoreszenzfärbung und qPCR. In vier analysierten Patienten, konnte die Co-
expression von NY-BR-1 in primären Sphäroiden mit Integrin-α6, HER2, GATA-3 und 
FOXA1 beobachtet werden, wohingegen keine Co-expression mit ER oder PR mRNA 
detektiert werden konnte. ER/NY-BR-1 IHC Färbungen in normalem Brustgewebe zeigten 
deutlich, dass sowohl ER
+
/NY-BR-1
+
 als auch ER
-
/NY-BR-1
+
 Brustdrüsenzellen vorhanden 
sind. Diese Resultate lassen darauf schliessen, dass NY-BR-1 in den ER
+
/ER
-
 luminalen 
Vorläuferzellen in der Brustdrüse exprimiert wird. 
Das NY-BR-1 Gen wurde auch hinsichtlich genetischer Variationen untersucht, um 
Erkenntnisse bezüglich Splice Varianten zu erlangen. Dabei wurden 69 schadhafte 
(„damaging“) nsSNPs innerhalb der kodierenden Region des NY-BR-1 Gens und 39 
potentielle splicing SNPs mittels in silico Analyse identifiziert.  
Zusammengenommen, ist NY-BR-1 hauptsächlich in gut differenzierten Hormonsensitiven 
Östrogenrezeptor positiven Brustkrebs Subtypen exprimiert und es ist wahrscheinlich, dass 
NY-BR-1 Expression durch Erα und/oder PR Expression beeinflusst wird. Allerdings muss 
noch die Assozierung zwischen NY-BR-1 Expression und ER Signalisierung weiter 
aufgeklärt werden. Desweiteren, wurde bei transienten transfizierten NY-BR-1 
expremierenden Zellen eine inhibierende Proliferationsrate und Akkumulation in der G1 
Phase zeigt. In vivo, endogenes NY-BR-1 wird in nicht proliferirenden (Ki-67 negativ) Zellen 
in normalen Brustgewebe exprimiert. Das Protein interagiert potentiell mit Tubulin beta-4B 
chain, welches auf eine entscheidende Rolle in der Mitosis hindeutet. Außerdem konnte 
gezeigt werden, dass NY-BR-1 in Vorläuferzellen in der Brustdrüse exprimiert wird. Die 
phenotypische Charakterisierung der Vorläuferzellen und ob das Protein in Krebsstammzellen 
exprimiert wird, ist Bestandteil laufender Studien. 
Zusammenfassend konnte in der vorliegenden Arbeit das erste Mal gezeigt werden, dass NY-
BR-1 ein Vorläuferzellmarker in der Brustdrüse ist und den mitotischen Prozess beeinflusst. 
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Summary 
Breast cancer is one of the most common malignancies with increasing incidence every year 
and a leading cause of death among women. Although early stage breast cancer can be 
effectively treated, there are limited numbers of treatment options available for patients with 
advanced and metastatic disease.  
The breast cancer associated antigen NY-BR-1 was identified by a serological screening 
strategy (SEREX). NY-BR-1 is expressed in the majority of breast tumours (>70 %) as well 
as in metastases, in normal breast tissue, in testis, and occasionally in prostate tissue. Due to 
its restricted expression pattern, its immunogenicity and its subcellular localization to the 
cytoplasm and plasma-membrane, NY-BR-1 represents a promising target for 
immunotherapeutic approaches in breast cancer patients. The aim of this thesis was the 
molecular and functional characterization of NY-BR-1 to reveal its biological function in 
normal and tumorigenic breast tissues.  
To examine the effect of NY-BR-1 over-expression on cellular processes, such as 
proliferation, apoptosis and the cell cycle, HEK293, HEK293T, MCF-10A, and MCF-7 were 
transiently transfected with NY-BR-1. The results showed that NY-BR-1
+
 cells do not 
proliferate, do not have an increased apoptosis rate and accumulate in the G1 phase compared 
to the control cells. This finding is supported by IHC stainings of normal breast tissue sections 
for NY-BR-1 and Ki-67 (proliferation marker) displaying NY-BR-1
+
/Ki-67
-
 cells.   
Another approach to clarify the biological function of NY-BR-1 was the identification of 
specific protein interaction partners by co-immunoprecipitations with lysates of NY-BR-1 
transfected cells (HEK293, MCF-10A, MCF-7) followed by mass spectrometry. The protein 
identified in all three analysed cell lines is the tubulin beta-4B chain, which amongst other is 
involved in mitosis, underlining a crucial role of NY-BR-1 during the cell cycle.   
To investigate the transcriptional regulation of the NY-BR-1 gene, an in silico prediction for 
potential transcription factor binding sites in the NY-BR-1 promoter region was performed 
with the Alibaba 2.0 algorithm. Tissue pieces as well as isolated epithelial cells from healthy 
breast tissue and tumour cells from pleural effusions were treated with different hormones, a 
demethylation agent and histone deacetylase inhibitors. The NY-BR-1 expression was 
analysed via qPCR. Several estrogen receptor binding sites were mapped in the NY-BR-1 
promoter region and within the gene (up to Intron 21) by ChIP-Seq. The NY-BR-1 protein 
and the estrogen receptor (ER) are mainly co-expressed in normal breast tissues as assessed 
by IHC stainings and in silico analyses of RNA-seq data showed that NY-BR-1 is 
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predominantly expressed in ER positive luminal A and B breast cancers. However, the 
stimulation of normal breast cells as well as tumour cells from pleural effusions with 
estrogen, tamoxifen or progesterone did not systematically show an up- or down-regulatory 
effect. On the other hand, short term stimulations of tumour cells from pleural effusions with 
progesterone, estrogen, vitamin D3 and retinoic acid lead to an up-regulation of NY-BR-1 
expression (up to 8 fold) compared to the untreated controls. VPA treatment also induced 
NY-BR-1 expression. Of note, the combination of VPA with the above mentioned hormones 
only showed a weak up-regulation of NY-BR-1 expression (up to 3 fold) compared to the 
controls. These results suggest that NY-BR-1 expression is further regulated on histone level 
and/or non-histone proteins such as transcription factors modified by acetylation. Treatment 
of the cells with the demethylation agent 5´Aza-deoxycytidine did not show a distinct 
induction or up-regulation of NY-BR-1 expression. Moreover, the methylation status of 
selected promoter regions containing the predicted CpG islands was assessed in a selection of 
treated samples, but no association between methylation patterns and NY-BR-1 expression 
was observed. This finding could be confirmed by an in silico analysis of the TCGA database. 
Strikingly, a decreased NY-BR-1 expression in cultured normal breast tissue pieces and 
isolated epithelial cells versus snap-frozen cells was seen, which was not observed in breast 
tumour cells from pleural effusions cultured in conditioned medium. An in depth analysis of 
the conditioned medium containing the cell free effusion supernatant as well as cell culture 
experiments with normal breast epithelial cells in conditioned medium will reveal, which 
factors, e.g. cytokines, chemokines, hormones or growth factors, lead to a sustained NY-BR-1 
expression.  
Considering the complex regulation of NY-BR-1 gene expression, the mosaic-like protein 
expression in normal breast tissue and the inhibitory effect of NY-BR-1 over-expression on 
proliferation and the G1 phase cell cycle arrest in normal cells it was hypothesized, that NY-
BR-1 may be expressed by a specific breast progenitor cell population. Thus, mammospheres 
from isolated normal breast epithelial cells were generated and analysed by 
immunofluorescent staining and qPCR for NY-BR-1 expression and the presence of 
progenitor cell markers. In four analysed patients, NY-BR-1 was expressed in primary 
spheres and co-expression with integrin-α 6, HER2, GATA-3 and FOXA1 could be observed 
whereas no ER or progesterone receptor (PR) mRNA was detected. IHC staining with ER and 
NY-BR-1 in normal breast tissue showed that as well ER
+
/NY-BR-1
+ 
as ER
-
/NY-BR-1
+
 cells 
in the mammary gland are existing. These results suggest that NY-BR-1 is expressed in the 
ER
+
/ER
- 
luminal progenitor cells of the mammary gland.  
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The NY-BR-1 gene was investigated regarding genetical variations to receive a better 
understanding of splice variants. Thereby, 69 damaging nsSNPs within the coding region of 
NY-BR-1 gene and 39 potential splicing SNPs could be identified by using in silico anlaysis.   
Taken together, NY-BR-1 is expressed mainly in well differentiated hormone sensitive 
estrogen receptor positive breast cancer subtypes and it is likely that NY-BR-1 expression is 
influenced by ERα and/or PR expression, but the association of NY- BR-1 expression and ER 
signaling still needs to be elucidated. Furthermore, transiently NY-BR-1 expressing cells 
show an inhibited proliferation rate and accumulate in the G1 phase. In vivo, endogenous NY-
BR-1 is expressed in non proliferating (Ki-67 negative) cells in normal breast tissue. The 
protein potentially interacts with the tubulin beta-4B chain suggesting a crucial role during 
mitosis. Moreover, NY-BR-1 was shown to be expressed in progenitor cells of the mammary 
gland. The phenotypic characterization of these progenitor cells and the question whether the 
protein is also expressed in cancer stem cells is part of ongoing studies. In summary, the 
presented work could show for the first time that NY-BR-1 is a progenitor cell marker in the 
mammary gland and is influences the mitotic process.  
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Abbreviations 
% v/v: volume percent 
% w/v: weight percent 
5’Aza/Aza: 5’Aza-Deoxycytidine 
ALDH1: Aldehyde dehydrogenase 1 
ANKRD30A: Ankyrin Repeat Domain 30A        
AP1: Activator protein 1 
APC: Antigen presenting cell 
ATP: Adenine triphosphate 
BCA assay: Bicinchoninic acid 
BCL2: B cell lymphoma 2 
BiTE: Bispecific T-cell engager 
bp: Base pair 
BRCA: Breast cancer 1 
bZIP: DNA-binding site followed by leucine zipper motif) 
CAR: Chimeric antigen receptor 
C/EBP: CCAAT/enhancer-binding protein 
CCNE1: Cyclin E1 
CD: Cluster of differentiation 
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1 Introduction 
 
1.1 Cancer 
Cancer is known since the ancient world and was named by the Greek physician Hippocrates. 
He was already able to differentiate between carcinoma and sarcoma (Tzortzatou-
Stathopoulou, 1994). But it was not possible to diagnose it in a proper way or to cure it in 
these times. Today, cancer is still an overall issue: the World Health Organization (WHO) 
cancer report 2014 evaluated that approximately 14 million new cases of cancer and 8.2 
million cancer related deaths worldwide could be listed in 2012 (Stewart and Wild, 2014). 
The problem is that an overall cure of cancer is not within eyeshot even though that in the last 
decades a lot of research was done to understand the mechanisms behind cancer. But still 
many questions cannot be fully answered: How does cancer develop? Why some people more 
succesptible towards developing malignencies? Why do some patients develop resistance 
towards therapy?  Why do some patients get a relapse?  
Several theories try to find explanations and one of them is the “multi hit model”. It states that 
multiple somatic mutations in essential genes (oncogenes/tumour suppressor genes) are 
required to enable uncontrollable cell proliferation. Cell cycle regulatory mechanisms are 
mainly affected (Lodish, 2008). But it became clear that tumour genesis is a more and more 
complex process and can differ from patient to patient. It affects different regulatory levels 
and repair processes of a cell, e.g. epigenetic mechanisms (posttranslational histone 
modifications, DNA methylation, RNA-based processes (microRNAs)), mutations in the 
DNA itself or posttranslational modifications. Modifications like single nucleotide 
polymorphisms (SNPs) or mutations, which can alter protein expression, structure and/or 
function, can be induced through various ways: virus infections (e.g. human papillomavirus 
(HPV)), environmental factors (UV light, stress, chemicals), genetic inheritance (nucleotide-
excision repair instability (NIN), microsatellite instability (MSI), and chromosomal instability 
(CIN)), and mobile DNA elements (transposons) (Dunn et al., 2004a). As described in the 
immunoediting hypothesis also the interplay between cells can adjudicate whether abnormal 
proliferating cells become a clinical visible tumour or not.   
The origin of tumour cells is not fully clarified yet but it is proposed that tumour cell 
populations have a common ancestor and develop monoclonally at the beginning. It is just 
due to evolution of a tumour and its genetic instability that the initially homogenous tumour 
mass becomes heterogeneous and thus, visible and difficult to target for the immune system 
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(Weinberg, 2014). Furthermore, tumour cells have to develop different strategies to prevent 
death and hypoxia by ensuring a stable cell homeostasis due to the release of chemokines, 
cytokines and other signal molecules (e.g. vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGF-β)). These factors help to induce angiogenesis towards 
the growing tumour mass and ensure the important supply of nutrients (Auguste et al., 2005; 
Holopainen et al., 2011). By secreting a chemical cocktail different immune cells are attracted 
towards the tumour site and the imbalance of T regulatory (Tregs) versus T helper cells can 
support the tumour outgrowth.  
 
1.1.1 Immunoediting 
Over 100 years ago it was proposed that the immune system might play an important role in 
the fight against cancer. The German physician Paul Ehrlich was the first, who hypothesized 
that the immune system recognizes tumour cells and is able to fight against these cells 
(Niederkorn, 2009). Lewis Thomas and Frank Macfarlane Burnet formed the hypothesis of 
immunosurveillance independent from each other in the late 1950s and they assumed that T 
cells are crucial in these processes. The immunosurveillance hypothesis describes that the 
immune system is capable to monitor abnormal proliferating cells, recognizes cell surface 
structures and activates an elimination process to destroy the mutated cells (Dunn et al., 
2002). At this time it was a controversial idea and the hypothesis was criticized by many 
researchers. 
Today, the understanding of cellular processes becomes clearer and therefore the 
immunosurveillance hypothesis was refined further and is now known as immunoediting. The 
immunoediting process consists of three stages: elimination (the innate and adaptive immune 
system destroy all abnormal proliferating cells), equilibrium (the adaptive immune system 
avoids the tumour outgrowth) and escape (characterizes abnormal cell growth and neither the 
innate nor the adaptive immune system can hold back tumour growth and metastasis) (Dunn 
et al., 2002).  A tumour’s ability to avoid an immune response after a certain time period is 
depending on its microenvironment. Tumours shape their microenvironment in such a way 
that immune cells (T-lymphocytes, NK-cells) cannot prevent further outgrowth/tumour 
genesis and metastasis. The microenvironment itself consists of components varying from 
patient to patient: cancer and non-cancer cells, secreted soluble factors and non-cellular solid 
material (including extracellular matrix (ECM)) (Cretu and Brooks, 2007). Thus, the 
microenvironment drives the immune reaction until the immune system capitulates and the 
tumour becomes clinically visible. The time period, when and how these changes occur, 
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varies from patient to patient. The survival strategy of a tumour includes mimicking the 
immune system to suppress effector cell functions by shaping a specific tumour 
microenvironment. 
 
1.1.1.1 Elimination Phase 
The elimination of tumour cells is carried out by the cooperation between innate and adaptive 
immunity. Innate immunity is characterized to be an unspecific, not affording long lasting 
host protection. It is the first defence against invading microbes and bacteria. Adaptive 
immunity provides the host with long lasting prevention and can be divided into humoral and 
cellular responses. B- and T-cells and their subpopulations are characteristic for the adaptive 
immune system (Parham, 2009).  
The elimination phase can be divided into a four stage process: it starts with the activation of 
the innate immune system by the release of danger signals. Macrophages, NK cells, natural 
killer T (NKT) cells and γδ T-cells recognize the expressed antigens and/or natural killer cells 
receptor (NKR) ligands of the transformed cells. The danger signals are secreted due to 
stromal changes including invasive growth of surrounding tissues and starting of angiogenesis 
(Dunn et al., 2004a, 2004b). The cells of the innate immune system start to produce IFN-γ, 
which has immunostimulatory and -modulatory effects. The second stage is characterized by 
a local production of other chemokines to attract more cells of the innate immune system. 
More macrophages are migrating to the tumour site to secrete cytokines, including 
interleukin-2 (IL-2), to induce a further production of IFN-γ by NK cells.  The release of such 
a high amount of IFN-γ activates several pathways leading to tumour cell death. In the third 
stage the adaptive immune response is involved. The dendritic cells (DCs) process and 
present antigens to activate cellular immune defence (Kushwah and Hu, 2011). These cells are 
migrating to the transformed cells attracted by the cytokine environment, acquire tumour 
antigens and after maturation they activate on their part naïve T-cells in lymphoid organs. The 
activated CD4
+
 T helper (TH) 1 cells enhance the development of CD8
+
 cytotoxic T 
lymphocytes (CTLs) via antigen cross presentation. In the last step a tumour specific adaptive 
immunity is acquired to have a long lasting protection against the cancer cells. Thereby the 
CD4
+
 and CD8
+
 T cells migrate to the tumour. CD8
+
 T-cells induce tumour death via indirect 
or direct mechanisms affecting apoptosis, cell cycle inhibition and macrophage tumoricidal 
activity (Dunn et al., 2002, 2004a, 2004b). In the elimination phase the immune system 
functions as an extrinsic tumour suppressor.  
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Due to continuous replication of the transformed cells and arising of new neoplastic cells the 
immune system is constantly required to adapt to new situations. If tumour cells manage to 
reduce immunogenic signals, the innate immune system gets powerless and the second stage 
of immunoediting will be entered, with the adaptive immune system controlling the tumour 
cells. 
 
1.1.1.2 Equilibrium Phase 
The equilibrium phase describes a dynamic balance between the adaptive host immune 
system and the tumour cells, which escaped the elimination phase. The immune system is 
responsible for holding the tumour cells into dormancy. Therefore, this phase can last over a 
long period of time depending on the strength of the immune system.  
How is the adaptive immune system capable to prevent further proliferation and outgrowth of 
transformed cells? An explanation refers to evolution: different lymphocytes exercise a 
selection pressure on genetically unstable tumour cells (Dunn et al., 2004a; MacKie et al., 
2003). Therefore a dynamic process is maintained between adaptive immune system and 
cancer. Over a long time period, tumour cells might change their strategy and may develop 
resistance towards immune cells due to decreased immunogenicity. The tumour cells do not 
express any antigens (loss of human leukocyte antigen (HLA) class I, defects in major 
histocompatibility complex (MHC) genes), which could be recognized by T-cells. But also 
the immune system can promote further outgrowth of the tumour: if the balance between 
effector T cells and Tregs is disturbed Tregs down regulate the T-cells and tumour progression 
proceeds. CD4
+
 CD25
+
 Tregs cells inhibit proliferation of other T-cells and the IFN-γ 
production. A process partly mediated by TGF-β (Mougiakakos et al., 2010; Woo et al., 
2001). Different tumour entities (breast, head and neck, pancreas) were analysed with respect 
to Treg cell accumulation and patient survival. This study found a negative correlation between 
the amount of Treg cells in the tumour surrounding environment and the overall survival 
(Liyanage et al., 2002). 
The tumour refines through selection pressure and continuous proliferation. When the 
changes are too advanced the adaptive immune system cannot prevent further progression and 
the tumour cells escape. 
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1.1.1.3 Escape Phase 
The tumour cells in the escape phase contain a decreased immunogenicity and create their 
own microenvironment to prevent immune responses. They ensure a self-sustaining supply to 
grow out and metastasize. The adaptive immune system is no longer able to control the 
tumour.  
The tumour cells release immunosuppressive cytokines such as VEGF, TGF-β or indoleamine 
2,3-dioxygenase (IDO) and Chang et al. demonstrated that tumours can escape an immune 
response if they are capable of increasing TGF-β expression or stimulating surrounding cells 
to produce more TGF-β. The researchers used meth A sarcoma cells to produce clones with 
an TGF-β overexpression. The effects of overexpression were analysed in mice without a 
compromised immune system (Chang et al., 1993).  
Another way to escape an immune response is to become insensitive for specific cytokines 
such as IFN-γ. Kaplan et al. used mice insensitive to IFN-γ and treated them with MCA to 
induce tumour development. The mice lacking IFN-γ recognition developed tumours more 
rapidly and with higher frequency compared to the wild type mice. The researchers also 
analysed human tumours with a lost ability to bind IFN-γ and suggest that IFN-γ is essential 
for tumour survival (Kaplan et al., 1998). 
Beside the insensitivity against IFN-γ tumour cells have the ability to express additional 
receptors such as the natural killer group 2, member D (NKG2D) receptor, which has a 
restricted expression pattern in normal tissues. In an experimental set up 462 patients with 
primary colorectal cancer were screened and the expression of NKG2D ligands such as MHC 
class I–related chain (MIC), UL16 binding protein or retinoic acid early transcript 
(ULBP/RAET) proteins and NK cell infiltration were analysed by tissue microarrays. The 
results indicated that a selection pressure is on tumour cells which do not express NKG2D. 
Moreover, high expression of MIC could be associated with NK infiltration and better 
survival outcome for patients (McGilvray et al., 2009). 
The challenging task is now to find targets for developing drugs, which are able to support or 
reactivate the immune system to fight against cancer.  
 
1.1.2 Epigenetics in cancer 
Epigenetic regulation in cancer becomes more and more an important aspect to understand 
tumour genesis. The term “epigenetic” was introduced by Conrad Waddinton in the 1940s and 
includes the maintenance of the cellular identity and function (Armstrong, 2014). Epigenetic 
changes refer to be heritable and reversible in gene expression. These changes can alter the 
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phenotype but are not encoded in the genotype. DNA methylation, histone modifications, 
chromatin remodelling, and microRNAs (miRNA) belong to epigenetic regulation 
mechanisms.  
The DNA molecule is organized in chromatin wrapped around nucleosomes, an octamer of 
two copies of each histone (H3, H4, H2A, and H2B). This kind of organization helps to 
localize the genetic information into the cell nucleus and to regulate gene expression 
(Kouzarides, 2007). The histones contain tails, which are positively charged to interact with 
the negatively charged DNA backbone to form inactive heterochromatin. The histone tails 
contain a code of methylation, acetylation, phosphorylation, deimination, and ubiquitination 
and histone composition in conjunction with other non-histone proteins (Cedar and Bergman, 
2009; Jenuwein and Allis, 2001). To un-wrap or wrap the chromatin, acetylation is one of the 
key regulators. Acetyl groups can be added through histone acetyltransferases (HATs) and 
removed through histone deacetylases (HDACs). After transferring the acetyl groups to 
histone tails through HATs, their positive charge is neutralized and the interaction between 
histone tails and DNA backbone is interrupted, leading to a facilitated gene expression. 
HDACs inhibit gene transcription by removing the acetyl groups, what increases the histone 
tail/DNA backbone affinity. HDAC inhibitors, such as trichostatin A (TSA) and valproic acid 
(VPA), target the zinc cofactor at the active site of HDACs and are used in cancer therapy 
(Arts et al., 2003; Prince et al., 2009).  
Beside histone modification, DNA methylation (hypermethylation, hypomethylation, and loss 
of imprint) is crucial for making a gene accessible for transcription initiation and thus also 
plays an important role in tumour genesis (Kumar, 2014). In this process a methyl group is 
added to the 5-carbon position of cytosine (Widschwendter and Jones, 2002). CpG islands are 
enriched of cytosine and guanine and mostly located upstream of a promoter or exon 1. 
Expressed genes in normal cells have hypomethylated CpG islands. The opposite takes place 
in cancer cells, where CpG islands of 5’-end regions are hypermethylated causing gene 
silencing of e.g. tumour suppressor genes (Bird, 2007; Esteller, 2007). CpG islands can also 
be found within a gene, the so called gene bodies. The methylation there is associated with 
repressing transcriptional noise, inhibiting antisense transcription, and relate to replication 
timing (Aran et al., 2011). In breast cancer, epigenetic mechanisms were observed in two 
important proteins: ERα and E-cadherin. ERα is encoded by the oestrogen receptor 1 (ESR1) 
gene and overexpressed mainly in hormone driven breast cancers (luminal A and B). Five 
CpG islands are present in the promoter region and first exon, respectively. Deregulation of 
DNA and histone methylation of ESR1 can lead to treatment resistance. E-cadherin is 
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encoded by the CDH1 gene. It is an adhesion molecule and maintains the differentiated state 
of mammary gland epithelium. Hypermethylation of CpG islands of CDH1 gene can cause 
loss of E-cadherin expression in breast cancer and results in an increase of cellular motility 
with a high risk of invasion of surrounding tissue (Nass et al., 2000). Thus epigenetic 
regulation needs to be considered to understand the mechanisms of cancer. 
 
1.2 Immunotherapy 
The immunotherapy can be defined as a treatment of a disease to induce, enhance or suppress 
a certain immune response. With cancer immunotherapy, researchers have an additional 
option to stimulate an immune reaction to destroy cancer cells and direct the equilibrium back 
to the immune system (Disis, 2014). Depending on the cancer type different approaches can 
be applied: monoclonal antibodies (mAb) target signal transducing proteins like VEGF 
(Konno et al., 2010) and human epidermal growth factor receptor 2 (HER2/neu) (Cobleigh et 
al., 1999; Rueckert et al., 2005), small molecules inhibit for instance kinase domain functions 
or vaccines immunize the patient against cancer-associated pathogens (e.g. Human 
papillomavirus (HPV)) (Gillison et al., 2008). Other options of immunotherapy include T cell 
transfer and specific chimeric antigen receptors (CARs) expressed by T and NK cells to 
improve therapy outcome. 
The basis for cancer immunotherapy is the assumption that the immune system is capable of 
detecting and destroying abnormally proliferating cells. Today immunotherapy approaches 
use among others T cell transfer, mAb, small molecules, and different kinds of vaccines to 
interfere on the tumour itself, on its microenvironment or to start an immune response 
towards tumour cells. The targets differ depending on the characteristics of the tumour: 
Tumour cells, immunostimulatory pathways and co-inhibitory pathways can be attacked. The 
standard cancer therapies are surgery, chemotherapy and radiation but they can cause severe 
side effects and the therapeutic effect is not always satisfying. In early stages, they can help to 
reduce the tumour until complete remission. But patients can die because they do not respond 
towards therapy, become resistant or get a relapse. Another reason for patient mortality are 
opportunistic infections caused by bacteria, viruses or fungi. Researchers expect from cancer 
immunotherapy a curative effect with reduced side effects and a support for classical 
approaches to improve the patients’ outcome. Therefore the tumour biology with its 
microenvironment needs to be understood and new targets need to be defined.  
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1.2.1 Adoptive Cell transfer and CARs 
The general process of adoptive cell transfer includes the isolation of patient specific 
leukocytes to manipulate them ex vivo. These primed cells get injected back into the patient to 
induce a more effective immune response. The possibilities are not just promising but also 
versatile.  
Autologous T cells can be genetically engineered with so called CARs which recognize a 
tumour antigen independent of the human leukocyte antigen (HLA) presentation (Rini, 2014). 
These CARs are composed of a mAb fragment fused to a T cell receptor. Nowadays four 
generations of CARs are known and they differ in the amount of signalling and co-stimulatory 
domains. The so called first generation contains one signalling domain, the second one two 
signalling domains, the third two costimulatory domains and the fourth is primed with 
additional genes for e.g. pro-proliferative cytokine IL-12 (Brentjens and Curran, 2012). 
The CAR T cell approach was tested in different leukaemias and the results are promising. 
The Tregs of the patients were depleted by chemotherapy followed by an autologous CAR T 
cell transfer, which recognize the surface protein CD19 on B cells. Some patients went into 
remission of their advanced, progressive B-cell malignancies but some of them experienced 
severe toxicity due to a cytokine storm (Kochenderfer et al., 2012). Nevertheless, CAR T cells 
are a promising approach in immunotherapy and clinical trials in different tumour entities are 
ongoing. 
 
1.2.2 Monoclonal antibodies 
The production of mAbs was developed in the 1970s and they are applied for different tumour 
entities and often in combination with other therapy approaches. These antibodies are 
developed to target cell surface proteins, which are specifically (over)-expressed in tumours. 
They block them and prevent further tumour progression. The effect can differ between mAbs 
depending on their target binding affinity or mechanism of action. In HER2
+
 breast cancer 
patients’ trastuzumab, also known as Herceptin® (Roche), is used to target the HER2/neu 
receptor, which is overexpressed in 15-20 % of the breast cancer patients. By binding to the 
receptor, trastuzumab disrupts the signal cascade of the epidermal growth factor (EGF) and 
slows down the proliferation of tumour cells (Harries and Smith, 2002). Because patients can 
react poorly on trastuzumab therapy other mAbs were developed. One of them is pertuzumab, 
which blocks the HER2/HER3 heterodimerization by binding to the dimerization arm of 
HER2 (Agus et al., 2002). 
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The use of mAb in cancer immunotherapy covers a wide range of therapeutic strategies. 
However, the binding affinity towards a target is insufficient. In huge solid tumours, 
antibodies might not get equally distributed due to their huge molecular mass of about 150 
kDa. The best therapy approach is to use mAb in combination with classical methods. 
Another approach for the use of antibodies in immunotherapy is to target and modulate 
immune checkpoints. These checkpoints refer to inhibitory pathways, which exist in the 
immune system to prevent autoimmunity but to maintain self-tolerance and homeostasis 
(Bauzon and Hermiston, 2014). Tumours have the ability to escape the immune system and it 
is assumed that they trigger specific immune checkpoints to down-regulate T cell activation 
or effector functions. Several immune checkpoint inhibitors are now in different clinical 
phases but Ipilimumab (Yervoy, Bristol-Myers Squibb Co, Princeton, NJ), an antibody 
targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), is already approved in 
melanoma (Disis, 2014). 
Other mAbs are still situated in different preclinical states, e.g. the mAb P245 to target the 
transmembrane glycoprotein CD44, which is known to be a breast cancer stem cell marker 
(Marangoni et al., 2009). The epithelial cell adhesion molecule (EpCAM) is over-expressed in 
many carcinomas and is now targeted with the mAb MT110 (Solitomab) in a clinical trial 
phase I. Solitomab is a single-chain bispecific T-cell engager (BiTE) antibody and is tested in 
different solid tumours (Brischwein et al., 2006; Kwiatkowska-Borowczyk et al., 2015). 
 
1.2.3 Vaccines 
Vaccination is a long established method to immunize an organism against against specific 
pathogens. In cancer immunotherapy, it is one promising approach to use vaccines including 
whole tumour cell vaccines, tumour lysate vaccines, speciﬁc tumour antigens, tumour 
peptides, heat shock proteins, DNA vaccines, RNA vaccines, dexosomes, and DC-based 
vaccines (Myc et al., 2011). There are two basic principles in cancer vaccine therapy: on the 
one hand a preventive treatment to obviate cancer development and on the other hands a 
curative treatment. If it is used in a therapeutic manner, the patient’s tumour needs to express 
a certain antigen that serves as a target. This antigen is characteristic for the specific tumour. 
The task of a treatment vaccine is to delay or to stop cancer cell growth, to reduce tumour size 
by eliminating cancer cells and to prevent a relapse, where other treatments failed before. 
They have to boost the immune system by increasing the presentation of tumour-associated 
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antigens (TAAs) to the immune system and need to activate tumour-specific T and B cells 
(Disis, 2014).  
In the recent years mutanome specific vaccination comes into focus. The aim is to design 
personalized cancer vaccines to improve the therapy and outcome of a single patient. 
Mutations could serve as novel vaccine targets but unfortunately, just a small number of 
mutations are shared between the patients and the main amount of mutations is unique in the 
specific tumour (Stratton, 2011). To translate the individualized therapy approach into the 
clinic the tumour mutanome needs to be deciphered by next-generation sequencing. The 
immunogenic mutations are identified by HLA binding predictions or Elispots (Heemskerk et 
al., 2012). The next step is to generate an individualized mutation-targeted vaccine 
(Boisguérin et al., 2014). The advantage is that this approach is specially designed for each 
patient and the possibilities are great to combine different antigens to counteract the selection 
pressure during tumour evolution (Castle et al., 2012). But this procedure makes it also very 
cost intensive and it needs to be considered that not every tumour is immunogenic and the 
heterogeneity between primary tumour and metastases should also be taken in account.   
A successful cancer vaccine is sipuleucel-T (Provenge), applied to metastatic, hormone-
refractory prostate cancer patients. Autologous antigen presenting cells (APCs) are isolated 
and ex vivo cultured with PA2024 to force the maturation of APCs into mature dendritic cells 
(DCs). PA2024 is a fusion protein containing prostatic acid phosphatase (PAP), a prostate 
cancer-associated antigen, and granulocyte-macrophage colony-stimulating factor (GM-CSF). 
The primed DCs are injected back into the patient and an immune response is induced against 
PAP
+
 prostate cancer cells. Side effects are mainly due to the injection (Higano et al., 2009; 
Weber, 2014). 
An important aspect for the success of vaccines is to determine how the vaccine is 
administered (intramuscular, subcutaneous, intradermal and mucosal) and which adjuvant is 
given. One well known vaccine is against HPV infections, which are related to cervix 
carcinomas. The vaccine contains L1-proteins extracted from the capsid of the four types of 
papillomaviruses 6, 11, 16 and 18. They cluster spontaneously to virus-like particles (VLP) 
(No et al., 2011). In some cases the preventive vaccination has to be repeated after 10 years, 
the therapeutic one even more. Side effects of vaccination can be allergic reactions or 
inflammation on the site of injection but this is also in some way showing an ongoing immune 
response. Moreover, it has been reported that after injection of vaccines autoimmune diseases 
occurred (Amos et al., 2011). 
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1.2.4 Small molecules 
Small molecules have a molecule mass up to 800 Da and can reach every cell. They bind to 
proteins, polysaccharides, and nucleic acids and can trigger different signal cascades inducing 
inhibition of tumour progression and growth. In cancer immunotherapy they can target 
different kinases involved in certain pathways related to cancer incidence. Anderson et al. 
analysed certain small molecule inhibitors affecting the mitogen activated protein kinase 
(MAPK) pathway. Their results demonstrated that the combination of specific inhibitors 
resulted in an additive promotion of MAPK pathway by negative feedback release and 
priming (Anderson et al., 2011). The group of Huertas looked after small molecules 
connected to specific histones. They demonstrated that the small molecule CHR-6494 reduces 
phosphorylated histone H3 at Thr3 residue (H3T3ph) levels in a dose-dependent manner. The 
effect is a mitotic catastrophe characterized by metaphase misalignment, spindle 
abnormalities and centrosome amplification. This mitotic kinase inhibitor showed antitumor 
potential in xenografted nude mice without any observed toxicity and brings the cells into 
G2/M arrest followed by apoptosis (Huertas et al., 2012). 
Another approach in immunotherapy settings is the use of tyrosine kinase inhibitors (TKIs). 
Tyrosine kinases are enzymes and their task is to transfer a phosphate group from ATP to a 
protein. Due to an additional phosphate a protein can be in- or activated and thus cellular 
processes can be regulated (Lehninger, 2005). TKIs are applied in solid tumours (e.g. non-
small cell lung cancer) (Sorensen et al., 2014) as well as in leukaemia (chronic myeloid) 
(Brümmendorf et al., 2015). One successful story in different clinical trials is the small 
molecule TK inhibitor Imatinib (Glivec, Novartis) given to patients diagnosed with 
gastrointestinal stromal tumours or chronic myeloid leukaemia (Blanke et al., 2008; 
Christiansson et al., 2015). 
The field of application for small molecules in cancer therapy is manifold and the advantages 
are obvious. They can diffuse to every cell because of their size; they are even capable to 
passing the blood brain barrier to attack brain tumours. The problem is that small molecules 
can be distributed throughout the body and the specificity is thus insufficient. They can also 
bind to healthy cells and might trigger signal cascades with unexpected outcome and severe 
side effects. 
 
The potential of immunotherapy strategies emerges rapidly but the challenge is still to define 
new targets to individualize and improve the therapy for every patient.  
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1.3 Breast cancer  
Breast cancer is one of the most common malignancies with increasing incidences every year 
and a leading cause of death among women. Although early stage breast cancer can be 
effectively treated, there are limited numbers of treatment options available for patients with 
advanced and metastatic disease. Most women are diagnosed with breast cancer at the age of 
45-65 years. With this tumour entity the female mammary gland tissue and very rarely the 
male breast tissue are affected. Figure 1.1 represents the anatomy of a female breast (left) with 
the branching of the glandular tissue. On the right the detailed anatomy of ducts/lobes in pre-
pubertal/pubertal condition are shown (A) and branching of ducts and alveolar structures 
during pregnancy (B). 
 
Figure 1.1: Anatomy of the female breast (left) including ductal and lobular structures (right) with (A) 
the anatomy of ducts/lobes in pre-pubertal/pubertal condition are shown and (B) branching of ducts 
and alveolar structures during pregnancy. (Figure adapted from the National Cancer Institute, USA; 
and  (Gajewska et al., 2013)) 
 
The glandular breast tissue consists of two groups of epithelium: luminal epithelial and 
myoepithelial cells. The task of myoepithelial cells is to guide the milk through the ductal tree 
via contractions. The luminal epithelium can be divided into the ductal and alveolar cell 
lineage whereas the latter produces milk while breast feeding (Fu et al., 2014). The breast is a 
dynamic tissue and is shaped through different developmental stages in life time such as 
puberty, adulthood, pregnancy, breast feeding, and menopause. Breast cancer is classified, as 
any other cancer type as well, into histopathological types, stages and grade of the tumour and 
expression of specific proteins and genes. Compared to other tumour entities, the breast 
cancer classification and exact characterization of the tumour is of great importance because 
therapy strategies are very specialized, e.g. hormone sensitive (ER/PR) versus triple negative 
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tumours require different therapies. Breast cancer can be subdivided into four groups: HER2
+
, 
Luminal A or B, and triple negative. Depending on the molecular subtype, condition of the 
patient (health, age), and stage/grade/progression of the tumour, different treatment options 
are available such as surgery, chemo-, radiation-, hormone-, and targeted therapy. Table 1.1 
lists which targeted therapy options are available for the different molecular subtype. 
 
Table 1.1: Summary of treatment options for breast cancer patients according to their molecular 
subtype (Goldhirsch et al., 2013). 
Breast cancer 
type 
Receptor status Treatment options 
HER2
+
 Her2 over-expressed or ampliﬁed  
ER
-
/PR
-
 
Cytotoxics and anti-HER2 
(Trastuzumab, Pertuzumab,  
Ertumaxomab, and Lapatinib) 
Luminal A ER
+
/PR
+
/HER2
-
 
Ki-67 ‘low’ 
Endocrine therapy (Tamoxifen) 
Luminal B Luminal B-like (HER2
-
) 
ER
+
/HER2
- 
 
and at least one of:  
Ki-67 ‘high’  
PR ‘negative or low’  
Luminal B-like (HER2
+
) 
ER
+
/HER2 over-expressed or ampliﬁed  
Any Ki-67  
Any PR 
Endocrine therapy for all 
patients, cytotoxic therapy for 
most (Tamoxifen) 
 
 
Cytotoxics and anti-HER2 and 
endocrine therapy (Tamoxifen) 
Triple 
negative/Basal-like 
Triple negative (ductal) 
ER
-
/PR
-
/HER2
-
 
Cytotoxics 
 
As with all tumours, common risk factors are alcoholic abuse, low or no exercise, obesity 
respectively a high carb/fat diet, and genetic predisposition (BRCA1/BRCA2 mutations). 
Hormones are the key drivers in shaping the breast during life time. Therefore, additional risk 
factors for getting breast cancer can be hormones in contraceptives or hormones given in 
menopause, hormonal therapy, menstruation at early age, and dense, glandular breast tissue.  
It is assumed that pregnancy can prevent the outgrowth of hormonal driven cancer and it is of 
note that an early pregnancy is more preventive compared to a late one. A study compared 
parous versus nulliparous glands in mice and the results showed that the Wnt:Notch signalling 
ratio in the basal stem/progenitor cells was changed (Meier-Abt et al., 2013). Human breast 
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epithelial cells are under hormonal influence, which also shows consequences on the 
epigenome (Pal et al., 2013). 
The molecular subtypes express different genes/receptors and therefore respond differently to 
therapy. 50-60 % of breast cancer patients belong to the luminal A subtype and the tumours 
are characterized by a low histological grade, low degree of nuclear pleomorphism, and low 
mitotic activity (thus low levels of proliferation related genes). Beside ER expression and 
genes associated with ER regulation (hepatocyte nuclear factor 3 alpha (FOXA1), X-box 
binding protein 1 (XBP1), GATA binding protein 3 (GATA-3), B cell lymphoma 2 (BCL2), 
erbB3 and erbB4, the luminal A tumours also express luminal epithelial cytokeratin’s (CK) 8 
and 18. Patients diagnosed with luminal A have a good prognosis and a lower relapse rate 
compared to other subtypes. 
Compared to luminal A, luminal B tumours are more aggressive, more proliferative and have 
a higher histological grading. 15-20 % of breast cancers belong to this subtype. Patients have 
a worse prognosis, a higher recurrence rate, and become quicker insensitive to endocrine 
therapy. The luminal B tumours have a distinct gene expression pattern: they mainly express 
growth receptor signalling genes and proliferation-associated genes like myeloblastosis viral 
oncogene homolog (v-MYB), gamma glutamyl hydrolase (GGH), lysosome-associated 
transmembrane protein 4-beta (LAPTMB4), nuclease sensitive element binding protein 1 
(NSEP1) and cyclin E1 (CCNE1). The distinction between luminal A and B is difficult and 
therefore the Ki67 value, a proliferation marker, was established. This marker was introduced 
by Cheang et al., who set the cut-off point of Ki67 for luminal A tumours on 14 % and 
everything above is considered as luminal B. Unfortunately, the use of Ki67 marker is not 
standardized and thus it has limitations depending on the used antibody, and how it is 
analysed (Cheang et al., 2009). 
The HER2 gene, also known as ERBB2, encodes for a member of the EGF receptor family of 
receptor tyrosine kinases. 15-20 % of breast cancer patients carry the HER2 subtype. These 
tumours are characterized by a high expression of HER2 and genes associated with the HER2 
pathway, high proliferation rate and an aggressive behaviour, which refers to a higher tumour 
grading. Around 50 % of HER2
+
 tumours do express low levels of ER. The uncertainty of 
HER2 positivity on immune-histochemical level is circumvented by using the fluorescence-
in-situ-hybridization (FISH) technique. In general, patients with HER2
+
 tumours have a poor 
prognosis due to hormonal agent resistance and metastases in brain and visceral organs but 
can be treated inter alia with the monoclonal antibodies such as trastuzumab alone or in 
combination with pertuzumab (Yersal and Barutca, 2014).  
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The characteristic features of triple negative tumours are that they are infiltrating ductal 
tumours, highly aggressive, have a high histological and nuclear grade, and give rise to 
metastasis in brain and lung. The term “triple negative” is used in clinical setting and refers to 
no expression of ER, PR, and HER2.  The term “basal-like” originates from gene expression 
microarray analysis. These tumours express myoepithelial markers such as CK5, CK 14, CK 
17 and laminin and over-express P-cadherin, fascin, caveolins 1 and 2, αβ crystallin and 
epidermal growth factor receptor (EGFR). This tumour type is insufficient in DNA repair 
mechanisms and DNA damage sensing (DNA double strand breaks). 8-37 % of breast cancer 
patients receive the triple negative/basal-like diagnosis. The triple negative type can be 
divided into several subtypes - one of them is grouped as breast cancer 1 (BRCA1) positive. 
Mutations in the caretaker gene BRCA1 are frequently found in basal like tumours and 
characterized by an early relapse rate and metastasis formation. They do express abnormal 
basal cytokeratins, TP53, EGFR, and P-cadherin. Another subtype is referred to as claudin-
low and its main features are a low expression of tight junction gene and cell-cell adhesion 
(claudin 3, 4, and 7) genes but a high expression of stem cell features. The prognosis for all 
triple negative cancers is poor (Yersal and Barutca, 2014). 
Adjuvant and neo-adjuvant therapy is administered to breast cancer patients but this is 
depending on the molecular subtype and health condition of the patient (Miller et al., 2014). 
The challenge in breast cancer is to carefully characterize the heterogeneous tumour mass to 
overcome relapse and resistance and find new targets for immunotherapy. 
 
1.4 Stem cells in the female breast  
In the recent years stem cells have become an important issue because of their potential to 
differentiate into any specialized cell type. They can give rise to more stem cells by 
undergoing mitosis and are able to replenish adult tissues. Breast tissue contains several 
different multipotent stem/progenitor cells. But in contrast to other stem cell systems, (e.g. 
hematopoietic) breast stem cells are difficult to isolate and to expand without losing their 
characteristic features. It is of note that gene expression profiles of mammary stem cells 
(MaScs) can undergo dramatic changes during pregnancy, lactation, and menopause. 
Moreover, it seems that the adult MaScs differ strongly from fetal MaScs due to the hormonal 
influence during puberty. MaScs numbers vary between the myoepithelial/basal compartment 
and luminal epithelial cells and are enriched in the myoepithelial/basal compartment. It seems 
that the MaScs population is heterogeneous containing subsets either expressing leucine-rich 
repeat-containing G-protein coupled receptor 5 (Lgr5) or not (Visvader and Stingl, 2014). 
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Figure 1.2: Stem and progenitor cells in breast tissue with some specific expression features 
(adapted from (Visvader and Stingl, 2014)). 
 
Epithelial cells with high proliferative potential are mainly found in the ducts and with less 
frequently in the lobules, which holds true for luminal and myoepithelial cells. The different 
stages of potential stem and progenitor cells in the breast tissue can be viewed in figure 1.2.  
The MaSc have a low activity of aldehyde dehydrogenase 1 (ALDH1) and do not express ER, 
PR and ErbB2. By paracrine signalling of ER
+
/PR
+
 neighbouring cells, MaScs can be forced 
to proliferate. In contrast, the luminal progenitors (CD49f
+
/EpCAM
+
) consisting of ER+ as 
well as ER- cells and have a high ALDH1 activity (Eirew et al., 2012). Moreover, the luminal 
progenitors are under control of Elf5, Stat3, GATA-3, C/EBPβ and BRCA1 depending on the 
stage of development (Makarem et al., 2013). Elf5 expression can be stimulated through 
progesterone via receptor activator of nuclear factor kappa-B ligand (RANKL) signalling and 
is responsible for basal to luminal cell fate decisions. RANKL is a regulator of MaScs activity 
and as GATA-3 it forces luminal progenitors into alveologenesis during pregnancy. In 
summary the luminal progenitors are responsible for morphogenesis during puberty and 
alveologenesis. After involution, parts of the progenitor cells will diminish via apoptosis and 
a new pool is recruited for another round of alveologenesis. 
The myoepithelial progenitor cells are characterized to be CD24
low
 and expressing the basal 
marker CK14 and the adhesion molecule CD49f, also known as integrin alpha 6. But due to 
the low amount it is difficult to segregate all the different progenitor cells from each other. 
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In table 1.2 is an overview of the current markers for isolating stem and progenitor cells from 
human breast tissue. The marker panel of each subtype depends on how the cells were 
cultured, expanded and analysed. 
It is assumed, that the different molecular subtypes in breast cancer arise due to mutations and 
modifications in the different subsets of stem/progenitor cells of the female breast (Al-Hajj et 
al., 2003). Therefore, it is more and more important to characterize the gene and protein 
expression profile of progenitor cells for a better understanding of breast cancer.  
 
Table 1.2: Overview of characteristic features of each human stem/progenitor cell subtype 
(adapted from (Oakes et al., 2014)). 
Marker Multipotent stem cell Luminal lineage Myoepithelial lineage 
ALDH1 Breast stem/progenitor cells 
ALDH1+ 
Differentiated human luminal cells 
(EpCAM+/CD49f+/ALDH1-);  
Undifferentiated human progenitor 
luminal cells 
(EpCAM+/CD49f+/ALDH1+) 
/ 
CD10   Is expressed 
CD24 Depending on study: CD24-
/low 
CD24+/high CD24high 
CD44 Tumor initiating cell 
CD44+/CD24-/low 
/ / 
CD49f  CD49fneg/EpCAM+ (mature luminal) 
CD49f+/EpCAM+ (luminal progenitor) 
CD49fhigh 
cKIT / cKIThigh  
EpCAM CD49f+/EpCAMhigh or 
EpCAMlow/CD49f bright 
EpCAMhigh CD49f+/EpCAM-/low 
Sca1  CD24high/Sca1+  
Thy1/CD9
0 
Bipotent progenitor 
EpCAM+/CD49f+/MUC1-
/CD133- (CD10/Thy1)+ 
Luminal restricted progenitor 
EpCAM+/CD49f+/MUC1-/CD133- 
(CD10/Thy1)+ 
MUC1-/CD133- (CD10/Thy1)+ 
 
1.5 The breast cancer associated antigen NY-BR-1 
The breast cancer associated antigen New York-Breast-1 (NY-BR-1) was identified by a 
serological cloning strategy (SEREX) by Jäger et al. (Jäger et al., 2001). NY-BR-1, also 
known as ANKRD30A, is located on chromosome 10p11-p12. There are several transcripts 
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annotated in the Ensembl database. Due to alternative splicing processes transcripts are 
known containing between 36 and 42 exons. For transient transfection experiments the full 
length variant (aa 1-1397) was used, which corresponds to the Ensembl ID 
ENST00000611781. Computational analyses revealed several functional protein motives, 
including five tandem ankyrin motifs, a bZIP site (DNA-binding site followed by leucine 
zipper motif) and a bipartite nuclear localization signal motif. These structural features 
suggest on the one hand that NY-BR-1 might be involved in protein-protein interactions and 
on the other hand NY-BR-1 might function as a potential transcription factor (Jäger et al., 
2001). But up to date, the functional aspects of this 158 kDa protein are still unknown.  
NY-BR-1 is expressed in the majority (>70 %) of breast tumours as well as metastases, in 
normal breast tissue, in testis and occasionally in prostate tissue. Biochemical labeling and 
transient expression studies showed that NY-BR-1 encodes a novel membrane protein, which 
can be detected by a monoclonal antibody on the cell surface of transfected cells (Seil et al., 
2007). Furthermore, NY-BR-1 was confirmed as an immunogenic antigen since NY-BR-1-
specific spontaneous humoral immune responses in 7 % of breast cancer patients could be 
detected (Jäger et al., 2001; Seil et al., 2007; Varga et al., 2006). Theurillat et al. performed 
an in situ hybridization experiment for exon 4-7 and 30-33 and NY-BR-1 mRNA detection 
was stronger for exons 30-33 than for exons 4-7. From these results one can conclude that 
splice variants of NY-BR-1 might exist lacking 5’ sequences (Theurillat et al., 2008). 
Theurillat et al. also mapped putative oestrogen responsive elements (ERE) as binding sites 
for ERα and binding sites for stimulating protein 1 (SP1) as well as activator protein 1 (AP1) 
in the NY-BR-1 promoter region by in silico analysis, suggesting the transcriptional 
regulation of NY-BR-1 by ERα. Another analysis showed that NY-BR-1 mRNA expression 
correlates with ERα protein expression. In a cohort study the researcher analysed NY-BR-1 
expression in combination with oestrogen receptor alpha (ERα), HER2, EGFR, HLA class I 
antigen expression and overall survival. They could show that patients with strong NY-BR-1 
expression had a better prognosis compared to patients with NY-BR-1 negative tumours. NY-
BR-1 expression correlated with ERα and HLA class I antigen expression but not with HER2 
or EGFR (Theurillat et al., 2007).  
Thus, due to its restricted expression pattern and over-expression in the majority of breast 
tumours as well as its immunogenicity, NY-BR-1 represents a promising target antigen for 
immunotherapeutic approaches and may also serve as a target for antibody based therapies. 
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2 Aims of the project 
The latest studies show that breast cancer is still the second most common cancer in the world 
and the most common one among women. As described before (see 1.3) different kinds of 
therapies are available but due to resistance towards therapy and recurrence of cancer new 
targets need to be defined. NY-BR-1 would be an interesting target for immunotherapy for 
several reasons depicted in chapter 1.5 but up to date the biological function, regulatory 
mechanisms and interaction partners of NY-BR-1 in healthy and tumorous tissue is 
completely unknown.  
The aim of this project was to characterize this protein on the molecular and functional as 
well as genetic level and therefor the following questions were addressed: I) How is the NY-
BR-1 expression transcriptionally regulated? II) What is the effect of NY-BR-1 over-
expression on cellular processes such as proliferation and cell cycle? III) Are there specific 
protein interaction partners? IV) Is NY-BR-1 a progenitor cell marker in the mammary gland? 
And V) Does an integrative in silico analysis of the NY-BR-1 gene reveal interesting SNPs or 
differences in methylation on certain promoter fragments, which might alter transcription 
initiation? 
 
To investigate the transcriptional regulation of the NY-BR-1 gene, the promoter region was 
analysed for putative transcription factor binding sites with the Alibaba 2.1 tool. This 
algorithm predicted numerous binding sites for nuclear hormone receptors (oestrogen receptor 
alpha (ERα), progesterone receptor (PR), glucocorticoid receptor (GR) and retinoid X 
receptor (RXR)/retinoic acid receptor (RAR) in the assumed promoter region of ANKRD30A 
(figure 2.1) based on sequence comparison. To study the hormonal transcriptional activation 
in vitro, several NY-BR-1 negative or weakly positive breast cancer cell lines (e.g. T47D, 
226L, ZR-75-1, MCF-7), tissue pieces from breast reductions, isolated epithelial cells and 
pleural effusions from breast cancer patients were stimulated with different hormones, the 
demethylation agent 5’Aza-Deoxycytidine and the histone de-acetylation inhibitors VPA 
and/or TSA. NY-BR-1 expression was analysed by qPCR and the methylation status via 
EpiTyper MassARRAY technology.  
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Figure 2.1: Predicted binding sites for nuclear hormone receptors and CpG islands in the promoter region of 
NY-BR-1. (CpG Islands: genomic regions that contain a high frequency of CpG sites; HDAC Inhibitors: Histone 
deacetylase inhibitors; VPA: Valproic acid; TSA: Trichostatin A; and T3R: Thyroid hormone receptor) 
 
To examine the effect of NY-BR-1 over-expression on cellular processes, proliferation assays 
and cell cycle analyses by fluorescence-activated cell sorting (FACS) analysis were 
performed with transiently transfected HEK293, HEK293T, MCF-10A, and MCF-7 cell lines. 
Immunohistochemical analyses of mammary gland tissue derived from healthy patients show 
a mosaic-like NY-BR-1 expression pattern. Single luminal epithelial cells in a mammary 
gland are NY-BR-1 positive. This characteristic expression pattern can be due to expression 
on a specific progenitor cell population. To further evaluate this assumption, mammospheres 
were generated. The spheres were analysed by immunofluorescent staining and qPCR was 
performed to characterize the gene expression profile in more detail. Interaction partners can 
give hints in which pathways the protein of interest might be involved. To identify specific 
protein interaction partners of NY-BR-1, co-immune precipitations were performed with 
lysates of NY-BR-1 transfected cells (HEK293, MCF-10A, MCF-7) and lysates of normal 
breast/breast tumour tissue. Western Blot and silver staining were used to detect proteins after 
electrophoretic separation on polyacrylamide gels. Finally, an analysis of the proteins was 
done by mass spectrometry.  
Furthermore, an extensive analysis utilizing genomics, transcriptomics and epigenetics was 
performed with publicly available data from databases such as dbSNP, ICGC, ENCODE, and 
NCBI SRA. 
Considering our results, illustrated in the next chapters, we hypothesized that NY-BR-1 is a 
potential progenitor cell marker in breast tissue. Additionally, we suggest that NY-BR-1 is 
expressed in specific molecular subtypes of breast cancer patient, namely the ones which are 
hormone sensitive. It is likely that NY-BR-1 expression is influenced by ERα and/or PR 
expression.  
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3 Material and Methods 
 
3.1 Materials  
 
3.1.1 Chemicals 
 4-Hydroxytamoxifen (Sigma, H7904) 
 5'Azadeoxycytidine (Aza) (Sigma, A3656) 
 Dexamethasone (Dex) (Sigma, D4902) 
 β-Estrodiol (E2)  (Sigma, E2257) 
 Progesterone (Sigma, P0130) 
 9-cis Retinoic acid (Sigma, R4643) 
 Trichostatin A (TSA) (Sigma, T1952) 
 Vitamin D3 (Vit D3) (Sigma, D1530) 
 Valproic acid (VPA) (Sigma, P4543) 
 Silver nitrate (Sigma, 20139) 
 Ethanol (EtOH) (Roth, 9065.2) 
 Methanol (MeOH) (Roth, 4627.2) 
 Acetic acid (Roth, 52016) 
 Ethidium bromide (EtBr) (Roth, 2218.1) 
 Saponin (Roth, 4185.1) 
 Potassium tetrathionate (Sigma, P2926) 
 Potassium acetate (Grüssing, 12240) 
 Potassium carbonate (Roth, P743.1) 
 Sodium thiosulfate-pentahydrate (Sigma, 21,726-3) 
 Tris(hydroxymethyl)aminomethane (Tris) (Roth, 5429.3) 
 Hydrochlorid acid (HCl) (Roth, 46251) 
 Formalaldehyde [37 %] (Roth, 4979.1) 
 
3.1.2 Antibodies 
 α-NY-BR-1#2: monoclonal mouse (Jäger et al., 2007) 
 α-NY-BR-1 (C-18): polyclonal goat (SantaCruz Biotech, sc-163686) 
 α-Integrin alpha 6 (CD49f): monoclonal mouse (abcam, ab20142) 
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 α-Estrogen Receptor alpha: monoclonal rabbit (abcam, ab32063) 
 α-E-Catenin: polyclonal rabbit (Cell signaling, 3236) 
 E-cadherin (24E10): monoclonal rabbit (Cell signaling, 3195) 
 Keratin 17/19 (D4G2) XP®: monoclonal rabbit (Cell signaling, 12434) 
 EpCAM (D1B3): monoclonal rabbit (Cell signaling, 2626) 
 α-human Ki67: monoclonal mouse (MIB1, Dako, M7240) 
 Progesterone receptor A/B (D8Q2J) XP®: monoclonal rabbit (Cell signaling, 8757)  
 Purified Goat IgG (invitrogen™, 02-6202) 
 Purified Mouse IgG1 κ Isotype Control (BD, 554121) 
 Rabbit (DA1E) mAb IgG XP® Isotype Control (Cell signaling, 3900) 
 
 Goat α-mouse IgG Pox conjugated (Dianova, 115-035-003) 
 Donkey α-goat IgG-HRP (Santa Cruz, sc-2056) 
 Donkey α-rabbit IgG-HRP (Santa Cruz, sc-2077) 
 Donkey α-goat IgG H&L (FITC): polyclonal (abcam, ab7121) 
 Goat α-mouse IgG (FITC) (Dianova, 115-096-062) 
 Donkey α-goat IgG (FITC) (abcam, ab7121)     
 Goat α-rabbit (FITC) (Dianova, 111-096-045) 
 Goat α-mouse (FITC) (Dianova, 111-096-045) 
 Goat α-rabbit (Cy3) (Dianova, 115-166-045) 
 Mouse EpCAM-FITC  (BD, 347197)  
 HER2 – FITC (BD, 340553)  
 mouse IgG1-PE  Isotype Control (BD, 550953)   
 Mouse IgG1-FITC Isotype Control (BD, 555909)      
 mouse α-human  Cytokeratin 14, 15, 16, and 19 PE (BD, 550953)               
 
3.1.3 Dye 
 APC Annexin V (BD Pharmingen™, 550475) 
 7-AAD (BD Pharmingen™, 559925) 
 PKH26 (Sigma, 081M1013) 
 Propodium iodide (PI) (Sigma, P4170) 
 DAB Kit (Leica, DS9800) 
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3.2 Methods 
 
3.2.1 Primary material 
Healthy mammary tissues from breast reduction were obtained from Clinic for Plastic and 
Reconstructive Surgery, Aesthetic and Preventive Medicine, Heidelberg University Hospital-
Ethianum, Heidelberg, Germany. The pleural effusions were provided from the department of 
Gynecology and Obstetrics, National Center for Tumor Diseases (NCT), Heidelberg 
University Hospital, according to the ethic vote number S-069/2010. Paraffin embedded 
breast tumour tissue sections were kindly provided by the National Center for Tumor 
Diseases (NCT) Tissue Bank, Heidelberg in accordance to the ethic vote number S 206/05. 
Table 3.1 shows the obtained primary material used for several experiments. 
 
Table 3.1: Overview of the obtained primary material. HD-T-176 – HD-T-283: Tissue pieces; HD-T-
292 – HD-T-311: Isolated epithelial cells; HD-A-58 – HD-A-88: Ascites/pleural effusion cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2 Cell culture methods 
3.2.2.1 Cell culture 
Cell lines were cultured with the specific medium described in table 3.2 at 37 °C, 5 % CO2. 
The medium was refreshed every three to four days. Dulbecco's Modified Eagle's Medium 
(DMEM) (DMEM/F12) and Roswell Park Memorial Institute (RPMI) medium were 
purchased from Sigma (D0819; D8062; R2405). 
Sample ID Material 
HD-T-176  Healthy breast tissue 
HD-T-177  Healthy breast tissue 
HD-T-178  Healthy breast tissue 
HD-T-180  Healthy breast tissue 
HD-T-203 Healthy breast tissue 
HD-T-258 Healthy breast tissue 
HD-T-283 Healthy breast tissue 
HD-T-292 Healthy breast tissue 
HD-T-311 Healthy breast tissue 
HD-A-58 Ascites of breast cancer patient 
HD-A-66 Pleural effusion of breast cancer patient 
HD-A-68 Ascites of breast cancer patient 
HD-A-73 Ascites of breast cancer patient 
HD-A-78 Ascites of breast cancer patient 
HD-A-86 Ascites of breast cancer patient 
HD-A-88/HD-A-90 Ascites of breast cancer patient 
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Table 3.2: Overview of the used cell lines, the type of cells and their specific culture medium. 
Cell line Type Culture medium 
HEK293 Human embryonic kidney (ATCC-
Reference: CRL-1573) 
DMEM with 10 % FCS, 1 % 
Pen/Strep, 1 % Hepes, 1 % NEAA 
HEK293T Human kidney with SV40 large T 
antigen (ATCC-Reference: CRL-
11268) 
DMEM with 10 % FCS, 1 % 
Pen/Strep, 1 % Hepes, 1 % NEAA 
MCF-7 Mammary gland/breast derived from 
pleural effusion (ATCC-Reference: 
HTB-22) 
RPMI with 10 % FCS, 1 % 
Pen/Strep, 1 % Hepes, 1 % NEAA 
MCF-10A Mammary gland/breast (ATCC-
Reference: CRL-10317) 
DMEM/F12 with 10 % FCS, 1 % 
Pen/Strep, 5 µg/ml Insulin, 10 µg/ml 
Hydrocortisone, 8 µl/500ml Cholera 
Toxin, 20 ng/ml hEGF) 
KS 
 
Breast carcinoma (Kayser et al., 2003) RPMI with 10 % FCS, 1 % 
Pen/Strep, 1 % Hepes, 1 % NEAA 
ZR-75-1 Mammary gland/breast, derived from 
ascites (ATCC-Reference: CRL-1500) 
RPMI with 10 % FCS, 1 % 
Pen/Strep, 1 % Hepes, 1 % NEAA 
T-47D Mammary gland; derived from pleural 
effusion (ATCC-Reference: HTB-133) 
RPMI with 10 % FCS, 1 % 
Pen/Strep, 1 % Hepes, 1 % NEAA 
SK-BR-3 Mammary gland/breast; derived from 
pleural effusion (ATCC-Reference: 
HTB-30) 
DMEM with 10 % FCS, 1 % 
Pen/Strep, 1 % Hepes, 1 % NEAA 
MDA-MB-
453 
Mammary gland/breast; derived from 
pericardial effusion (ATCC-
Reference: HTB-131) 
DMEM with 10 % FCS, 1 % 
Pen/Strep, 1 % Hepes, 1 % NEAA 
 
3.2.2.2 Transfection 
Cell lines were transfected according to the manufacturer´s protocol either with lipofectamine  
(Invitrogen™, Lipofectamine® 2000 Transfection Reagent, 11668-019) or with X-
tremeGENE HP DNA Transfection Reagent (Roche, 06366236001). The ratio between DNA 
and Transfection reagent was always 1:3. Cells in 6 well plates and in T-25 culture flasks 
were transfected with 4 µg DNA, cells in T-75 culture flasks with 20 µg DNA. However, 4 µg 
pc3 GFP was used in T-75 culture flasks due to achieve comparable GFP fluorescence to the 
NY-BR-1-GFP fusion protein. Before adding the DNA-transfection mixture to the cells, the 
culture medium was removed and replaced by DMEM or RPMI without any additives.  
 
3.2.2.3 Cell counting 
For counting the cells were diluted 1:2 with trypan blue, a vital stain to separate dead from 
living cells. Cell counting was done using a hemocytometer. 
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3.2.2.4 Pleural effusion or ascites regeneration 
Pleural effusion or ascites are accumulations of fluids either close to the lungs or the 
peritoneal cavity. They can contain blood and various other cells like tumour cells and 
lymphocytes. Due to potential infectious material, before starting, all equipment (collection 
container, drain) was carefully desinfected. The material was filled into sterile bottles, then 
divided into 50 ml falcon tubes and centrifuged for 10 min at 1500 rpm, at room temperature. 
Supernatant was removed, filled into new falcon tubes and centrifuged again for 10 min at 
3500 rpm, at room temperature. The cleared supernatant was later used to produce 
conditioned medium (supernatant mixed with RPMI 1:2). The cell pellets were brought 
together, resuspended in RPMI medium without any additives and centrifuged for 10 min at 
1500 rpm, at room temperature. The supernatant was discarded and RPMI without additives 
was added. The cells were seeded into T75 culture flasks with a density of 2,5x10
6
/ml – 
5x10
6
/ml in max. 8 ml RPMI and incubated between 1 – 1.5 hours at 37 °C, 5 % CO2, to 
allow macrophages to stick to the flask ground. The macrophage-free supernatant was 
removed containing only the non-adherent cells and tumour cells respectively and placed into 
new falcon tubes. The cells in the culture flasks were washed three times with PBS, which 
was then added to the non-adherent cells. Conditioned medium was added to the macrophages 
and they were cultured at 37 °C, 5 % CO2. The non–adherent cells were centrifuged for 10 
min at 1500 rpm, at room temperature. They were counted with trypan blue using a 
hemocytometer. Depending on the amount of cells and the following experiments, the cells 
were seeded into T25/T75 culture flasks with a density of 2.5x10
6
/ml or in 6 well plates with 
a density of 1x10
6
/ml. 
 
3.2.2.5 Isolation of mammary gland epithelial cells 
Skin and fat were removed from the supposed glandular tissue, which was stored in 
DMEM/F12 medium until the preparation of the whole tissue was finished. 50 ml falcon 
tubes were prepared containing 70 % EtOH for the first wash and DMEM/F12 for the second 
and third wash. The tissue pieces were dipped quickly three times in each wash solution by 
holding them with sterile pincers. They were left in wash solution three. Few tissue pieces 
were transferred to a big petri dish without medium and were cut into small pieces with fine 
scissors. Before the minced glands were transferred into new falcon tubes for further 
digestion, they were checked for big organoids and then equally distributed among the 
falcons. 
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The composition of the digestion mix was 1 x collagenase (Roche, 10103586001), 
hyaluronidase (Sigma, H3506-1G), 1 x glutamine (Life technologies, 25030123), 5 % FCS 
and DMEM/F12 medium with a total volume of 20 – 30 ml/falcon. Collagenase A was 
dissolved in HBSS (Gibco®, 24020-091) and filtered through a 0.22 µM filter. Hyaluronidase 
(stock: 1 mg/ml (8X)) was freshly prepared because its activity lasts for just 10 min. It was 
dissolved in HBSS and sterile filtered using a 0.22 uM filter. 1.25 ml of the 1 mg/ml solution 
was added to 10 ml digestion mix. The falcon tubes were sealed with parafilm and incubated 
overnight at 37 °C with gentle shaking (40 rpm). After digestion a fat layer, a medium layer 
and at the bottom the organoid layer was observed. The falcons were centrifuged for 2 min at 
80 g and 4 °C. Carefully the supernatant was removed starting with the fat layer until the 
organoid layer was reached. The organoids were washed with 1x HBSS and centrifuged for 5 
min at 350 g and 4 °C. The supernatant was taken off and the second enzymatic digestion was 
performed. 0.25 % Trypsin – EDTA (Life technologies, 25300096) was pre-warmed and 
depending on the organoid amount 10-15 ml were added and resuspended for 3 to 5 min or 
until the organoids got smaller in size. The enzymatic reaction was stopped with 30 ml cold 
HF (1x HBBS, 2 % FCS) and then centrifuged for 5 min at 350 g and 4 °C. The supernatant 
was removed carefully and if erythrocytes were present 0.2 % NaCl solution was added for 3 
to 5 min. The reaction was stopped by adding HBSS and then centrifuged for 5 min at 350 g 
and 4 °C. 
Dispase (Roche, 4942078001) was dissolved in modified HBSS (HBSS + 1 % Hepes) to get a 
5 mg/ml concentration and sterile filtered using a 0.22 µM filter. 10 ml of pre-warmed dispase 
was used for each pellet. DNAse (stock: 10 mg/ml) (Roche, 11284932001) was filtered using 
0.22 µM filter and added in a 1:15 ratio (DNAse:Dispase). After adding the dispase/DNase 
mix the organoids were resuspended to fully dissociate them. The enzymatic reaction was 
stopped with 30 ml cold HF (1x HBBS, 2 % FCS). On top of a 50 ml falcon tube a 40 µM 
mesh (BD, 352340) was placed and wet with 2 ml HBSS. The digested organoids were 
filtered by pipetting slowly and gently over the mesh to avoid clogging of the filter. The cells 
were centrifuged for 5 min at 350 g and 4 °C. The supernatant was removed carefully and the 
cells were washed with 1x HBSS to remove residual FCS. They were centrifuged again for 5 
min at 350 g and 4 °C. The cell pellet was resuspended in plating medium (HuMEC medium 
with 5 µg/ml Insulin (Sigma, I9278), 4µg/ml Heparin (Sigma, H3149), 100 U/ml Penicillin 
(Sigma, P4458), 100 µg/ml Streptomycin (Sigma, P4458), 0.5 µg/ml Hydrocortisone (Sigma, 
H0888), 20 ng/ml hEGF (Sigma, E9644), 20 ng/ml bFGF (Life technologies, PHG0021), and 
1x B27 (Life technologies, 17504044)) or frozen (45 % medium, 50 % FCS, 5 % DMSO). 
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3.2.3 Functional assays 
3.2.3.1 Proliferation Assay 
To examine the effect of NY-BR-1 over-expression or down-regulation on cellular processes 
in different cell lines (HEK293, HEK293T, MCF-10A, and MCF-7), cells were transiently 
transfected as described before with 20 µg of pcDNA3-NY-BR-1-GFP plasmid to 
discriminate NY-BR-1 expressing cells from non-transfected cells. A pcDNA3-GFP plasmid 
and non-transfected cells served as controls. The cells were cultured at 37 °C, 5 % CO2 in 
serum free medium. 24 hours after transfection the cells were labeled with PKH26 
(proliferation marker) according to the manufacturer’s instructions, and were incubated for 
one-five days.  
 
3.2.3.2 Apoptosis and viability assay 
Shortly before FACS analysis, the cells were stained with 7-AAD (live/dead staining) and 
Annexin V APC (apoptosis marker) at each time point according to the manufacturer´s 
instructions.  
 
3.2.3.3 Cell cycle analysis 
Cell cycle analysis is done to reveal the information about cell ploidy, cell position in the cell 
cycle and the amount of apoptotic cells arising from fractionated DNA.  
To analyse the effect of NY-BR-1 over-expression on the cell cycle the following assay was 
performed. The cell lines (HEK293, HEK293T, MCF-10A, and MCF-7) were transiently 
transfected with either 20 µg of pcDNA3-NY-BR-1-GFP or 20 µg of pcDNA3-GFP (as a 
control) 24 hours prior to the cell cycle analysis. The second control was composed of non–
transfected cells treated the same way as transfected cells. The supernatant was taken off 
containing the dead cells and placed into falcon tubes. All three cell populations were 
harvested with a cell scraper, added to the appropriate supernatant and centrifuged for 10 min 
at 1500 rpm. The supernatant was discarded and the cell pellets were washed with 30 ml PBS. 
After counting a minimum of 1x10
6
 cells/population the cells were used for cell cycle 
analysis. This time point is referred to as day one. The rest of the cells were seeded into 6 well 
plates for cell cycle analysis on day two and three. While vortexing the cell pellet 5 ml ice 
cold 70 % ethanol was added drop by drop. For a minimum of two hours the cells were stored 
at -20 °C. The cells were washed twice with PBS/2 % FCS, resuspended in 425 µl PBS and 
brought to a FACS tube. RNase A (Qiagen, 19101) was added to the cells with a final 
concentration of 100 µg/ml and incubated for 30 min at 37 °C in the dark. PI (live/dead 
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marker) was administered with a final concentration of 100 µg/ml. The cells (min. 50.000) 
were slowly (max. 300 cells/sec) measured in a FACS CantoII.  
 
3.2.3.4 Intra and extracellular antibody staining 
Ascites cells were analysed by FACS using the α-NY-BR-1#2 (mouse) antibody for 
intracellular (IC) and extracellular (EC) staining as well as EpCam (EC), CK 14/15/16/19 (IC) 
and HER2 (EC) antibodies. EpCam/HER2/CK14/15/16/19 antibodies were used according to 
the manufacturer´s instructions. The equivalent isotypes were used as a control.  
For an intracellular (IC) staining, the cells were fixed with 2% PFA for 15 min at room 
temperature, whereas the cells for extracellular (EC) staining were kept on ice. The fixed cells 
were centrifuged for 5 min at 1500 rpm and permeabilized with 0.5 % saponin buffer (PBS, 5 
% FCS, 0,5 % BSA, 0,1 % - 0,5 % saponin) for 15 min at room temperature. The cells were 
centrifuged for 5 min, 1500 rpm and the primary antibodies, diluted in either saponin buffer 
(IC) or FACS buffer ( PBS, 5 % FCS, 0.1 % NaN3) (EC), were added to cells for IC and EC 
staining for 30 min at room temperature (IC) or ice (EC). The α-NY-BR-1#2 (Mouse) 
antibody was diluted to a final concentration of 26 µg/ml, α-NY-BR-1 (C-18) to 4 µg/ml, the 
mouse IgG1 isotype to 26 µg/ml and the goat IgG isotype to 4 µg/ml.  
The cells were washed after adding 1 ml saponin buffer (IC) or FACS buffer (EC) for 5 min 
at 1500 rpm. The secondary antibodies, diluted in either saponin buffer (IC) or FACS buffer 
(EC), were administered and incubated for 20 min at room temperature (IC) or ice (EC). The 
final concentrations were 30 µg/ml for α-mouse conjugated with FITC of and 20 µg/ml for α-
goat FITC. The cells were washed with either saponin buffer or FACS buffer for 5 min, 1500 
rpm and were analysed via FACS CantoII.  
 
3.2.3.5 Flow cytometry 
FACS is a method to analyse single cells. The method is based on the specific light scattering 
and fluorescent pattern of each cell (Jaye et al., 2012). 
The cells were analyzed at a FACS CantoII (BD Biosciences, Heidelberg) with the software 
FACS DIVA (Version 6.1.2, BD Biosciences, Heidelberg). The FACS CantoII system 
contains three different lasers: a blue (488-nm), a red (633-nm) and a violet (405-nm) laser. 
Auto-fluorescence cells were taken as a control to determine the individual auto-fluorescence 
of a cell population. By combinations of multiple fluorescence marker single labeled cells 
were used for compensation. The cells were sorted at first according their size (forward scatter 
(FSC)) and granularity (side scatter (SSC)). The adjacent gate settings depend on the analysis. 
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Proliferation assay: A gate was set in the FSC/SSC application to get all cells for further 
analysis but leaving the cell debris out. The next application was to discriminate GFP positive 
from GFP negative cells. Therefore, the PE-A (area) vs. FITC-A channel was adjusted. The 
PKH26 label beams in the PE channel, the GFP transfected cells in the FITC channel. To 
analyse the proliferation profile of each cell population a histogram was used with the PE-A 
setting. The last step was to discriminate the apoptotic cells from living/dead cells and for this 
a quad gate was set in the Annexin APC-A/7-AAD-A setting.  
Cell cycle analysis: No gate was set in the FSC/SSC application. The next step was to 
discriminate NY-BR-1 GFP positive from NY-BR-1 GFP negative cells. This was done using 
the FITC-A channel and a histogram. In both cell population (NY-BR-1 GFP
+/-
) a gate was set 
in the PI-A vs. PI-W (width) setting to gate the doublets out. The cell cycle was analysed in 
the PI-A histogram setting on the basis of the previous gate setting. 
Intracellular and surface staining: A gate was set in the FSC/SSC application to get all the 
tumour cells for further analysis but leaving lymphocytes and cell debris out. In a histogram, 
using the FITC-A setting or PE-A setting, the appropriate isotpye control was taken and the 
appendant staining. 
The final analysis and graphical representation was performed using the software FlowJo 
(Version 7.6.5, Tree Star, Ashland, USA). 
 
3.2.3.6 Stimulation Assay 
To analyse a hormone dependent transcriptional regulation of NY-BR-1, healthy mammary 
gland tissues of 3 to 5 mm size, isolated epithelial cells from healthy breast tissues or pleural 
effusions were used. The mammary gland-containing tissue pieces were incubated with 
phenolred-free DMEM/F12 medium, the isolated epithelial cells with HuMEC basal medium 
(Gibco, 12753-018) and the pleural effusion cells with conditioned medium (cleared 
supernatant of pleural effusion mixed 1:2 with serum free RPMI medium).  
The healthy mammary gland tissues and the different kinds of cells were treated with different 
hormones/histone deacetylase (HDAC) inhibitors/reagents (see Table 3.2.3) alone or in 
combination. The stimulation time was depending on the agent, which was used. 
5‘Azadeoxycytodine was added each day to the cells for four to six days, and all the other 
substances were added for six-seven hours. After stimulation was done the tissue pieces were 
collected with a needle, frozen in liquid nitrogen and stored at -80 °C. The cells were 
harvested with a cell scraper, washed twice with PBS to remove the medium, the cell pellet 
was divided for either RNA or DNA isolation and stored at -80 °C. 
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Table 3.3: Overview of the hormones, HDAC inhibitors and reagents used for up- and down 
regulation of NY-BR-1 in stimulation experiments. 
Hormones  HDAC inhibitors Reagents 
10 nM E2 1 mM VPA 100 nM 4-Hydroxytamoxifen 
1 µM Progesterone 200 nM TSA 1 µM 5‘Azadeoxycytodine 
1 nM Vit D3   
1 µM 9-cis retinoic acid   
1 µM Dexamethasone    
1 nM T3   
 
 
Table 3.4: Overview of the used agent for the stimulation experiments and their mechanism of action. 
Agent Function 
5’Aza  Causes DNA demethylation or hemi-demethylation  
 DNA demethylation can regulate gene expression by "opening" the 
chromatin structure detectable as increased nuclease sensitivity 
 Allows transcription factors to bind to the promoter regions, assembly of the 
transcription complex, and gene expression (www.sigmaaldrich.com) 
Dex  Glucocorticoid anti-inflammatory agent, acts through GR 
 Regulates T cell survival, growth, and differentiation 
 Inhibits the induction of nitric oxide synthase (www.sigmaaldrich.com) 
E2  Major estrogen secreted by the premenopausal ovary, acts through ER 
 Estrogens direct the development of the female phenotype by regulating 
gene transcription  
 It also induces the production of gonadotropins which, in turn, induce 
ovulation. 
 Exposure to estradiol increases breast cancer incidence and proliferation 
(www.sigmaaldrich.com) 
VitD3  Vitamin D acts through its VDR that is a member of the ligand-dependent 
transcription factor superfamily  
 Modulates the proliferation and differentiation of both normal and cancer 
cells.  
 Has antiproliferative and antimetastatic effects on breast cells 
(www.sigmaaldrich.com) 
Progesterone  Endogenous steroid hormone, acts through the different kind of PRs 
 Its effect is amplified by oestrogens 
Retinoic 
acid (9cis) 
 Ligand for both the retinoic acid receptor (RAR) and the retinoid X receptor 
(RXR) that act as transcription factors to regulate the growth and 
differentiation of normal and malignant cells 
(www.sigmaaldrich.com) 
VPA  Histone deacetylase inhibitor 
TSA  Histone deacetylase inhibitor 
Tamoxifen  Tamoxifen is a selective estrogen response modifier (SERM), protein kinase 
C inhibitor and anti-angiogenetic factor 
 Tamoxifen is a prodrug that is metabolized to active metabolites 4-
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hydroxytamoxifen (4-OHT) and endoxifen by cytochrome P450 isoforms 
CYP2D6 and CYP3A4 
 In breast cancer, the gene repressor activity of tamoxifen against ERBB2 is 
dependent upon PAX2 
 Blocks estradiol-stimulated VEGF production in breast tumor cells 
(www.sigmaaldrich.com) 
 
3.2.4 Mammospheres 
3.2.4.1 Generation of mammospheres 
Mammospheres have the ability to renew and differentiate into cells with unipotent and 
bipotent potential (Dontu et al., 2003). To generate mammospheres, the cells were 
resuspended at a density of 1x10^5 cells/ml and plated in a 10 cm plate (Corning Petri Dishes, 
Ultra low binding surface, Sigma, CLS3262-20EA) with 10 ml plating medium. The plate 
was swirled to avoid having cells attaching to the periphery and incubated at 37 °C, 5 % CO2.  
If secondary or tertiary spheres are required more cells need to be plated. Four to five days 
after plating 5 ml of plating medium was added, Seven to nine days after plating the 
mammospheres were collected in cap filters of FACS tubes. It is of note that the pipettes and 
cap filters should be pre-wetted with medium, otherwise the spheres will stick to it. The ultra-
low culture dishes were washed with more medium to collect remaining spheres, and filtered 
through the mesh again. The cap filters were tapped on a plate cover to remove remaining 
medium and then flipped over a 15 ml falcon tube. The spheres were eluted by slowly adding 
medium with releasing the pressure every once in a while to avoid bubble formation from 
below. The spheres were centrifuged for 5 min at 350 g and 4 °C. The supernatant was 
removed and 1 ml pre-warmed Accumax (Sigma, A7089) was added. The spheres were 
resuspended until all spheres were dissociated. To stop the reaction medium was added and 
the cells were centrifuged for 5 min at 350 g and 4 °C. The cells were resuspended in freshly 
prepared HuMEC with additives, and were plated by pooling in half of the initial volume. To 
generate tertiary spheres the process was repeated after one week of incubation at 37 °C, 5 % 
CO2. 
 
3.2.4.2 Immunofluorescence of mammospheres 
The spheres were collected in cap filters of FACS tubes. They were washed 3 times with 1X 
PBS, fixed with 4 % PFA in PBS for one hour at room temperature, washed 3 times with 1 x 
PBS and permeabilized with 0.1 % Triton-X100 in PBS for 5 min at room temperature. 
Blocking was done with 1 % BSA in 0.1 % Triton-X100 in PBS for 30 min at room 
temperature. The primary antibodies were diluted in blocking solution and added to spheres in 
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filters. The filters were sealed before with parafilm to avoid leaking. The incubation lasted for 
one hour at room temperature. The spheres were washed 3 times with 1 x PBS and incubated 
with the secondary antibodies FITC-coupled goat anti-mouse or Cy3-coupled goat anti-rabbit 
(1:450 in PBS with Hoechst, 1:1000 w/v, to detect DNA) for 45 min at room temperature. 
Hoechst was added to the secondary antibody solution (1:1000 w/v in PBS) to detect DNA. 
Finally, the spheres were collected with 50 µl PBS and transferred to slides. PBS was allowed 
to dry for 30 min to one hour in the dark, before adding Aquatex
®
 (Merck Millipore, 
1085620050) and covering with rectangular coverslips. During and after incubation with 
secondary antibodies the slides were protected from light. The cells were examined using a 
confocal laser scanning microscope (IX81, Olympus) with an x20, x40 and x60 oil objective. 
Images were collected and processed using the FV10- ASW 2.0 Viewer software (Olympus) 
and ImageJ. 
The staining was performed in the Research Group Cellular Senescence of Dr. Thomas 
Hofmann, German Cancer Research Center (DKFZ), DKFZ-ZMBH Alliance, Heidelberg, 
Germany. 
 
3.2.5 Molecular techniques 
3.2.5.1 Bacteria (E.coli) preparation 
The XL1 blue bacteria (endA1 gyrA96 (nalR) thi-1 recA1 relA1 lac glnV44 F'[ ::Tn10 
proAB+ lacIq ∆(lacZ)M15] hsdR17(rK- mK+))  were obtained from StrataGene (Heidelberg). 
They were cultured in Lysogene Broth-Medium (LB - medium), pH 7.5 consisting of pepton 
10 g/L, yeast extract 5 g/L, NaCl 10 g/L over night at 180 rpm and 37°C. Depending on the 
plasmid the bacteria contained 100 µg/ml carbenicillin (Roth, 6344.2) or 40 µg/ml 
chloramphenicol (Roth, 3886.2) was added to the LB - medium. 
 
3.2.5.2 Plasmids 
Table 3.2.5 summarizes the used plasmids for transfection and transient expression of the 
encoded proteins in different assays. 
  
3 Material and Methods 
 
- 52 - 
 
 
Table 3.5: Overview of used plasmid constructs in several experiments. Plasmid numbers 58/65 are 
NY-BR-1 full length constructs (Seil et al., 2007) and 42/126 are the empty pcDNA3.1 vector. 
Filemaker 
No. 
Construct NY-BR-1 
amino acid  
Size of encoded protein 
[kDa] 
58 pc3-NY-BR-1 1 - 1397 154 
65 pc3-NY-BR-1-GFP 1 - 1397 181 
42 pcDNA3.1 (-)   
126 pcDNA3.1 (+)   
99 pcDNA3.1 (+)-GFP  Derivative with extended 
cloning site and a C-terminal 
“Green fluorescent protein” 
(GFP) sequence (Rosorius et 
al., 1999) 
 
3.2.5.3 RNA Isolation 
RNA isolation was performed according to the manufacturer’s protocol (Qiagen; RNeasy Plus 
Mini Kit, 74134). An additional DNase digestion was done according to the manufacturer’s 
protocol to remove genomic DNA (Invitrogen™; DNase I, Amplification Grade; 18068-015). 
 
3.2.5.4 Genomic DNA Isolation 
DNA isolation was performed according to the manufacturer’s instructions (Promega; Wizard 
SV Genomic DNA Purification System, A2360) 
 
3.2.5.5 Genomic DNA Isolation with bisulfit conversion 
DNA isolation was performed according to the manufacturer’s protocol (Zymoresearch; EZ 
DNA Methylation-Direct™ Kit; D5020). 
 
3.2.5.6 Plasmid-DNA Isolation 
Plasmid-DNA Isolation was done with either Plasmid Miniprep Kit (Qiagen, 27104) or with 
Plasmid Midiprep Kit (Qiagen, 12145) according to the manufacturer’s protocol. 
 
3.2.5.7 Photometric determination of DNA/RNA concentration 
DNA/RNA concentration was measured with nanodrop (Nanodrop ND-1000, Thermo 
Scientific). Either aqua dest. or elution buffer (EB buffer (10 mM Tris-Cl, pH 8.5), Qiagen, 
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19086) served as blank. 1 µl/sample was used and the extinction was measured at 260 nm and 
280 nm. The ratio of the wavelengths 260 nm/280 nm shows the purity of the sample: a value 
of 1.8 for DNA 1.8 and 2.0 for RNA testifies great purity. 
 
3.2.5.8 DNA Sequencing 
To sequence plasmids or DNA sequences the service of GATC Biotech (Konstanz, Germany) 
was used. The sequences were analysed with the programmes BioEdit (Version 7.053, Tom 
Hall) and MegAlign (LaserGene Suite, Version 10.1, DNAStar, USA). 
 
3.2.5.9 Reverse transcriptase for cDNA synthesis  
For cDNA 150 ng RNA was used and was performed according to the manufacturer’s 
protocol either with (Invitrogen™; SuperScript® III Reverse Transcriptase; 18080-044) or 
(Thermo Scientific; Maxima H Minus First Strand cDNA Synthesis Kit; K1651). 
 
3.2.5.10 Generation of whole cell lysates 
Medium was removed and the cells were washed with cold PBS. Cells were harvested with a 
cell scraper in cold PBS and centrifuged for 5 min at 1300 rpm and 4 °C. After removing the 
PBS the cells were lysated with Co-IP buffer (50 mM Tris-HCl, pH 8; 5 mM EDTA, pH 8; 
150 mM NaCl; 0.5 % NP-40) containing 1 mM DTT and 1 % protease inhibitor cocktail 
(PIC) (Roche, 10261000) for 20 min on ice. The lysate was centrifuged for 10 min at 14.000 
rpm and 4 °C to get the proteins separated from the rest of the cells. The supernatant 
containing the proteins was taken off and filled into a new tube. The lysates were kept on ice 
all the time and later stored at -80 °C.  
 
3.2.5.11 Protein quantification 
Protein analysis was performed with the BCA assay according to the manufacturer’s protocol 
(BCA Protein Assay Kit, Thermo Scientific, 23227). Lysates were diluted 1:5 and 1:10 with 
aqua dest. The amount of protein was determined with a photometer (BioPhotometer plus, 
eppendorf). 
 
3.2.5.12 Oligo nucleotides 
All oligo nucleotides were purchased by Biospring AG, Frankfurt. They were created with the 
program Seqbuilder (LaserGene Suite, Version 10.1, DNAStar, USA). The parameter of each 
was calculated with OligoCalc (http://www.basic.northwestern.edu/biotools/oligocalc.html) 
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and the specificity was controlled with the tool Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
 
Table 3.6: Oligos used for expression analysis with filemaker number of the AG Jäger laboratory; 
name of the gene of interest; forward/reverse sequence, melting temperature and size of the product. 
Filemaker 
number 
Gene Oligo-Sequence TM 
[°C] 
Size[bp] 
1 
2 
ß-Actin FW: 5’-GGCATCGTG ATGGACTCC G-3‘ 
RV: 5’-GCTGGAAGGTGGACAGCG A-3’ 
55.4 
55.4 
631 
21 
22 
NY-BR-1  FW: 5’-CAAAGCAGAGCCTCCCGAGAAG-3’ 
RV: 5’-CCTATGCTGCTCTTCGATTCTTCC-3’ 
58.6 
57.4 
931 
23 
24 
NY-Eso-1 FW: 5’-CAGGGCTGAATGGATGCTGCAGA-3’ 
RV: 5’-GCGCCTCTGCCCTGAGGGAGG-3’ 
58.8 
64.1 
332 
182 
183 
SSX2 FW: 5’- GGATCCATGAACGGAGACGACGCCTTTGC-3’ 
RV: 5’- GTCGACCTCGTCATCTTCCTCAGGGTC-3’ 
65.7 
64.3 
642 
67 
68 
ß-Actin FW: 5´-GCGGGAAATCGTGCGTGACATT-3´ 
RV: 5´-GATGGAGTTGAAGGTAGTTTCGTG-3´ 
56.7 
55.7 
232 
110 
109 
ERα FW: 5’-AGGCTGCGGCGTTCGGC-3’ 
RV:5’-AGCCATACTTCCCTTGTCAT-3’ 
56.7 
49.7 
272 
113 
111 
ERβ FW: 5’-TTCCCAGCAATGTCACTAACT-3’ 
RV: 5’-TCTCTGTCTCCGCACAAGG-3’ 
50.5 
53.2 
527 
115 
114 
pS2 FW: 5’-TGGAGCAGAGAGGAGGCAA-3’ 
RV: 5’-GCCGAGCTCTGGGACTAATCA-3’ 
53.2 
56.3 
347 
241 
242 
Maspin FW: 5’-TGCTGCCTACTTTGTTGGCAAGT-3’ 
RV: 5’-TGATACTGTCAATGTTTCCCATACAGA-3’ 
55.3 
55.2 
149 
249 
250 
VDR  FW: 5’-ATGGCGGCCAGCACTTCCCTGCCTGAC-3’ 
RV: 5’-CTCCTCCTTCCGCTTCAGGATCATCT-3’ 
67.3 
61.1 
330 
259 
258 
p21 FW: 5’-CAGGAGGCCCGTGAGCGATGGA-3’ 
RV: 5’-TCAGCCGGCGTTTGGAGTGGTAGA-3’ 
62.3 
60.8 
346 
262 
263 
Cyp24 FW: 5’-CTCATGCTAAATACCCAGGTG-3’ 
RV: 5’-TCGCTGGCAAAACGCGATGGG-3’ 
52.4 
58.3 
300 
264 
265 
RXRα FW: 5’-CGACCCTGTCACCAACATTTGC -3’ 
RV: 5’-GAGCAGCTCATTCCAGCCTGCC-3’ 
56.7 
60.4 
142 
276 
277 
GR FW: 5’-TGGCTGTCGCTTCTCAATCAGACT-3’ 
RV: 5’-ACACAGCAGTGGATGCTGAACTC-3’ 
57.4 
57.1 
300 
286 
287 
PR FW: 5’-CCGACGCCGAGCCCAAGGACGAC-3’ 
RV: 5’-CGACCCCGAGGAGGACGCAGACGA-3’ 
66.0 
65.9 
275 
402 
403 
Sgk1 FW: 5’-CCTTGGGCTACCTGCATTCACTG-3’ 
RV: 5’-CCCGAGCCGCTTTGTCCTG-3’ 
58.8 
57.6 
398 
880 
881 
YY1 FW: 5’-ACCTGGCATTGACCTCTCAG-3’ 
RV: 5’-TCTCCGGTATGGATTCGCAC-3’ 
53.8 
53.8 
345 
883 
882 
JunB FW: 5’-ACTTTTCTGGTCAGGGCTCG-3’ 
RV: 5’-GTAGCTGCTGAGGTTGGTGT-3’ 
53.8 
53.8 
362 
885 
884 
CEBPα FW: 5’-AGACGTCCATCGACATCAGC-3’ 
RV: 5’-TTGCTGTTCTTGTCCACCGA-3’ 
53.8 
51.8 
673 
887 
886 
C1orf61 FW: 5’-CTCCGTGTGGACGATAGAGC-3’ 
RV: 5’-CTCCCAACTTAGCCATGCCA-3’ 
55.9 
53.8 
303 
904 
905 
c-Jun FW: 5’-GTCCGAGAGCGGACCTTATG-3’ 
RV: 5’-CTTTTTCGGCACTTGGAGGC-3’ 
55.9 
53.8 
756 
909 
908 
SP1 FW: 5’-GCCTGTAGCGCCCTTTGTGG-3’ 
RV: 5’-TCCTGGCCTGGGCTGGTAGAGAA-3’ 
57.9 
60.6 
417 
911 
910 
Max1 FW: 5’-GGAGAGCGACGCTGACAAA-3’ 
RV: 5’-TTCTTCCTGCTTTGGGGCTC-3’ 
53.2 
53.8 
408 
913 
914 
CTCF FW: 5’-TGCCGTTACTGTGATGCTGT-3’ 
RV: 5’-TAGCTGTTGGCTGGTTCTGT-3’ 
51.8 
51.8 
604 
919 
920 
c-Myc FW: 5’-GTGGTCTTCCCCTACCCTCT-3’ 
RV: 5’-GCTGCGTAGTTGTGCTGATG-3’ 
55,9 
53.8 
356 
921 
922 
THRα FW: 5’-GCCGCACAATCCAGAAGAAC-3’ 
RV: 5’-CCAATGTCATCGGGCAGGAA-3’ 
53.8 
53.8 
358 
60 
59 
NY-BR-1 FW: 5’-CAAGAGCTCTGCAGTGTGAGATTG-3’ 
RV: 5’-CTGGTATTGGTGTTTCAGTGTGGC-3’ 
57.4 
57.4 
315 
100 NY-BR-1 FW: 5’-GAGGTGCTCCATCAACCACTTTC-3’ 57.1 456 
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80 RV: 5’-TCATGAGTTTTCTGTTTCTGCTTTC-3’ 52.8 
225 
226 
ABCG2 FW: 5’-TGGAGATTCCACTGCTGTGGCA-3’ 
RV: 5’-TGACCTGCTGCTATGGCCAGTG-3’ 
56.7 
58.6 
690 
943 
944 
GATA-3 FW: 5’-GAACCGGCCCCTCATTAAG-3’ 
RV: 5’-GTTAAACGAGCTGTTCTTGGG-3’ 
53.2 
52.4 
288 
923 
924 
Integrin-α 6 FW: 5’-GCTAAACCTTCCCAGGTGTATT-3’ 
RV: 5’-AGACTCCGTTAGGTTCAGGGA-3’ 
53.0 
54.4 
274 
931 
932 
FoxA1 FW: 5’-AGGGCTGGATGGTTGTATTG-3’ 
RV: 5’-TGGCATAGGACATGTTGAAGG-3’ 
51.8 
52.4 
245 
256 
257 
ERBB2 FW: 5’-TGACCTGCTGGAAAAGGGGGAGCG-3’ 
RV: 5’-TCCCTGGCCATGCGGGAGCATTCAG-3’ 
62.5 
64.2 
150  
 
3.2.5.13 Real-time Polymerase chain reaction (RT-PCR) 
In the RT-PCR defined DNA sequences are amplified. Amongst others, it can be used to 
check the presence of genomic DNA within RNA samples. The following protocol was 
performed with the GoTaq® Flexi DNA polymerase (Promega, M8305) (see Table 3.2.6) and 
PCR reactions were carried out in a T3000-„Cycler“ (Biometra, Jena).  
 
Table 3.7: Master mix per sample using the GoTaq® polymerase. 
Reagents PCR 
H2O 13,3 µl 
5x Green or Colorless GoTaq®Flexi Buffer 5 µl 
25 mM MgCl2 3 µl 
10 mM each d’NTP Mix 2 µl 
10 µM Oligo Each 0.5 µl 
GoTaq®G2 Flexi DNA Polymerase (5u/µl) 0.2 µl 
Template (RNA/cDNA) 1 µl 
 
 
Table 3.8: Protocol to amplify specific sequences in RT-PCR. * Time for annealing was calculated 
due to oligo length and its GC-amount, time for elongation was depending on the size of the specific 
gene part. 
Step Temperature Time  Cycle 
Initial denaturation 94-96 °C 60-120 s  
Denaturation 94-96 °C 30-60 s  
35 Annealing * TM-5 °C 20-60 s 
Elongation * 70-72 °C 20-300 s 
Final elongation 72 °C 60-180 s  
Cooling 16 °C Until remove 
 
3.2.5.14 Quantitative - Real time PCR (qPCR) 
The qPCR works on the same principle as RT-PCR but it measures the amplification of the 
gene of interest in real time. The value is expressed either in “Threshold Cycle” (CT) or in 
“Crossing Point” (CP) and describes the amplification cycle in the exponential phase where 
the fluorescence of the amplicon is higher than the background fluorescence. Different kinds 
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of reporter systems are available but here the SYBR Green dye was used, which can have the 
disadvantage of detecting all double strand DNAs including primer dimers. All samples were 
normalized against the housekeeper gene ß-Actin and water was used as a negative control. 
After the run was finished the results were quality checked by analysing the melting curves 
and CP values. If the melting curve was not suitable or the CP value was missing the 
measurement was repeated. If the CP value of ß-Actin was ≥25, even after repeating the 
measurement, the sample was not taken into account for analysis due to poor RNA quality. If 
the melting curve was suitable, the CP values of ß-Actin were right and the CP values of the 
triplicates did not differ more than one value from each other the CP values were taken for 
further analysis. To compare the expression between two genes first the median of the 
triplicates of ß-Actin and NY-BR-1 was determined. -∆CP (median ß-Actin–median NY-BR-
1) was calculated. 2^
(-∆CP)
  was calculated to receive the expression ratio between NY-BR-1 
and ß-Actin (Schefe et al., 2006). 
 
Table 3.9: Master mix for the qPCR/sample. 
Components Volume [µL] 
2x SYBR Green Mix  5 
„Forward“-Primer (10 µM) 0,2  
„Reverse“-Primer (10 µM) 0,2  
H2O 2,6  
Non - diluted cDNA  2  
 
 
Table 3.10: Protocol to amplify specific sequences in qPCR. The best results for used ß-Actin and NY-
BR-1 primer were obtained at the indicated annealing temperature. If other primers were used the 
annealing temperature was adjusted.  
Step Temperature Time Cycle 
Initial denaturation 95 °C 120 s  
Denaturation 95 °C 15 s  
40 Annealing 57 °C 25 s 
Elongation/Detection 72 °C 20 s 
Melting curve 62-95 °C   
Cooling < 40 °C Until remove 
 
3.2.5.15 Quantitative DNA Methylation Analysis by EpiTyper MassArray  
Quantitative analysis of DNA methylation was performed using mass-spectrometry based 
EpiTyper MassArray technology (Sequenom, San Diego, USA) as described before (Ehrich et 
al., 2005). Using this system, methylation differences ≥5 % are detectable by quantifying 
median methylation of CpG units (single CpGs or two or more CpGs analysed together). 500 
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ng genomic DNA was subjected to sodium bisulfite treatment using the EZ DNA 
Methylation™Kit (Zymo Research, Orange, USA), according to the manufacturer’s 
instructions. Subsequent PCR amplification and base-specific cleavage of nucleic acids 
enabled separation of methylated and unmethylated CpG units according to their mass to 
charge ratio (m/z). Genomic locations and positions of amplicons are summarized in Table x. 
The data were generated in the AG Gerhäuser, Division of Epigenomics and Cancer Risk 
Factors, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 
Heidelberg, Germany. 
 
Table 3.11: Summary of MassArray amplicons of NY-BR-1. (*tss: transcription start site) 
Prim
er ID 
Gene 
Name 
Chr Start End Distance t 
o tss* 
Left Primer Right Primer Length CpGs 
53 NYBR-
1A 
10 37413170 37413581 -1614 TTGGTTTATG
TTTGTTTTGT
AGTTTT 
CCAAACTAA
TATATTCCCT
TCTAATAAA 
412 12 
54 NYBR-
1F 
10 37413626 37413953 -1158 GATTTATGG
GTTAGAAGT
TTTTAGGG 
AAATTCCAA
AACTACCTA
ACCAACA 
328 15 
55 NYBR-
1G 
10 37413925 37414222 -859 TTTATGTTGG
TTAGGTAGT
TTTGG 
CCCTAAAAA
CTTCTAACCC
AAAAAT 
298 14 
56 NYBR-1I 10 37414198 37414505 -586 ATTTTTGGGT
TAGAAGTTT
TTAGGG 
CAACTCAAC
AAACTAAAA
AAACAC 
308 21 
57 NYBR-
1L 
10 37414771 37415126 -13 GTATTTTAA
GTTTGGGGG
TTTGTTT 
ACCCTTTCA
ACCAACTAA
TCTATACC 
356 12 
58 NYBR-
1M 
10 37414556 37414797 -228 TGGTATAGA
TTAGTTGGTT
GAAAGGG 
AACCTAAAT
ATACAAAAA
CTTAAC 
242 19 
 
3.2.5.16 Agarose gel electrophoresis 
1 % (w/v) agarose gel (agarose + 1x TAE buffer (40 mM TrisHCl, pH 8.0, 20 mM acetate, 1 
mM EDTA)) at 4-6 V/cm in a Sub-Cell-System (Biorad) was used to separate DNA 
fragments. To make the DNA fragments visible at 312 nm (UV light) 0.2 µg/mL ethidium 
bromide was administered to the liquid agarose. As a DNA marker a 100 bp or 1 kb ladder 
(New England biolabs, N3231L/N3232L) was used.  
 
3.2.5.17 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
This technique is used to separate proteins according to their electrophoretic mobility. The 
mobility depends on the charge, length and conformation of the molecule.  
6–12 % SDS–polyacrylamide gels were used depending on the size of the molecule of 
interest. The liquid gels were poured into 1 mm thick glass chambers (BioRad). The 
polymerized gels were placed into a Mini-PROTEAN-System (BioRad) filled with running 
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buffer. 5 x Laemmli buffer (Sigma, S3401-10VT) was added to the lysates. They were heated 
up for 5-10 min at 95 °C, cooled down on ice and shortly centrifuged. To separate the proteins 
60 V was adjusted for the collecting gel and 130–145 V for the separation gel. The used 
ladder with a defined molecular weight was the peqGold Protein marker (peqLab, 27-2110). 
 
Table 3.12: Composition of buffer used in SDS-Page. 
Buffer Composition 
Separation gel buffer 1.5 M TrisHCl, pH 8.8 
Collecting gel buffer 0.5 M TrisHCl, pH 6.8 
1x SDS running buffer 25 mM TrisHCl, pH 8.3, 192 mM Glycin, SDS 0.1 % (v/v) 
 
3.2.5.18 Western Blot 
The “semi-dry” immunoblot system was used (Trans-Blot SD Chamber, BioRad) to transfer 
the proteins from SDS-PAGE to a Polyvinylidene fluoride (PVDF) membrane (Millipore, 
IPVH00010). Each blot contained blot paper (Chromatographypaper, GE, 3030-931), the 
PVDF membrane and the SDS gel. The transfer for NY-BR-1 lasted 2 h with a current of 70 
mA/blot. 
The general procedure consisted of blocking the PVDF membrane with blocking buffer for 
one hour at room temperature or overnight at 4 °C. The primary antibody was added diluted 
in blocking buffer and before adding the secondary antibody diluted in blocking buffer, the 
membrane was washed three times with PBS-Tween. The washing step was repeated after 
secondary antibody incubation to remove all unspecific antibody bindings. To receive a signal 
through an enzymatic reaction ECL plus (ECL Plus Western Blotting Detection System, GE 
healthcare, RPN2132) was added to the PVDF membrane and incubated for 1 min at room 
temperature. The ECL was removed, the PVDF membrane was placed into a cartridge, a film 
was put atop (Lucent Blue Film for Western Blot, Biozym) and incubated for 30 sec to 15 
min. The film was developed in an AGFA CP1000 machine. 
The polyclonal antibody α-NYBR-1 (C-18), and the monoclonal α-NY-BR-1#2 (mouse) 
antibody were tested on either cell lines (MCF-7) or primary material (stimulated samples, 
pleural effusions). 
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Table 3.13: Buffer composition used for Western blotting. 
Buffer Composition 
Anode buffer I 300 mM Tris, Methanol 10 % (v/v) 
Anode buffer II 30 mM Tris, Methanol 10 % (v/v) 
Cathode buffer 30 mM Tris, 40 mM Glycin, Methanol 10 % (v/v) 
PBS-Tween 1x PBS, Tween-20 (Polysorbate 20) 0.1 % (v/v) 
Blocking buffer 1x PBS, Tween-20 (Polysorbate 20) 0.1 % (v/v), milk powder 5 % (w/v) 
 
 
Table 3.14: Overview of primary/secondary antibodies used in Western blot with their dilutions.  
Primary antibody Dilution Secondary antibody Dilution 
α-NYBR-1 (C-18) 1:200 Donkey α-goat HRP conjugated 1:5000 
α-NY-BR-1#2 (Mouse) 1:500 Goat α-mouse IgG Pox conjugated 1:5000 
 
3.2.5.19 Silver staining – Mass spectrometry compatible  
After SDS–Page the gel was placed into a petri dish filled with fixation buffer (30 % ethanol, 
10 % acetic acid, 60 % aqua dest.) and incubated overnight. The fixation buffer was removed 
and replaced with sensitize solution (0.3 % (w/v) potassium tetrathionate, 0.5 M potassium 
acetate, 30 % ethanol) for 45 min. The gel was washed six times 10 min with aqua dest. 0.2 % 
(w/v) silver nitrate solution was added and incubated for 1– 2 h. The gel was washed 15 sec 
by rinsed aqua dest. Developing solution (3 % (w/v) potassium carbonate, sodium thiosulfate-
pentahydrate [10 %], formalin [37 %]) was administered and incubated between 5 – 10 min. 
The process was stopped by adding stop solution (4 % (w/v) tris, 2 % (v/v) acetic acid) for 45 
min. At the end the gel was washed twice 30 min with aqua dest. The whole silver staining 
process was done at room temperature. A photo was taken and the gel was stored in aqua dest. 
until mass spectrometry analysis. 
 
3.2.5.20 Protein complex immunoprecipitation (Co-IP) 
To identify specific protein interaction partners of NY-BR-1, co-immune precipitations were 
performed on lysates of pc3-NY-BR-1 and pcDNA3-empty vector transiently transfected cells 
(HEK293, MCF-10A, and MCF-7). 24 h after transfection the cells were lysed as described 
before (protein analysis). 30 µl A/G Plus agarose beads (Santa Cruz, sc 2003) were combined 
with either 200 µg lysate (for pre-clearing) or with 2 µg α-NY-BR-1 (C-18) antibody. The 
samples were filled up to 500 µl final volume with Co-IP buffer plus 1 mM DTT and 1 % 
PIC. The beads were incubated for 2 h at 4 °C while rotating. All beads were centrifuged for 
30 sec at 8000 rpm and 4 °C. The pre-cleared supernatant of the lysate incubation was filled 
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into a fresh pre-chilled tube. The beads were washed three times with 500 µl Co-IP buffer 
plus 1 mM DTT and 1 % PIC for 30 sec at 8000 rpm and 4 °C and stored as the first control at 
-80 °C. The supernatant of the samples, with the beads incubated with the antibody, was 
discarded and 450 µl of the pre-cleared lysate was added. The beads were incubated over 
night at 4 °C while rotating. The rest of the pre-cleared lysate was stored at -80 °C as a second 
control. 10 µl A/G Plus agarose beads were added additionally and incubated for 2 h at 4 °C 
while rotating. The beads were collected by centrifugation for 30 sec at 2500 rpm and 4 °C. 
The supernatant was stored as third control. The beads were washed three times with Co-IP 
buffer plus 1 mM DTT and 1 % PIC by inverting the tubes. The beads were centrifuged for 30 
sec at 800 rpm, 4 °C and the supernatants were stored as fourth, fifth and sixth control. 5x 
Laemmli sample buffer was added to the beads and they were heated for 10 min at 95 °C. The 
beads were centrifuged for 30 sec at 2500 rpm, 4 °C and the supernatant was collected (IP 
reaction). The beads were washed three times with 500 µl Co-IP buffer plus 1 mM DTT and 1 
% PIC for 30 sec at 8000 rpm, 4 °C and used as seventh control. Just the IP reaction of pc3-
NY-BR-1 and pcDNA3-empty vector transiently transfected cells was applied in triplicates on 
a SDS-Page for mass spectrometry analysis. Western Blot and mass spectrometry compatible 
silver staining were used to detect proteins after electrophoretic separation on polyacrylamide 
gels. Finally, an analysis of the proteins was done by mass spectrometry.  
  
The raw data, kindly provided from the Functional Proteome Analysis, German Cancer 
Research Center (DKFZ), INF 280, 69120 Heidelberg, Germany, contained information about 
accession number, protein description, score, mass [Da], protein matches, significant protein 
matches, protein sequences, significant protein sequences, and coverage [%]. The complete 
data set can be found in the laboratory of the Jäger group. To receive a better overview the 
raw data were analysed as followed: unique proteins in the NY-BR-1 fraction were taken and 
a cut-off was applied to a score of ≥ 40 and to significant protein sequences with a cut-off of 
at least two. Moreover, the unique proteins found in the NY-BR-1 fraction of each cell line 
were compared to each other to see which proteins are shared by either two or in all three cell 
lines. 
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Figure 3.1: Workflow to identify specific interaction partner of a protein of interest (adapted from 
(Free et al., 2009)). 
 
3.2.5.21 Immunohistochemistry (IHC) staining 
Formalin-fixed paraffin embedded (FFPE) tissue was used for the serial tissue sections and 
cryo-preserving for the stimulated tissue pieces. Therefore, the FFPE tissue, collected from 
breast reductions, was fixed overnight in 4 % buffered formalin and then placed into a tissue 
processor (Microm, STP 420D) (protocol see appendix). After sample processing the FFPE 
block was stored at room temperature until cutting. The thickness of the tissue section was 
between four-six µM. 
The tissue was fixed with Tissue-Tek OTC-Mounting medium (Sakura, Staufen) for tissue 
sections of cryo-preserved tissue. The tissue sections with 8-12 µm thickness were produced 
in a Kryostat-Mikrotom Microm 550 MVP (Thermo Fisher Scientific, Dreieich) between -20 
- -24 °C depending on the fat and connective tissue amount in the tissue itself. The tissue 
sections were brought to HistoBond+ (Marienfeld, Lauda Königshofen) slides. They were 
stored at -80 °C until staining. For staining the sections were fixed with 4 % PFA 20 min at 
room temperature in the dark. Afterward the slides were washed 6 times 10 min with 1x PBS.  
MeOH/EtOH was added for 10 min in a 1:3 ratio and the slides were dried at room 
temperature. At last TTX was added for 5 min.  
The staining of cryo-preserved or FFPE tissue with different kind of antibodies was done with 
the BOND-Max (Leica, Nussloch) detection system. The stained slides were scanned with 
NanoZoomer2.0-HT (Hamamatsu Photonics, Herrsching) and viewed with NanoZoomer 
Digital Pathology Virtual Slide Viewer-Program (Version 1.2.36, Hamamatsu Photonics, 
Herrsching). 
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Table 3.15: Antibodies with their specific dilutions and retrievals used for IHC staining on FFPE 
tissue. ER1 (Leica, AR9961) citrate based buffer, ER2 (Leica, AR9640) an EDTA based buffer. 
Antibody Dilution Retrieval 
ERα 1:1000 ER1 
Progesterone 1:250 ER1 
Ki-67 1:100 ER2 
α-NY-BR-1#2 1:50 (stock: 0.1 µg/µl) ER1 
 
 
3.2.6 In silico analysis 
3.2.6.1 Transcription factor binding 
By using the tool Alibaba 2.0, transcription factor binding sites can be predicted. The Alibaba 
algorithm uses a dataset of known binding sites to predict potential binding sites in any input 
sequence. This approach was shown to achieve high accuracy (Grabe, 2002). The Alibaba 2.0 
algorithm was used to predict transcription factor binding sites in the ANKRD30A promoter 
up to 2000 bp upstream of transcription start site. 
 
3.2.6.2 SNP Mining 
dbSNP is hosted by the National Center for Biotechnology Information (NCBI) and is the 
largest repository of SNP data with over 140 million submitted variations.  
Another source of variation data is provided by the “The National Heart, Lung and Blood 
Institute” (NHLBI). The protein coding regions of each individual genome (i.e. exome) is 
sequenced and the variation data is made publicly available (Dorschner et al., 2013).  
The Ensembl Variation database incorporates variation data from several sources including 
dbSNP and NHLBI ESP. The web interface MartWizard 
(http://central.biomart.org/martwizard/) of the BioMart Central Portal was used. 
The Ensembl transcript ID ENST00000611781 of the ANKRD30A gene was used to retrieve 
all available germline variations together with the corresponding genomic coordinates, the 
variant descriptions, and the validation status. Using the variant descriptions, coding non-
synonymous SNPs (nsSNPs), coding synonymous SNPs (sSNPs) and intronic SNPs were 
filtered.  
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3.2.6.3 Prediction of the functional impact of coding nsSNPs using SIFT, PROVEAN, and 
Polyphen 
The tools SIFT and PROVEAN are available online at http://provean.jcvi.org/. On the 
website, the tool PROVEAN Human Genome Variants, which provides PROVEAN and SIFT 
predictions for a list of human genome variants were used. The list of genomic coordinates 
and variants of our filtered 191 nsSNPs were submitted, and the default threshold of delta 
score <= -2.5 to detect deleterious variations was chosen. PolyPhen-2 is available online at 
http://genetics.bwh.harvard.edu/pph2/. Here, the option ‘Batch query’ was taken and the list 
of genomic coordinates and variants of our filtered 191 nsSNPs was submitted. 
The prediction tool SIFT evaluates the functional impact of SNPs based on sequence 
homology. The prediction is based on the degree of conservation of each amino acid residue 
of the query sequence. To assess the degree of conservation, SIFT compiles a dataset of 
functionally related protein sequences by searching the protein databases UniProt and 
TrEMBL using the PSI-BLAST algorithm and builds an alignment of the found sequences 
and the query sequence. In the second step a normalized probability for each substitution at 
each position of the alignment is calculated and is then recorded in a scaled probability 
matrix. This scaled probability is also called the SIFT score and a substitution is considered to 
be tolerated if the score is greater than 0.05; those less than 0.05 are predicted to be 
deleterious. The SIFT approach assumes that a highly conserved position is intolerant to most 
substitutions, whereas a poorly conserved position can tolerate most substitutions. 
The tool PROVEAN also uses an alignment approach to assess the functional impact of 
SNPs. For this, a set of homologous and distantly related sequences from the NCBI NR 
protein database is collected using BLASTP. To remove redundancy, the collected sequences 
are clustered, based on a sequence identity of 80 %. A so called supporting set of sequences is 
assembled by adding sequences from clusters most similar to the query sequence, until a 
sufficient number of clusters are achieved in the supporting set. In the second step, for each 
sequence in the supporting sequence set, a delta score is computed using the BLOSUM62 
substitution matrix. For each cluster, an average delta score is computed, and the averaged 
delta scores are again averaged among all clusters. This unbiased averaged delta score is the 
final PROVEAN score. The impact of a variation on protein function can be measured as the 
change in alignment score, the delta score. Low delta scores are interpreted as variations 
leading to a deleterious effect on protein function, while high delta scores are interpreted as 
variations with neutral effect. 
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PolyPhen-2 combines information on sequence features, multiple alignments with 
homologous proteins, and structural parameters to predict the impact of a SNP on protein 
function. For sequence-based assessment, PolyPhen-2 tries to identify the query as an entry in 
the UniProtKB/Swiss-Prot database. Using the feature table of the corresponding entry, 
PolyPhen-2 checks if a given SNP occurs at functional relevant site, e.g. if the SNP lies 
within a transmembrane, signal peptide, or binding region. For each variant PolyPhen-2 
calculates a position-specific independent counts (PSIC) score. The PSIC score difference 
between the two variants describes the impact of a particular amino acid substitution: the 
higher the PSIC score difference, the higher functional impact the substitution is likely to 
have. A BLAST query of the query sequence against protein structure databases is carried out 
to identify corresponding 3D protein structures. If corresponding structures are found, they 
are used to assess, whether the SNP is likely to destroy the hydrophobic core, interactions 
with ligands or other important features of the protein. Finally, all parameters are taken 
together and empirical prediction rules are applied to make the final decision, whether the 
SNP is damaging or benign. 
 
3.2.6.4 NY-BR-1 expression in breast cancer subtypes (Breast Cancer RNA-Seq Dataset) 
Varley et al. published a RNA-Seq study on recurrent read-through fusion transcripts in breast 
cancer. 168 samples were analysed in this study, including samples from estrogen positive 
(ER
+
) and triple negative breast cancer (TNBC), as well as samples from uninvolved adjacent 
tissues (Varley et al., 2014). All data generated in this study is available for download from 
the NCBI Gene Expression Omnibus (GEO) through accession number GSE58135.  
RNA-Seq raw reads were downloaded from the NCBI Sequence Read Archive 
(http://www.ncbi.nlm.nih.gov/sra) and aligned against the Gencode reference genome using 
STAR aligner. Subsequently, RNA abundances were assessed using the transcript per million 
(TPM) calculation. Significance of NY-BR-1 expression differences between the sample 
groups was assessed using a two-sided Student's t-Test (Varley et al., 2014). 
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4 Results 
 
The breast cancer associated antigen NY-BR-1 fulfils several criteria to be a target for 
immunotherapy. NY-BR-1 over-expression in primary breast tumours as well as in metastases 
and spontaneous humoral responses has been found. But up to date the biological function in 
healthy and breast tumour tissue is unknown. Therefore, our study aimed at describing this 
protein in more detail. The results of the molecular and functional characterization of NY-BR-
1 are presented in this chapter.  
One main focus in our study was to analyze how NY-BR-1 is transcriptionally regulated by 
combining in silico data with wet lab techniques. Functional assays like proliferation assay 
and cell cycle analysis were performed to observe the effect of NY-BR-1 overexpression in 
four transiently transfected cell lines. Co-IP of transiently transfected cells lines was done, 
followed by mass spectrometry analysis to get evidence for potential interaction partners of 
NY-BR-1. IHC stained healthy breast tissue and mammosphere generation was done to look 
at NY-BR-1 expression in potential progenitor cells. In silico analysis was administered to 
receive an overview of SNPs in the ANKRD30A gene and its assumed promoter, to show the 
exon coverage and to correlate NY-BR-1 expression data with methylation status, and 
expression data of other genes. An overview of the performed experiments is depicted in 
figure 4.1. 
 
Figure 4.1: Overview of the experiments to characterize NY-BR-1 on molecular and 
functional levels. 
 
4.1 NY-BR-1 expression pattern 
The NY-BR-1 expression pattern was analysed before on mRNA level in a panel containing 
different normal tissues. The results showed that NY-BR-1 is strongly expressed in the 
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mammary gland and testis (Jäger et al., 2001). Several different studies also looked at the NY-
BR-1 expression pattern in breast carcinoma samples. In one of the first studies 25 breast 
cancer samples were analysed with 21 samples being positive for NY-BR-1 on mRNA level 
(Jäger et al., 2001). Using quantitative and qualitative RT-PCR the second study could 
demonstrate that NY-BR-1 is over-expressed in 80 % of the patients. An additional 
microanalysis revealed that NY-BR-1 was up-regulated >2-fold in 69 % of the patients. IHC 
stainin in normal breast tissue revealed that the ductal epithelium of the mammary gland is 
weakly positive for NY-BR-1 (Seil et al., 2007).  
The endogenous NY-BR-1 expression was analysed in twelve different breast cell lines by 
qRT-PCR and Western blot. Four cell lines (MDA-MB-453/HTB 131, BT474, T47D, ZR-75-
30) were positive for NY-BR-1 expression on RNA level but this finding could not be 
confirmed on protein level (Seil, 2005). The publicly available RNA-Seq dataset by Varley et 
al. contained the RNA expression profile of 28 samples of breast cancer cell lines (Varley et 
al., 2014). Only in six breast cell lines (BT-474, MDA-MB-134, DY30T2, MDA-MB-361, 
ZR-75-30, MDA-MB-453) a weak NY-BR-1 gene expression was detected on RNA level.  
MCF-10A, MCF-7, HEK293 and HEK293T cell lines, used for the subsequent experiments, 
were tested in either qPCR or western blot. Except for MCF-7 (weakly NY-BR-1
+
) all cell 
lines were negative on RNA level (figure 4.2). NY-BR-1 could be detected on protein level in 
MCF-7 cells. Thus, no suitable cell culture system was available expressing endogenous NY-
BR-1. Therefore, the cells needed to be transiently transfected to peform certain experiments 
with facing the challenge that the transfection efficacy varies strongly between the cell lines 
and NY-BR-1 expression decreases rapidly after three to four days (figure 4.23). 
 
 
 
 
 
 
 
 
Figure 4.2: NY-BR-1 expression was analyzed by qPCR in MCF-7, MCF-10A and HEK293 cells. The 
NY-BR-1 expression was normalized against the housekeeping gene ß-Actin. HEK293T cells 
were tested before by Inka Seil (Seil, 2005). 
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Not only was the cell culture system a limiting factor but also the available tools for NY-BR-1 
detection in e.g. Western Blot. Beside one mon(Jäger et al., 2007) a polyclonal antibody (α-
NY-BR-1 (C-18)) is commercially receivable. Unfortunately, this antibody shows unspecific 
bindings in Western Blot. Also with α-NY-BR-1#2 antibody it was challenging to detect 
endogenous NY-BR-1 in Western Blot in different settings, e.g. stimulated healthy samples 
(figure 4.3A) and pleural effusion cells (figure 4.3B). It is noteworthy to mention that the NY-
BR-1 band of transfected cells is approximately at 180 kDa (A: lane 2, B: lane 1), whereas 
endogenous NY-BR-1 can be found at approximately 160 kDa (B: lane 3). 
  
 
 
 
Figure 4.3: Endogenous NY-BR-1 expression was analyzed by Western Blot in different samples. The 
α-NY-BR-1#2 antibody was used (A) 1:HEK293 transfected with pc3 empty vector, 2: HEK293 
transfected with pc3 NY-BR-1, 3: Ladder [kDa], 4: HD-T-203 not cultured, 5: HD-T-203 TSA, 6: HD-
T-203: Aza/VitD3, (B) 1: HEK293 transfected with pc3 NY-BR-1, 2: Ladder [kDa], 3: HD-A-90 
Progesterone 
 
The α-NY-BR-1#2 antibody is suitable for IHC staining and FACS analysis as shown in 
figure 4.4/figure 4.5 and as Seil et al. already reported (Jäger et al., 2007; Seil et al., 2007). 
 
4.1.1 IHC staining of healthy breast tissue 
Normal breast tissue is abounding in fat and connective tissue (figure 1.1). This can be a 
problem for cryo-preserved tissues: the production of tissue sections is difficult because the 
tissue section coils up while cutting and in the automated staining process (BOND system, 
Leica) the tissue sections tend to get off the slides or the tissue sections look disruptive. In 
normal breast tissue, only few luminal epithelial cells express NY-BR-1 as assessed by 
immunohistochemical staining with the α-NY-BR-1#2 antibody on FFPE tissue. In figure 4.4 
stained FFPE tissue sections of nine different healthy patients (HD-T-203 - HD-T-316) are 
shown. As indicated with the arrows the NY-BR-1 expression pattern is mosaic like.  
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Figure 4.4: IHC staining of FFPE tissue sections derived from nine healthy patientss. The nucleus is 
stained blue (haematoxylin) and the brown stained cells are NY-BR-1 positive. The tissues derived 
from breast reductions. The magnification is 20 fold. (‡: connective tissue, *: lumen of mammary 
gland, arrow: NY-BR-1 positive cells)  
 
4.1.2 IHC staining of breast cancer tissue or metastases 
The staining of breast cancer samples and metastases show a different NY-BR-1 expression 
pattern than in healthy breast tissue. Based on the fact that the different progenitor subsets in 
the mammary gland might be responsible for giving rise to the different molecular subtypes of 
breast cancer the expression level of NY-BR-1 will depend on the molecular subtypes. 
Therefore, some patients are negative or weakly positive for NY-BR-1 (1G01UQ, 6617), 
whereas patients HD-T-202 and 6646 are highly positive for NY-BR-1 expression. Patients 
6311 and 1OH7FL show a heterogeneous NY-BR-1 expression (figure 4.5). 
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Figure 4.5: IHC staining of FFPE tumour samples or metastases (HD-T-202) of breast carcinoma 
patients. The nucleus is stained blue (haematoxylin) and the brown stained cells are NY-BR-1 positive. 
The magnification is 10 or 20 fold.) (*: lumen of potential mammary gland, arrow: NY-BR-1 positive 
cells) 
 
4.2 How is NY-BR-1 transcriptionally regulated? 
 
4.2.1 In silico analysis of transcription factor binding 
Transcriptional regulation is a process occurring on many different levels. If a gene is 
transcribed depends on the methylation status of histones and CpG islands, transcription 
factor binding, SNPs and many more factors. The use of the Alibaba 2.0 tool formed the basis 
to get a more detailed look in the transcriptional regulation of the NY-BR-1 gene. This tool 
predicts transcription factor binding sites in the assumed promoter region of ANKRD30A as 
well as binding sites for nuclear hormone receptors and CpG islands (figure 4.6) (Grabe, 
2002). Table 4.1 summarizes all predicted transcription factors with the respective number of 
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binding sites in the NY-BR-1 promoter region up to 2000 bp upstream of the transcription 
start site. 
 
 
Figure 4.6: Predicted binding sites for nuclear hormone receptors and CpG islands in the promoter 
region of NY-BR-1 with Alibaba 2.0. (CpG Islands: genomic regions that contain a high frequency of 
CpG sites; HDAC Inhibitors: histone deacetylase inhibitors; VPA: valproic acid; TSA: trichostatin A; 
and T3R: thyroid hormone receptor) 
 
 
Table 4.1: Overview of all predicted transcription factors with the number of binding sites in the 
ANKRD30A promoter region by using the Alibaba 2.0 algorithm. 
Transcription 
factor 
Binding 
sites 
Transcription 
factor 
Binding 
sites 
Transcription 
factor 
Binding 
sites 
Transcription 
factor 
Binding 
sites 
Adf-1 2 E4 2 HOXA4 1 Oct-1 1 
AP-1 5 E47 1 HSF 2 Oct-2.1 1 
AP-2 2 Egr-1 3 ICSBP 1 Pit-1a 1 
AP-2α 7 ER 1 Krox-20 5 PR 1 
ATF 3 ETF 1 Max1 2 RAP1 4 
C/EBPα 13 GATA-1 3 MEB-1 2 RARβ 1 
C/EBPβ 3 GBF1 1 MEF-2 1 represso 1 
C/EBPγ 1 GCN4 1 Myf-3 1 RXRα 1 
c-Fos 3 GR 3 MyoD 4 SP1 68 
c-Jun 4 Hb 5 myogenin 2 T3R 1 
c-Myc 3 HEB 1 NF-1 18 TBP 2 
c-Rel 1 HNF-1 2 NF-muE1 2 USF 3 
dioxin r 1 HNF-1C 1 NF-κ 1 WT1 1 
Dl 1 HNF-3 5 NF-κB 2 YY1 4 
E1 4 HNF-3B 1 NRF-1 1     
 
Besides the nuclear hormone receptor binding sites, other interesting transcription factors 
such as AP-1, C/EBPα, C/EBPβ, C/EBPγ, c-Fos, c-Jun, c-Myc, GATA-1, HNF-3, Max1, SP1 
and YY1 have predicted binding sites in the promoter region. But the main focus in this 
project was on the nuclear hormone receptor binding sites because mammary glands are under 
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hormonal influence. Furthermore, Theurillat et al. could show that NY-BR-1 is co-expressed 
with ER in breast tumours (Theurillat et al., 2007). 
 
4.2.2 Stimulation assay 
To study the hormonal influence on transcriptional activation in vitro, several NY-BR-1 
negative or weakly positive breast cancer cell lines (T47-D, 226L, ZR-75-1, MCF-7) were 
stimulated for 72 h with different hormones and other agents (demethylation agent, histone 
deacetylation inhibitors) either alone or in combination. In these preliminary data NY-BR-1 
expression was analyzed by quantitative PCR with NY-BR-1 copy number normalization 
against the housekeeper gene cyclophilin-B. In figure 4.7, results of MCF-7 (weak NY-BR-
1
+
) and ZR-75-1 (NY-BR-1
-
) are shown as an exemplary representation of our data, generated 
by Thomas Giese (Department of Orthopaedics and Institutes of Immunology and Pathology, 
University of Heidelberg, Germany). The sequences of the used primer are described in 
Wallwiener et al (Wallwiener et al., 2011). Compared to the copy number of cyclophilin-B 
(~1000) the NY-BR-1 copy numbers range from one to 63, which is very low. This suggests 
that by stimulation with the respective agents no considerable transcriptional activation of 
NY-BR-1 was achieved. 
 
 
Figure 4.7: NY-BR-1 expression was analyzed in MCF-7 and ZR-75-1 cells after 72 h of incubation 
with 1µM 5’Aza, 200nM TSA, 1mM VPA and different hormones (10 nM E2, 1 µM progesterone, 1 
µM Dex, 1 nM VitD3, 1 µM retinoic acid). Cells stimulated just with the vehicle are serving as 
controls.  
 
The next step was to repeat the stimulation assays with normal mammary gland tissues 
derived from breast reductions. The idea was that in contrast to cell lines, primary tissues 
reflect the in vivo situation and maintain the natural environment of breast epithelial cells.  
Therefore, fresh needle biopsies of healthy mammary gland tissue derived from breast 
reductions of different female patients (18 to 64 years) were used. The tissue pieces were 
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cultured in phenol-free DMEM/F12 medium fully covered and stimulated over 2 to 48 hours 
with either 5’Aza, Dex, E2, VitD3 or in combination. The samples were then cryo-preserved 
and tissue sections were prepared for either immunohistological staining or RNA isolation to 
perform a quantitative PCR. Non-stimulated cultured tissue pieces as well as snap-frozen 
tissue pieces served as controls. As described at the beginning the cryo-preserved tissue 
sections were difficult to bring on a slide and were disrupted after staining. Therefore, a 
detailed analysis on protein level was not possible. 
For the qPCR analysis the following primer were used for ß-Actin and NY-BR-1 because the 
same annealing temperature could be used (the binding sites of the NY-BR-1 primer within 
the gene can be found in the appendix (figure 6.1)): 
 
Table 4.2: Oligos used for expression analysis with filemaker number of the AG Jäger laboratory; 
name of the gene of interest; forward/reverse sequence, melting temperature and size of the product. 
Filemaker 
number 
Gene Oligo-Sequence TM 
[°C] 
Size[bp] 
67 
68 
ß-Actin FW: 5´-GCGGGAAATCGTGCGTGACATT-3´ 
RV: 5´-GATGGAGTTGAAGGTAGTTTCGTG-3´ 
56.7 
55.7 
232 
100 
80 
NY-BR-1 FW: 5’-GAGGTGCTCCATCAACCACTTTC-3’ 
RV: 5’-TCATGAGTTTTCTGTTTCTGCTTTC-3’ 
57.1 
52.8 
456 
 
Other NY-BR-1 primer combinations were tested as well but they were excluded from 
analysis for three reasons: 
1. The water control was positive because of primer dimers and SYBR Green detects all 
double strands. 
2. The annealing temperature of both primer sets (NY-BR-1, housekeeping gene) was 
not compatible with each other. 
3. The melting curves of other primer combinations approved. 
 
4.2.2.1 Stiumulation of tissue pieces 
The stimulated tissue pieces were analysed via qPCR and IHC staining to overcome the 
heterogeneity of the tissue and to detect a difference of NY-BR-1 expression on protein level. 
The cryo-preserved tissue pieces could not be IHC stained in an adequate way because some 
of the tissue sections did not stick on the slides while staining was performed and due to high 
amount of fat and connective tissue the tissue sections were disrupted. Therefore, no cyrp-
preserved stimulated tissue pieces are shown.   
First, the two control tissues in culture without any additives (w.a.) versus snap-frozen tissues 
of tissue pieces derived from breast reductions of healthy patients are compared regarding 
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their NY-BR-1 expression (figure 4.8). The NY-BR-1 expression was normalized against the 
housekeeping gene ß-Actin because it is not regulated by NY-BR-1. The formula for 
normalization is described in 3.2.5.  The CP values of ß-Actin range in the tissue pieces 
between 16 and 24, in the isolated epithelial cells between 15 and 23, and in the pleural 
effusion cells between 14 and 24. 
The results indicate that NY-BR-1 expression is lost due to culturing because the non-cultured 
tissues have in almost all cases (except patient HD-T-177) a higher NY-BR-1 expression (CP: 
24-28) compared to the cultured tissues (CP: 26-31). It is of note that the tissues are very 
heterogeneous and differ in the amount of glands and therefore also in the amount of 
epithelial cells, which are considered to be involved in NY-BR-1 expression. To compare the 
effects on NY-BR-1 expression after applying certain agents the cultured but not stimulated 
tissues (w.a.) were taken as a control. 
 
 
 
 
 
 
 
 
Figure 4.8: NY-BR-1 expression in the controls of tissue pieces derived from healthy patients after 
breast reductions. The dark grey bars (without additives (w.a.)) represent the NY-BR-1 expression in 
tissues cultured as long as all tissues but no supplements were given. The light grey bars show the NY-
BR-1 expression in tissues never being in culture. 
 
The results of the hormonal stimulation of the tissue pieces are represented in figure 4.9A. It 
seems that 5’Aza (CP: 24) can up-regulate the NY-BR-1 expression in patient HD-T-176 
compared to the non-stimulated but cultured cells (w.a.). In all other patients no up-regulation 
in NY-BR-1 expression can be detected by adding 5’Aza (CP: 27-31). E2 stimulation in 
patient HD-T-177 (CP: 29) can cause a NY-BR-1 up-regulation but in all other patients (HD-
T-176, -178, -180, -258) (CP: 27-32) this effect could not be observed. Stimulation with Dex 
(CP: 27) has in patient HD-T-176 no effect on NY-BR-1 expression on RNA level. In all other 
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patients Dex and VitD3 down-regulate NY-BR-1 expression (HD-T-176 – HD-T-203) (Dex: 
(CP: 27-32), VitD3 (CP: 28-35)).  
Dex, E2, and VitD3 were also given in combination with the demethylation agent 5’Aza 
(figure 4.9 B). In two out of three patients the combination Aza/Dex (CP: 34/27) and Aza/E2 
(CP: 32/33) has a down regulatory effect on NY-BR-1 expression compared to the control. 
The level of NY-BR-1 expression increases as a result of Aza/VitD3 stimulation in two 
patients (HD-T-178/HD-T-180) (CP: 31/26) but the other two (HD-T-203/HD-T-258) (CP: 
28/33) show a decrease compared to the control. These opposed effects can be explained by 
the heterogeneity of each tissue piece and the amount of epithelial cells varying from patient 
to patient. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: A: Up- or down-regulation of NY-BR-1 expression of cultured tissue pieces derived from 
breast reductions of six healthy patients by adding specific substances. The non-stimulated tissue piece 
functions as control (w.a.) B: The stimulation of cultured tissue pieces with hormones combined with 
5’Aza. (1µM 5’Aza, 1 µM Dex, 10 nM E2, 1 nM VitD3) (†: no value available) 
 
Depending on the amount of obtained material, additional stimulations were carried out with 
either 1 µM progesterone, 1 µM retinoic acid, 200 nM TSA or in combination with 5’Aza 
(figure 4.10). The single agents down-regulate the NY-BR-1 expression in both patients, 
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whereas the combinations Aza/Progesterone (CP: 27/28) and Aza/TSA (CP: 25/31) up-regulate 
NY-BR-1. The combination Aza/Retinoic acid in patient HD-T-203 (CP: 27) results in a weak 
up-regulation, in patient HD-T-258 (CP: 31) in a down-regulation of NY-BR-1 compared to 
the control. 
 
 
 
 
 
 
 
 
Figure 4.10: Results of the stimulation experiments of cultured tissue pieces derived from breast 
reductions of two healthy patients with additional substances. The non-stimulated tissue piece 
functions as control (w.a.) (1 µM 5’Aza, 200 nM TSA, 1 µM progesterone, 1 µM retinoic acid (†: no 
value available). 
 
4.2.2.2 Stimulation of isolated epithelial cells 
As mentioned before the tissue pieces are very heterogeneous and the amount of glands can 
vary between each patient and even between the single tissue pieces. Moreover, during 
preparation it is difficult to distinguish between connective and glandular tissue. To receive a 
more homogeneous cell population it was decided to isolate epithelial cells from tissues 
derived from breast reductions of healthy patients. With this step connective tissue and fat 
cells will be diminished after adding a digestion mix containing collagenase (digestion of 
collagen in the ECM and hyaluronidase (digests hyaluronic acid, an important component of 
ECM of connective tissues. 
The single epithelial cells (luminal and myoepithelial cells) were taken into culture and 
stimulated with hormones or other agents for four to five days soon after isolation. Two 
patients could be analysed so far.  
As described before the two control cells in culture without any additives (w.a.) versus snap-
frozen cells are compared regarding their NY-BR-1 expression (figure 4.11). The results 
indicate that NY-BR-1 expression is lost due to culturing because in both cases the non-
cultured cells have a higher NY-BR-1 expression (CP: 26/25) compared to the cultured tissues 
(CP: 26/35).  
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Figure 4.11: NY-BR-1 expression in the controls of isolated epithelial cells derived from healthy 
patients after breast reductions. The dark grey bars (without additives (w.a.)) represent the NY-BR-1 
expression in cells cultured as long as all/cells but no supplements were given. The light grey bars 
show the NY-BR-1 expression in cells never being in culture. 
 
After stimulation with Aza (CP: 27), E2 (CP: 27) and Tamoxifen (CP: 35) a decrease in NY-
BR-1 expression can be observed in patient HD-T-292. With all other substances (Dex (CP: 
26), VitD3 (CP: 26), progesterone (CP: 25), retinoic acid (CP: 26), TSA (CP: 26), VPA (CP: 
28)) an up-regulation is detected compared to the control cells. The control cells of patient 
HD-T-311 are NY-BR-1
-
 (CP: 35). In patient HD-T-311 an up-regulation of NY-BR-1 can be 
observed with all applied agents with the highest increase induced by Tamoxifen (CP: 30) and 
the lowest by retinoic acid (CP: 31) (figure 4.12A). In the combination setting with 5’Aza 
almost no change is visible for patient HD-T-311 compared to the single stimulation except 
for Aza/Tamoxifen (CP: 35), which results in no detectable NY-BR-1 expression on RNA 
level. The same effect can be observed in patient HD-T-292. Aza/E2 (CP: 31) and 
Aza/retinoic acid (CP: 29) lower NY-BR-1 expression whereas all other combinations 
increase it compared to the non-stimulated cells in patient HD-T-292 (figure 4.12B). It is 
noteworthy that the general NY-BR-1 expression in both patients is very low due to a mixed 
cell population (myoepithelial/luminal cells) and not all cells express NY-BR-1 (figure 4.4).  
 
4 Results 
 
- 77 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: A: The effect on NY-BR-1 expression of isolated epithelial cells derived from breast 
reductions of two healthy patients by adding specific substances. The non-stimulated isolated 
epithelial cells functions as control (w.a.) B: The stimulation of isolated epithelial cells with hormones 
combined with 5’Aza. (1 µM 5’Aza, 1 µM Dex, 10 nM E2, 1 nM VitD3, 200 nM TSA, 1 mM VPA, 1 
µM progesterone, 1 µM Dex, 1 nM VitD3, 1 µM retinoic acid, 100 nM Tamoxifen) 
 
4.2.2.3 Stimulation of pleural effusion cells 
Tumour derived cells behave differently than healthy cells and as mentioned in chapter I 
“breast cancer” breast cancer cells also depend on the presence or absence of hormones. As 
primary breast cancer tissues were not available, pleural effusions of breast cancer patients 
were collected. The effusions contain different kinds of lymphocytes and tumour cells and are 
thus a valuable source for primary breast tumour cells. After depletion of macrophages the 
cells were cultured in 6 well plates and as soon as possible stimulated with different agents 
over a time period of 4-5 days. The “conditioned” cell culture medium contained cell free 
effusion supernatant and RPMI medium mixed in a 1:2 ratio. 
The two controls (cells in culture without any additives (w.a.) versus cells after depletion of 
macrophages and snap frozen uncultured cells) of pleural effusion derived from breast cancer 
patients (HD-A-58 – HD-A-88) are compared regarding their NY-BR-1 expression (figure 
4.13). The NY-BR-1 expression was normalized against the housekeeping gene ß-Actin. 
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Compared to controls of the tissues and isolated epithelial cells the opposite effect can be 
observed in the controls of pleural effusions: NY-BR-1 expression is lower in the uncultured 
cells than in the cultured cells in 6 out of 7 patients. In patient HD-A-66 no NY-BR-1 
expression is detectable (CP: 35) in both controls. The NY-BR-1 expression of non-cultured 
cells in patients HD-A-66 andHD-A-68 is not detectable (CP: 35) but in cultured non-
stimulated cells a weak expression (CP: 31/30) can be measured. Patient HD-A-86 has no NY-
BR-1 expression in w.a. cells (CP: 35) but a very low expression in non-cultured (CP: 34).  
The ß-Actin CP-values range from 14 to 24 depending on the patient.  
 
 
 
 
 
 
 
 
 
Figure 4.13: NY-BR-1 expression in the controls of pleural effusions derived from breast cancer 
patients at different stages of therapy. The dark grey bars (without additives (w.a.)) represent the NY-
BR-1 expression in cells cultured as long as all cells but no supplements were given. The light grey 
bars show the NY-BR-1 expression in snap-frozen uncultured cells. 
 
Figure 4.14A shows the results of the stimulation of seven different patients. The NY-BR-1 
expression on RNA level in patients HD-A-66, -68 and -86 is in general very weak or not 
existing (CP: 30-35). In patient HD-A-58 a high NY-BR-1 expression was observed (CP: 20-
24). 5’Aza (CP: 21), Dex (CP: 22), E2 (CP: 21) and VitD3 (CP: 21) up-regulate NY-BR-1 
expression in patient HD-A-58, whereas progesterone (CP: 22), retinoic acid (CP: 22) and 
TSA (CP: 20) down-regulate it compared to the control (w.a.). In patients HD-A-73 and HD-
A-88 a weak effect induced by TSA (CP: 23) can be observed, which down-regulates the NY-
BR-1 expression. In patient HD-A-78 a clear down-regulation can be detected after adding 
Dex (CP: 23), progesterone (CP: 22), retinoic acid (CP: 22) and TSA (CP: 22) compared to the 
non-stimulated cells. 
Also the pleural effusion cells were stimulated with 5’Aza in combination with all other 
agents (figure 4.14B). The combinations Aza/Dex (CP: 21-24) and Aza/TSA (CP: 22-24) 
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down-regulate the NY-BR-1 expression in patients HD-A-58, -78 and -88. All other 
combinations (Aza/E2 (CP: 21), Aza/VitD3 (CP: 20), Aza/Progesterone (CP: 22), Aza/Retinoic 
acid (CP: 21)) induce an up-regulation of NY-BR-1 in patient HD-A-58 with Aza/Retinoic 
acid inducing the strongest effect. Aza/E2 (CP: 21/22) and Aza/Progesterone (CP: 23) seem to 
down-regulate the expression in two patients (HD-A-78 and HD-A-88). The cells of patient 
HD-A-73 do not show a definite effect after adding the combinations except for Aza/TSA 
(CP: 23), which down-regulates the NY-BR-1 expression compared to the control. The 
combined stimulated cells of HD-A-66/68/86 just have a low NY-BR-1 expression (CP: 30-
35). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: A: The effect on NY-BR-1 expression in pleural effusion cells derived from breast cancer 
patients at different stages of therapy. The non-stimulated cells functions as control (w.a.) B: The 
stimulation of pleural effusion cells with hormones combined with 5’Aza. (1 µM 5’Aza, 1 µM Dex, 10 
nM E2, 1 nM VitD3, 200 nM TSA, 1 µM progesterone, 1 µM Dex, 1 nM VitD3, 1 µM retinoic acid) (†: 
no value available)  
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Due to a higher amount of obtained cells from four patients it was possible to test other 
stimulation agents like Tamoxifen and VPA, also in combination with 5’Aza (figure 4.15). 
All tested agents down-regulate NY-BR-1 expression compared to the control in patient HD-
A-88 with Aza/VPA (CP: 23) having the strongest effect. In all three patients (HD-A-73, -78, 
-88) a down-regulation could be detected after adding the HDAC inhibitor VPA (CP: 22-23). 
Tamoxifen (CP: 21), which binds to oestrogen receptor, and Aza/Tamoxifen (CP: 22/21) 
results in an up-regulation of NY-BR-1 expression in two patients (HD-A-73 and HD-A-78). 
Aza/VPA does not affect NY-BR-1 expression in patient HD-A-78 (CP: 21) and shows a 
weak effect in patient HD-A-73 (CP: 22). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Results of the stimulation experiment of pleural effusion cells derived from breast cancer 
patients with additional substances. The non-stimulated cells function as control (w.a.). (1 µM 5’Aza, 
1 mM VPA, 100 nM Tamoxifen) 
 
Approximately two months later another pleural effusion from patient HD-A-88 was obtained 
(HD-A-90). Due to the high amount of cells time kinetics (6,8,10, 12 h) were performed with 
E2, progesterone, VitD3, retinoic acid, VPA, TSA and in combination (figure 4.16). The 
primary tumor was scheduled as triple positive (ER/PR/HER2). The highest up-regulation of 
NY-BR-1 compared to the controls can be achieved with E2 (6 h) (CP: 21), progesterone (6, 8, 
and 12h) (CP: 21, 23, 21), VitD3 (6, 8, and 12h) (CP: 23, 23, 22), retinoic acid (6 and 12 h) 
(CP: 23, 22), and VPA (6 and 12 h) (CP: 24, 22). The combinations VPA/Progesterone (CP: 
24, 24, 24, 22), VPA/VitD3 (CP: 24, 23, 23, 22) seem to up-regulate NY-BR-1 expression 
throughout the whole time period but to a lower extent than the single applied hormones. 
Many combinations with TSA (TSA/E2, VPA/TSA/E2, VPA/TSA/Progesterone, TSA/VitD3, 
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VPA/TSA/VitD3, VPA/TSA/Retinoic acid) seem to inhibit NY-BR-1 expression at specific 
time points.  
 
Figure 4.16: The effect on NY-BR-1 expression in pleural effusion cells derived from a triple positive 
breast cancer patient after stimulation with different agents. A time kinetic was performed to analyze 
whether the effect on NY-BR-1 expression will change over time after adding specific hormones and 
HDACs inhibitors. The non-stimulated (w.a.) and uncultured (no culture) cells function as controls.  
 
4.2.2.4 Characterization of pleural effusion cells 
As described in chapter 1.4 breast tumours are characterized by different molecular subtypes 
and due to these subtypes therapy needs to be adjusted. The pleural effusion cells were 
obtained from breast carcinoma patients and thus they have a specific molecular subtype 
pattern. In table 4.3 the characteristics of the primary tumours is summarized.  
 
Table 4.3: Summary of the characteristics of the primary tumours of the patients whereof the pleural 
effusions were obtained. The breast cancer classification is done according to TNM staging. The 
receptor status is calculated either with IRS score, Allred score or given in percent. (ID: 
Identification, T: Tumor, N: Lymph node, M: Metastases, G: Grade, -: negative, NA: not available) 
ID Diagnosis Material T N M G ER PR Her2 p53 bcl-2 Ki 67 Histological 
type 
HD-
A-58 
MaCa 
2006 
Ascites 4 3 0 2 - - -  NA  NA NA  invasive 
lobular 
HD-
A-66 
MaCa 
2004 
Pleural 
effusion 
4 3   2 90% 30% 0 0 0 5% invasive 
ductal 
HD-
A-68 
MaCa 
2010 
Ascites 2 0 0 2 12 12  -  NA NA  NA  invasive 
ductal 
HD-
A-73 
MaCa  Ascites 3 3 1 2 12 6 2+ NA   NA  NA invasive 
lobular 
HD-
A-78 
MaCa  Ascites 2 3 1 NA  9 6 - NA  NA  10% invasive 
lobular 
HD-
A-86 
MaCa  Ascites  NA  NA NA   NA 0/8  3/8 - 0 0 60% invasive 
ductal 
HD-
A-88 
MaCa Ascites 2 0 1  NA 100% 100% 1+ 5% 3 30% invasive 
ductal 
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In FACS analysis α-NY-BR-1#2 (mouse) antibody was used for intracellular (IC) and 
extracellular/surface (EC) staining, a surface staining was done for EpCAM and for HER2 
and an IC staining with mouse α-human  Cytokeratin 14, 15, 16, and 19-PE. Here, exemplary 
results are shown for three different patients (figure 4.17). In all measurements the red line 
represents the isotype control and the blue line indicates the results of particular 
receptor/protein of interest. A gate was set in the FSC/SSC setting to get the tumour cells for 
further analysis (figure 4.17A). In figure 4.18B the results for the CK (EC) staining are shown 
and HD-A-73/88 are negative for all tested CK and a small population is positive for CK in 
patient HD-A-68. All three patients are positive for HER2 (figure 4.17C) and except patient 
HD-A-68 also for EpCAM (figure 4.17C/D). In figure 4.18E/F the results of the NY-BR-1 
staining is shown and all three patients are NY-BR-1 negative on the surface but patient HD-
A-73 and HD-A-88 are intracellular positive for NY-BR-1. HD-A-68 is completely NY-BR-1 
negative. 
 
 
Figure 4.17: Results of the FACS analysis of pleural effusion cells of three patients. A: A gate was set 
to receive the tumour cell population for further analysis. B: Intracellular cytokeratin 14, 15, 16, and 
19 staining. C: Patient HD-A-68/73: Cell surface Her2 staining, Patient HD-A-88: Her2 (orange) and 
EpCAM (blue) staining. D: Patient HD-A-68/73: cell surface EpCAM staining. E: Cell surface NY-
BR-1 staining. F: Intracellular NY-BR-1 staining. (red line: appropriate isotype, blue line: results of 
the staining of the protein/receptor of interest. 
 
Due to therapy applications and time the expression of the receptor can change. Therefore, the 
pleural effusion cells were characterized again by qPCR analysis. The Her2, ERα, PR and 
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integrin-α 6 expressions were normalized against the housekeeping gene ß-Actin. The CP 
values of ß-Actin range in these analyses between 14 and 21. Integrin-α 6 was chosen because 
this integrin is a progenitor marker of basal/bipotent cells in human breast cells (Stingl et al., 
2006). The CP values of HER2 range between 16 and 27 (figure 4.18A), for ERα between 30 
and 35 (figure 4.17B), for PR between 28 and 35 (figure 4.18C), for integrin-α6 22 and 31 
(figure 4.18D). The HER2 expression is in some samples (HD-A-88/90) the highest compared 
to the other samples but also compared to ERα, PR and intgrein-α 6 expression. The missing 
samples of ERα (HD-A-86, -88, -90), PR expression (HD-A-86, -88, -90) and integrin-α 6 
(HD-A-78) could not be analysed due to poor melting curves.  
 
 Figure 4.18: Receptor status analysis in pleural effusion cells by qPCR. A: Pleural effusion cells of 
eight patients were tested regarding their Her2 expression level. B: Pleural effusion cells of five 
patients were tested regarding their ERα expression level. C: Pleural effusion cells of five patients 
were tested regarding their PR expression level. D: Pleural effusion cells of seven patients were tested 
regarding their integrin-α 6 expression level. (Patient HD-A-75 correlates to patient HD-A-73) 
 
 
In transiently transfected cell lines NY-BR-1 expression is lost after three to four days (figure 
4.24). Therefore, it was interesting to analyse how quickly NY-BR-1 expression is down-
regulated or whether it can be maintained by culturing with conditioned medium in pleural 
effusion cells. 
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The cells of patient HD-A-26 were cultured for at least four weeks with conditioned medium 
and the NY-BR-1 expression on day zero, 11, 14, 18, 22 and 28 was analysed by qPCR. The 
CP value at day zero is 20 and decreases to 23 at day 28 (figure 4.19). The ß-Actin CP values 
range between 14 and 15. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Time kinetic of pleural effusion cells of patient HD-A-26 analysed by qPCR. The cells 
were tested regarding their NY-BR-1 expression. 
 
Summarizing these results, it is important to consider that in vitro culturing affects the NY-
BR-1 expression in tissue pieces, isolated epithelial cells and pleural effusion cells. The effect 
on NY-BR-1 expression of a specific agent is depending on the setting: healthy vs. tumour 
cells or hormone sensitive vs. hormone negative. In general it could not be demonstrated that 
a substance generally leads to an up- or down-regulation of NY-BR-1 expression.  
In table 4.3 the characterization of the primary tumour of each patient is summarized to give 
an overview of the grading and receptor status. The qPCR data of the pleural effusion cells 
showed that the receptor status, analysed on RNA level, has changed compared to the analysis 
of the primary tumour. NY-BR-1 expression can be mainly detected intracellulary via FACS 
analysis and time kinetics showed that NY-BR-1 is detectable over several weeks when 
cultured with conditioned medium. 
 
4.2.2.5 Methylation status analysis 
Methylation in the promoter region is an important regulatory mechanism in the transcription 
machinery. High methylation in a promoter region blocks transcription activation, whereas 
methylation downstream of the transcription start site enhances gene activation (Armstrong, 
2014).  
The methylation pattern can alter the transcription initiation and thus it was investigated 
whether a specific methylation pattern can be detected and correlated to NY-BR-1 expression 
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in stimulated samples. DNA was isolated from selected stimulated samples and bisulfit 
conversion was done. The methylation status of various fragments in the promoter region of 
NY-BR-1 was analysed using the EpiTYPER – MassARRAY technology in collaboration 
with the group of C. Gerhäuser, German Cancer Research Center. Amplicons were designed 
up to 1300 bp upstream from the transcription start site. As the promoter region has many 
repetitive elements, only six amplicons (number 53-58) could be designed and used for 
analysis (figure 4.20). Amplicons 55-57 are located in the CpG islands of the NY-BR-1 
promoter. 
 
Figure 4.20: Overview of the designed amplicons with their binding sites. Amplicons number 54-58 
with the full black bar were used for analysis. 
 
The methylation status of several stimulated samples of pleural effusion cells (HD-A-73 and 
HD-A-78) and isolated epithelial cells (HD-T-292) were analysed in various amplicons in the 
promoter region of NY-BR-1 (figure 4.21). The median amplicon methylation was calculated 
and single dots represent different experimental settings. They are connected by lines for a 
better classification. Values on the y-axis indicate the percentage of methylation with one 
representing a 100 % methylation.  
Interestingly, the amplicon 58, which ranges from the promoter over to the transcription start 
site, is highly methylated (median 1.0) in all samples except for patient HD-A-73 after 
Aza/TSA (median 0.4) stimulation. NY-BR-1 expression is decreased in this sample 
compared to the control cells as the qPCR results show (figure 4.14). In amplicon 57 
differences between each patient become visible. All patients show a lower methylation 
compared to amplicon 58 (median around 0.9). Patient HD-A-73 has a lower methylation 
status after TSA application (median 0.8) but an increase after VPA (median 1.0) stimulation 
in amplicon 57. In both cases the NY-BR-1 expression is lower compared to the control cells. 
In patient HD-A-78 an increase of methylation is observed after 5’Aza stimulation (median ~ 
0.98) compared to the control cells, which is striking because 5’Aza is a demethylation agent. 
The combination Aza/VPA decreases the methylation (median 0.8) in patient HD-A-78 in 
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amplicon 57. The NY-BR-1 expression is higher with 5’Aza stimulation and with Aza/VPA it 
stays the same. The isolated epithelial cells of patient HD-T-292 have a methylation increase 
after Aza/VPA) stimulation (median ~0.98). All samples detected with amplicon 56 have a 
decreased methylation pattern compared to all other amplicon areas (median between 0.2 and 
0.4). In patient HD-T-292 the methylation is decreased by Tamoxifen stimulation (median 
0.1) but slightly increased with Aza/VPA (median 0.25). Also in patient HD-A-78 a weak 
increase of methylation can be observed with Aza/VPA (median 0.4) stimulation in amplicon 
56 compared to the control cells (median 0.29). After TSA or Tamoxifen stimulation a 
decreased methylation pattern of approximately 50 % (meodian 0.5) is observed in patient 
HD-T-292 in the area of amplicon 55. Patient HD-A-78 has an increased methylation after 
Aza/TSA (median 0.9) stimulation in amplicon 55. In amplicon area of 54 a demethylation 
occurs by TSA stimulation in patient HD-A-73 but not in the other two patients. Tamoxifen 
induces a demethylation (median ~ 0.6) in patient HD-A-78 compared to the control cells 
(median 0.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Methylation status analysis of stimulated pleural effusion cells (HD-A-73/78) and 
isolated epithelial cells (HD-T-292) of various fragments in the NY-BR-1 promoter region up to 1300 
bp upstream of transcription start site. Median amplicon methylation values were calculated for all 
samples (1=100%). 
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To summarize this part of the results: no unique methylation pattern can be related to NY-BR-
1 expression after a certain stimulation agent was applied. The effects on NY-BR-1 up- or 
down-regulation by an agent vary from patient to patient and from cell subset to cell subst. 
Moreover, in pleural effusion cells the receptor status of the cells self and not compulsory the 
receptor status of the primary tumour needs to be considered.  
 
 
4.3 The effect of NY-BR-1 over-expression on proliferation and on the cell cycle 
4.3.1 Proliferation assay 
Preliminary data from soft agar assays (Group of Professor Jäger) revealed that transient over-
expression of NY-BR-1 in contrast to controls leads to colony formation suggesting that NY-
BR-1 may play a role in tumourgenesis in vitro.  
To test the effect of NY-BR-1 over-expression in more detail, proliferation assays were 
performed and cells were analysed by flow cytometry. In contrast to soft agar assays, the 
transfection efficiency can be determined very quickly, the analysis of all settings is fast, 
single cell populations can be analysed, NY-BR-1
+
 cells can be discriminate from NY-BR-1- 
cells in one cell population, different kind of settings can be applied at once (e.g. 
proliferation, apoptosis).  
Four different cell lines, the normal epithelial embryonic kidney cell line HEK293, and the 
normal epithelial breast cell line MCF-10A as well as the epithelial embryonic kidney, 
containing the SV40 large T-antigen, cell line HEK293T and the breast cancer cell line MCF-
7  were transiently transfected with the pc3 NY-BR-1 GFP plasmid. The cells were labeled 
with the proliferation marker PKH26, which stably incorporates a yellow orange fluorescent 
dye with long aliphatic tails into lipid regions of the cell membrane (Wallace et al., 2008). 
During cell proliferation the PKH26 dye gets distributed equally between daughter cells and 
the intensity decreases with each division. The cells were kept in culture over a time period of 
one to six days and prior to flow cytometric analysis, they were labeled with 7-AAD and 
Annexin V APC to determine the living/dead and apoptosis ratio. Non-transfected and pc3 
GFP transfected cells served as controls. The evaluation was done with the software Flowjo 
7.6.5. Exemplary results are shown for the two cell lines HEK293 and MCF-7, results for 
MCF-10A and HEK293T cells are in the appendix (figure 6.3-6.6). 
The following settings for the flow cytometric analysis were applied: forward (FSC)/sideward 
(SSC) scatter to discriminate the cells due their size and density, PKH26 (PE)/GFP (FITC) to 
separate the cells into GFP positive/negative. The next step was to analyse the proliferation 
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profile of each population on all days with PKH26 (PE)/Count in a histogram. The last setting 
was Annexin (APC)/7-AAD to detect the amount of live/dead and apoptotic cells (see 
3.2.3.5). 
The first gate comprised of almost the whole cell population, just leaving the cell debris out 
(figure 4.22A). This population was divided into GFP
+ 
and GFP
- 
cells (figure 4.22B) and 
analyzed for PKH26 fluorescence (figure 4.22C). The cells were labeled with 7-AAD, a 
live/dead cell marker, and Annexin V, an apoptosis marker (figure 4.22D). The left lower 
quadrant contains the cells, which are 7-AAD and Annexin V negative. The left upper 
quadrant represents the cells, which are 7-AAD positive but Annexin V negative. The right 
upper quadrant shows the double positive cells-cells, which are dead through apoptosis. The 
7-AAD negative but Annexin V positive cells are shown in the right lower quadrant.  
The PKH26 labeling decreases from day one to day six and this indicates that the 
untransfected HEK293 cells (GFP
-
) proliferate. The main cell population is 7-AAD/Annexin 
V negative (80-89 %) in all checkpoints. The double positive cell population decreases from 6 
% (day one) to 0.7 % (day six), therefore the 7-AAD cell population increases from 3.9 % to 
9.6 %. The apoptotic cell rate (Annexin V positive) decreases from 3.9 % to 0.8 %. The 
untransfected cells are vital and just a small part of the population is dying due to apoptosis. 
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Figure 4.22: Overview of the proliferation assay of untransfected HEK293 cells. A: Selected cell 
population for further analysis leaving without cell debris. B: The cell population divided into GFP 
positive/negative cells for further analysis. C: Proliferation analysis of the GFP negative cell 
population from day one to day six. D: Cell population staining with 7-AAD and Annexin V to 
discriminate between living/dead and apoptotic cells. 
 
 
The same was done with the pc3 GFP transfected HEK293 cells as described above. The GFP 
transfected HEK293 cells are here shown exemplary for all other cell lines. The GFP
-
 cell 
population was analyzed independently from the GFP
+
 population. The GFP
+
 population 
decreases over the measured time from 22.6 % to 15.7 % (figure 4.23B). The PKH26 amount 
decreases as well in both populations leading to the conclusion that both cell populations 
proliferate (figure 4.23C). The main GFP
-
 population is double negative ranging from 80.9 % 
to 87.7 %. The amount of double positive cells decreases from 10 % to 0.6% on day six. The 
same can be observed in the GFP
+
 population with 69 % to 95 % double negative for 7-AAD 
and Annexin V and a decrease of the double positive cells from 4 % on day one to 0.1% on 
day 6 (figure 4.23D). The results show that the transfection itself had no influence on the 
proliferative manner of the cells and is not increasing the apoptosis rate. 
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Figure 4.23: Overview of the proliferation assay of HEK293 pc3GFP transfected cells. A: Selected 
cell population for further analysis leaving without cell debris. B: The cell population divided into 
GFP positive/negative cells for further analysis. C: Proliferation analysis of the GFP negative cell 
population from day one to day six. D: Cell population staining with 7-AAD and Annexin V to 
discriminate between living/dead and apoptotic cells. 
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The HEK293 cells were also transfected with pc3 NY-BR-1 GFP and analysed the same way 
as the untransfected and pc3 GFP transfected cells. Although the NY-BR-1 positive cells 
decrease rapidly, starting on day one with 11.6 % ending with 0.39 % on day six (figure 
4.24B), the proliferation profile of both populations (NY-BR-1 negative vs. positive) could be 
analysed. The NY-BR-1 GFP negative population shows the same proliferative profile as the 
untransfected and GFP transfected cells: they proliferate over throughout the whole 
observation time. The NY-BR-1 GFP positive population does not proliferate at all (figure 
4.24C). Both cell populations are mainly 7-AAD/Annexin negative. 7.7 % of the NY-BR-1 
GFP negative population is double positive with decreasing incidence until day six (0.48 %). 
The NY-BR-1 GFP positive population contains 1.6 % double positive cells on day one and 
declines to 0.9 % on day six. It is worth to mention that the 7-AAD positive cell population 
increases over time in both populations (NY-BR-1 GFP
-
: 3.9 -15.5 %, NY-BR-1 GFP
+
: 0.4 – 
4.7 %), whereas the Annexin V positive population decreases (NY-BR-1 GFP
-
: 6.9 -0.3 %, 
NY-BR-1 GFP
+
: 8.8 – 1.9 %) (figure 4.24D). 
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Figure 4.24: Overview of the proliferation assay of HEK293 pc3NY-BR-1 GFP cells. A: Selected cell 
population for further analysis leaving without cell debris. B: The cell population divided into GFP 
positive/negative cells for further analysis. C: Proliferation analysis of the GFP negative cell 
population from day one to day six. D: Cell population staining with 7-AAD and Annexin V to 
discriminate between living/dead and apoptotic cells. 
 
As NY-BR-1 is over-expressed in approximately 70 % of all breast tumors, the effect of NY-
BR-1 over-expression on the proliferation was also analysed in the breast cancer cell line 
MCF-7.   
In general, the MCF-7 cell line is growing slower compared to the HEK293 cell line in our 
culture system. The measured cells were gated to leave the cell debris out (figure 4.25A) and 
then divided into GFP
+/-
 population for further analysis (figure 4.25B). In figure 4.25C the 
untransfected MCF-7 cells loose the proliferation marker PKH26 from day one to day six 
indicating that they proliferate. The main population can be found in the double negative 
compartment at all times but a lot of cells are also double positive ranging between 33.2 % on 
day one, dropping to 3.8% on day two but increasing to 28.6 % on day six. The single 7-AAD 
positive population rises up from 5 % (day one) to 22 % (day six) but the Annexin V positive 
population decreases from 7.9 % (day one) to 2.4 % (day six) (figure 4.25D). Taken these 
results together, the MCF-7 untransfected cells proliferate but due to culturing or labeling a 
higher population is apoptotic or dead compared to the HEK293 non-transfected cells. 
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Figure 4.25: Overview of the proliferation assay of untransfected MCF-7 cells. A: Selected cell 
population for further analysis leaving without cell debris. B: The cell population divided into GFP 
positive/negative cells for further analysis. C: Proliferation analysis of the GFP negative cell 
population from day one to day six. D: Cell population staining with 7-AAD and Annexin V to 
discriminate between living/dead and apoptotic cells. 
 
Breast cell lines are in general difficult to transfect. That is the reason why the transfection 
efficacy is low (16.7 % day one) and NY-BR-1 GFP expression is lost during the 
measurements (1.89 % day six) (figure 4.26B). The NY-BR-1 GFP negative cell population 
proliferates but the NY-BR-1 GFP positive population does not (figure 4.26C). The 7-
AAD/Annexin V staining of the NY-BR-1 GFP negative population shows that a lot of cells 
are double negative (37.9 – 52.9 %). The amount of the double positive cells drops down 
starting at 32.4 % on day one and ending at 23.3 % on day six. The 7-AAD cell population 
ranks around 20 % on all days, whereas the Annexin V positive population of the NY-BR-1 
GFP negative cells decreases from 11.2 % (day one) to 3 % (day six). The 7-AAD/Annexin 
staining of the NY-BR-1 positive cell population shows that the double positive cells increase 
from 15 % (day one) to 23.8 % (day six) while dropping down in between to 8.4% on day 
three. Also the single positive cells for 7-AAD or Annexin V increase from day one to day six 
but decrease on day two and three (figure 4.26D). 
4 Results 
 
- 94 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26: Overview of the proliferation assay of MCF-7 pc3NY-BR-1 GFP cells. A: Selected cell 
population for further analysis leaving without cell debris. B: The cell population divided into GFP 
positive/negative cells for further analysis. C: Proliferation analysis of the GFP negative cell 
population from day one to day six. D: Cell population staining with 7-AAD and Annexin V to 
discriminate between living/dead and apoptotic cells. 
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The results of all four cell lines show that the non-transfected, GFP transfected and NY-BR-1 
GFP transfected but being NY-BR-1 GFP negative cells are proliferating compared to the 
NY-BR-1 GFP positive cells. Moreover, the double positive cells (7-AAD/Annexin V) 
decrease over time except for in MCF-7 cells. 
 
4.3.2 Cell cycle analysis 
The cell cycle can be divided into the interphase (cell prepares for cell division), the mitotic 
phase (cell splits in two cells) and cytokinesis (describes the fully divided cells). In cell cycle 
analysis by flow cytometry the differences of DNA content are measured. The DNA content 
reveals information about cell ploidy, cell position in the cell cycle and shows the amount of 
apoptotic cells because their DNA is fractional. As shown in figure 4.27 four different phases 
can be discriminate in cell cycle analysis. The sub G1 peak (“sub-diploid”) represents the 
dead cells due to the fact that apoptotic cells have fragmented mono- and oligo-nucleosomal 
DNA. In normal dividing cells the G0/G1 peak shows the cells in the pre-replicative cells. At 
this point the biosynthesis rate will be the highest and the duration of how long a cell stays in 
this phase can vary from cell to cell. During the S phase the DNA replication actually starts 
and the cells checks whether it is ready to enter the mitotic phase (G2 +M) (Darzynkiewicz et 
al., 2010). 
 
 
 
 
  
 
 
Figure 4.27: Schematic representation of the unique cell cycle phases (left) and its display in cell 
cycle analysis by flow cytometry (right). (adapted from (Darzynkiewicz et al., 2010) ) 
 
The dye PI was used to analyse the cells. PI intercalates with the DNA bases but also with 
RNA. Therefore, RNase was added after EtOH fixation to ensure that only the DNA content 
is analysed (see 3.2.3.3).  
The results of the proliferation assay showed no proliferation of NY-BR-1
+
 cells and also 
almost no increase in dead or apoptotic cells. Therefore, a cell cycle analysis of all four cell 
lines (HEK293, HEK293T, MCF-7, and MCF-10A) was performed to analyse whether these 
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cells undergo G1 phase arrest. Here, two cell lines (HEK293, MCF-7) are shown exemplary. 
The other two analysed cell lines can be found in the appendix (figure 6.7-6.10) 
The cells were transiently transfected with either pc3-NY-BR-1-GFP or pc3 GFP plasmid and 
fixed after 24 h with ice cold EtOH. RNase digestion was done followed by a staining with PI 
(living/death marker). The cells were analysed by FACS and Flowjo. Non-transfected cells 
function as a control. The pc3 GFP transfected cells could not be analysed because the GFP 
was washed out during EtOH fixation due to the small size of the protein.  
The whole cell population (figure 4.28A) was separated into GFP positive and GFP negative 
cells (figure 4.28B). A gate was set (PI-Area vs. PI-Width) on the discriminated cell 
population to leave duplets and cell debris out (figure 4.28C). The accumulation of the cells in 
the single phases is shown in figure 4.28D of all three days. Between 2.84 % and 4.49 % of 
the HEK293 non-transfected cells can be found in the sub G1 phase. Around 50 % of the 
analysed cells are detected in the G1 phase on all three days. Between 9.9 % and 14.9 % of 
the cells prepare themselves for DNA replication and are represented in the S phase. The 
amount of cells accumulating in the G2 phase varies between 26.6 % and 37.3 %. 
 
 
 
 
Figure 4.28: Results of the cell cycle analysis of HEK293 non-transfected cells. A: Showing the cell 
population for further analysis taking all cells into account. B: The cell population divided into GFP 
positive/negative for further analysis. C: Gates set to leave the duplets and cell debris out. D: Cell 
cycle analysis dividing the cells into subG1, G1, S, and G2 phase after PI staining. 
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The same analysis was carried out with the pc3 NY-BR-1 GFP transfected cells. Here some 
differences are revealed compared to the non-transfected cells. First of all the measured cells 
were divided into NY-BR- GFP positive vs. negative cells (figure 4.29B). The gate was set to 
leave the duplets and cell debris out (figure 4.29C) and with this population the cell cycle 
analysis was done.  
The amount of cells in the sub G1 phase of the NY-BR-1 GFP negative population decreases 
from 13.2 % (day one) to 5.28 % (day three). Around 55 % of this population accumulate in 
G1 phase during all three measuring points. Between 4.36 % and 10.4 % of the cells are in S 
phase and between 23.1 % and 32.5 % of the cells are found in G2 phase. The cells present in 
the sub G1 phase of the NY-BR-1 GFP positive cell population increase from 1.14 % (day 
one) to 3.36 % (day three). Compared to the NY-BR-1 GFP negative cells more cells of the 
NY-BR-1 GFP positive population accumulate in G1 phase (between 67.1 % and 74.4 %). 
Approximately 4 % of the NY-BR-1 GFP
+
 cells are in S phase and about a fifth can be found 
in the G2 phase (figure 4.29D). 
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Figure 4.29: Results of the cell cycle analysis of HEK293 NY-BR-1 GFP transfected cells. A: Showing 
the cell population for further analysis taking all cells into account. B: The cell population divided 
into GFP positive/negative for further analysis. C: Gates set to leave the duplets and cell debris out in 
either NY-BR-1 GFP negative or NY-BR-1 GFP positive cell population. D: Cell cycle analysis 
dividing the cells into subG1, G1, S, and G2 phase after PI staining. 
 
The second analysed cell line was the breast cancer cell line MCF-7. The cells were treated 
the same way as HEK203 cells with measuring points on day one, two and three. The whole 
cell population (figure 4.30A) was divided into GFP positive or negative populations (figure 
4.30B). The non-transfected cell population is GFP negative and in figure 4.30C a gate was 
set to get the duplets out for further cell cycle analysis (figure 4.30D). 
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The amount of cells found in subG1 phase rises from 13.1 % (day one) to 27.2 %. The 
numbers of cells in the G1 phase decrease, starting at 63.4 % on day one and being at 47.5 % 
at day three. Cells, which replicate their DNA (S phase), increase from 2.54% (day one) to 
4.18 % (day two) to 4.92 % (day three). Approximately 20 % of the analysed cells accumulate 
in G2 phase, with a drop down on day two to 15.7 %. 
 
 
 
Figure 4.30: Results of the cell cycle analysis of MCF-7 non-transfected cells. A: Showing the cell 
population for further analysis taking all cells into account. B: The cell population divided into GFP 
positive/negative for further analysis. C: Gates set to leave the duplets and cell debris out. D: Cell 
cycle analysis dividing the cells into subG1, G1, S, and G2 phase after PI staining. 
 
The MCF-7 NY-BR-1 GFP transfected cells were divided into NY-BR-1 GFP positive or 
negative populations (figure 4.31B).  A gate was set on each cell populations to leave cell 
debris and duplets out for further analysis (figure 4.31C). 16 % of the NY-BR-1 GFP
- 
population can be found back in the sub G1 phase on day one with increasing amount on day 
three until 30 %. The amount of cells in the G1 phase decreases from 61.2 % on day one to 
50.5 % on day three. Therefore the cells in the S phase increase from 0.81 % to 2.28 % (day 
one to three). Less cells of the NY-BR-1 GFP
- 
population are present in the G2 phase: starting 
at 22 % (day one) and dropping down to 17.2 % (day three). More cells of the NY-BR-1 
GFP
+ 
population accumulate in the sub G1 phase: 2.19 % to 6.71 %. The cells in the G1 phase 
decrease from 77.3 % (day one) to 73.8 % (day three) but having the highest accumulation on 
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day two with 85.6 %. The S phase contains between 0.19 % and 1.56 % of the NY-BR-1 
GFP
+
 cells. The amount of cells in the G2 phase decreases from 20.3 % (day one) to 17.9 % 
(day three) but with the lowest peak of 12.1 % on day two (figure 4.31D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.31: Results of the cell cycle analysis of MCF-7 NY-BR-1 GFP transfected cells. A: Showing 
the cell population for further analysis taking all cells into account. B: The cell population divided 
into GFP positive/negative for further analysis. C: Gates set to leave the duplets and cell debris out in 
either NY-BR-1 GFP negative or NY-BR-1 GFP positive cell population. D: Cell cycle analysis 
dividing the cells into subG1, G1, S, and G2 phase after PI staining. 
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4.3.3 Ki-67 staining in normal breast tissue 
Serial FFPE tissue sections of healthy patients were generated to analyse the co-localization 
of NY-BR-1 with the proliferation marker Ki-67.  
The Ki-67 staining (left) and the NY-BR-1 staining (right) of three different patients are 
shown exemplary in figure 4.32. The epithelial cells of patient HD-T-280 are Ki-67 negative 
but NY-BR-1 positive. Epithelial cells of the other two patients (HD-T-292, HD-T-311) are 
Ki-67 positive but NY-BR-1 negative.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.32: IHC staining of 4 µM FFPE tissue sections derived from three healthy patients. The 
nucleus is stained blue (haematoxylin) and the brown stained cells are Ki67 positive (left) and NY-BR-
1 positive (right). The tissues derived from breast reductions. The magnification is 10 fold (HD-T-283) 
or 20 fold (HD-T-292/311).  
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To summarize the results of this chapter: the proliferation assay showed in all four tested cell 
lines that NY-BR-1 GFP positive cells do not proliferate compared to the non-transfected and 
GFP transfected cell populations. Furthermore, the results of the cell cycle analysis indicate 
that NY-BR-1
+
 cells accumulate more in G1 phase compared to the NY-BR-1
-
 fraction and 
non-transfected cells. IHC staining with Ki-67 and NY-BR-1 of serial tissue sections 
demonstrated that Ki-67 positive cells are not NY-BR-1 positive.  
 
4.4 Interaction partner of NY-BR-1 
All proteins interact in a dynamic network to regulate cellular processes in a time-dependent 
manner. They have to communicate with each other to react to signals, stimulus or a specific 
cell state. The proteins form stable or transient complexes depending on their location and 
involvement of cellular processes and thus interact with each other. 
Co-IP belongs to the strongest biochemical approaches to identify specific interaction partner 
of a protein of interest. Thereby an antibody, directed against the protein of interest, is 
coupled on beads containing immobilized protein A or protein G. This complex “fishes” then 
from cell lysates the protein-protein complex. The Co-IP is combined with mass spectrometry 
(MS) to reveal potential interacting partners. The advantages of this method are low-cost, 
ease-of-use, compatibility with other downstream methods and relatively high specificity 
(Ngounou Wetie et al., 2014).  
To classify significant interaction partner of NY-BR-1 three cell lines (HEK293, MCF-10A, 
and MCF-7) were either transfected with the empty pc3 vector (as a control) or pc3 NY-BR-1. 
Co-IP reactions were performed in triplicates with the α-NY-BR-1 (C18) antibody. The IP 
lysates were loaded onto a SDS-Page gel, a silver staining was performed and the gels (figure 
4.33) were brought to the proteomics core facility of the German Cancer Research Center for 
mass spectrometry analysis.  
Figure 4.33: SDS Page gels after mass spectrometry compatible silver staining for mass spectrometry 
analysis. The cell lines HEK293, MCF-10A and MCF-7 were transfected either with pc3 empty vector 
(lane A-C) or pc3 NY-BR-1 (lane D-F). 
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4.4.1 Mass spectrometry results 
Tables 4.4 - 4.6 show the unique proteins that were identified in each NY-BR-1 expressing 
cell line (transiently transfected MCF-10A, MCF-7, and HEK293) compared to the respective 
control cells and thus represent possible interaction partners of NY-BR-1.  
The identification of proteins from peptide sequences was done with the Mascot software. 
Before entering mass spectrometry analysis the proteins are digested to form smaller peptides, 
which can be analysed by a mass spectrometer. During analysis the molecular weight of the 
peptides is measured and then compared by Mascot with database known peptides. 
Considering the cleavage enzyme used for digestion Mascot can calculate a theoretical mass 
for each peptide. Next a score is calculated based on the probability that the peptides match 
those in the database. The evaluated score in the raw data describes how many peptides 
Mascot could identify from a particular protein: the more the higher the score (Koenig et al., 
2008). 
For our analysis the merge files were used. The lanes were sliced prior mass spectrometry 
analysis and thus a protein could be present in multiple slices. To receive an appropriate score 
the repeatedly present proteins were summated.  The number of scores or significant protein 
sequences indicates that the protein was detected in an equivalent number of lanes. NY-BR-1 
is displayed as AN30A and could be detected in all three cell lines in all three lanes. The 
differences between the NY-BR-1 scores/significant protein sequences between the three cell 
lines can be due to a difference in transfection efficacy resulting in different protein 
expression levels.  
 
Table 4.4: Overview of the unique proteins detected in the IP fraction of pc3NY-BR-1 transfected 
MCF-10A cells. 
MCF-10A NY-BR-1 
(Unique) 
Gene Name Score Sign Prot 
Sequences 
ABCE1_HUMAN ATP-binding cassette sub-family E member 1  115 2 
ACTN4_HUMAN Alpha-actinin-4  100 2 
AN30A_HUMAN Ankyrin repeat domain-containing protein 30A  2593;1523;1765 42;29;32 
ARF5_HUMAN ADP-ribosylation factor 5  140 2 
CH60_HUMAN 60 kDa heat shock protein, mitochondrial  83 2 
GSTM2_HUMAN Glutathione S-transferase Mu 2  130 2 
GSTM3_HUMAN Glutathione S-transferase Mu 3  122 2 
HS71L_HUMAN Heat shock 70 kDa protein 1-like  225;157 3;2 
K22O_HUMAN Keratin, type II cytoskeletal 2 oral  466;458 9;8 
K2C7_HUMAN Keratin, type II cytoskeletal 7  238;239 4;4 
KV201_HUMAN Ig kappa chain V-II region Cum  107 2 
KV304_HUMAN Ig kappa chain V-III region Ti  116 2 
LDHB_HUMAN L-lactate dehydrogenase B chain  96 2 
PHB_HUMAN Prohibitin  62 2 
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PRDX4_HUMAN Peroxiredoxin-4  73 2 
RAB2A_HUMAN Ras-related protein Rab-2A  124 3 
RL15_HUMAN 60S ribosomal protein L15  134;108 2;2 
RL27A_HUMAN 60S ribosomal protein L27a  96 2 
RL35A_HUMAN 60S ribosomal protein L35a  165 4 
RL6_HUMAN 60S ribosomal protein L6  67 2 
RS6_HUMAN 40S ribosomal protein S6  79 2 
S10A9_HUMAN Protein S100-A9  78 2 
SMD3_HUMAN Small nuclear ribonucleoprotein Sm D3  65 2 
SPB3_HUMAN Serpin B3  79 2 
SPB7_HUMAN Serpin B7  115 2 
SRSF1_HUMAN Serine/arginine-rich splicing factor 1  110;167 2;3 
TBB4B_HUMAN Tubulin beta-4B chain  477 8 
TPM2_HUMAN Tropomyosin beta chain  170 4 
U520_HUMAN U5 small nuclear ribonucleoprotein 200 kDa helicase  81;68 2;2 
 
 
Table 4.5: Overview of the unique proteins detected in the IP fraction of pc3NY-BR-1 transfected 
MCF-7 cells. 
MCF-7 NY-BR-1 
(Unique) 
Gene Name Score Sign Prot 
Sequences 
ACTA_HUMAN Actin, aortic smooth muscle  307 4 
AN30A_HUMAN Ankyrin repeat domain-containing protein 30A  787;813;1091 13;16;21 
ATPA_HUMAN ATP synthase subunit alpha, mitochondrial  135 3 
EPIPL_HUMAN Epiplakin  166 4 
G6PD_HUMAN Glucose-6-phosphate 1-dehydrogenase  139 2 
HS71L_HUMAN Heat shock 70 kDa protein 1-like  146;170 2;3 
K22O_HUMAN Keratin, type II cytoskeletal 2 oral  380 7 
K2C75_HUMAN Keratin, type II cytoskeletal 75  676 10 
KRT34_HUMAN Keratin, type I cuticular Ha4  649 11 
KRT35_HUMAN Keratin, type I cuticular Ha5  128 2 
KRT81_HUMAN Keratin, type II cuticular Hb1  591 9 
KRT84_HUMAN Keratin, type II cuticular Hb4  255 5 
KT33B_HUMAN Keratin, type I cuticular Ha3-II  769 13 
MYH10_HUMAN Myosin-10  155 3 
MYH14_HUMAN Myosin-14  109 2 
PRDX2_HUMAN Peroxiredoxin-2  90 2 
RCN2_HUMAN Reticulocalbin-2  223 3 
RL12_HUMAN 60S ribosomal protein L12  74 2 
RLA0_HUMAN 60S acidic ribosomal protein P0  103 2 
RLA0L_HUMAN 60S acidic ribosomal protein P0-like  123 2 
SNX27_HUMAN Sorting nexin-27  162;182 3;4 
SRSF3_HUMAN Serine/arginine-rich splicing factor 3  86 2 
SRSF7_HUMAN Serine/arginine-rich splicing factor 7  177 3 
TBB4B_HUMAN Tubulin beta-4B chain  266;484;462 4;7;7 
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Table 4.6: Overview of the unique proteins detected in the IP fraction of pc3NY-BR-1 transfected 
HEK293 cells. 
HEK293 NY-BR-1 
(Unique) 
Gene Name Score Sign Prot 
Sequences 
 
AN30A_HUMAN Ankyrin repeat domain-containing protein 30A  2717;2799;2836 47;40;43 
ATPA_HUMAN ATP synthase subunit alpha, mitochondrial  181 5 
GIT1_HUMAN ARF GTPase-activating protein GIT1  132 2 
H12_HUMAN Histone H1.2  99 2 
H4_HUMAN Histone H4  79 2 
IGHG3_HUMAN Ig gamma-3 chain C region  115 2 
K1C15_HUMAN Keratin, type I cytoskeletal 15  570 9 
K1C24_HUMAN Keratin, type I cytoskeletal 24  200 3 
K2C75_HUMAN Keratin, type II cytoskeletal 75  705;649 10;11 
KDIS_HUMAN Kinase D-interacting substrate of 220 kDa 550;355;329 10;6;7 
KRT34_HUMAN Keratin, type I cuticular Ha4  214;301 4;5 
KRT36_HUMAN Keratin, type I cuticular Ha6  187 3 
KRT83_HUMAN Keratin, type II cuticular Hb3  313 5 
PLEC_HUMAN Plectin  116 2 
RL7A_HUMAN 60S ribosomal protein L7a  71 2 
SATB1_HUMAN DNA-binding protein SATB1  93;146 2;3 
SNX27_HUMAN Sorting nexin-27  1076;1096 19;18 
TBA1A_HUMAN Tubulin alpha-1A chain  349;430 4;7 
TBB4B_HUMAN Tubulin beta-4B chain  273 5 
TR150_HUMAN Thyroid hormone receptor-associated protein 3  147;185;103 2;3;2 
VANG1_HUMAN Vang-like protein 1  84;119 2;2 
ZO2_HUMAN Tight junction protein ZO-2  303;193;346 7;4;7 
PRDX1_HUMAN Peroxiredoxin-1  75 2 
 
The unique proteins of the NY-BR-1 fraction of each cell line were compared to see whether 
some possible interaction partners of NY-BR-1 is shared between all three tested cell lines.  
In MCF-7 and HEK293 six proteins, in MCF-10A and MCF-7 cells four proteins and in 
MCF-10A and HEK293 cells just two proteins are shared including NY-BR-1 (Table 4.7-4.9). 
The HS71L protein could be detected in two lanes in both cell lines (MCF-10A/MCF-7). This 
Heatshock protein is involved to maintain the right folding of a newly synthetized protein 
(chaperone character) and to prevent aggregation of existing proteins 
(http://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&dopt=full_report&list_uids=3305).  The 
other two proteins (K220, TBB4B) could be detected in two lanes in just one of the compared 
cell line (table 4.7). K220, also known as KRT76, belongs to the type II keratin family. This 
family includes keratins constitute for type II intermediate filaments of the intracytoplasmatic 
cytoskeleton of epithelial cells. Keratins help to maintain the normal tissue structure and 
function (Ambatipudi et al., 2013). KRT76 is mainly expressed in the suprabasal epithelial 
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cells of the hard palate and gingiva and is down-regulated in oral cavity tumours (Ambatipudi 
et al., 2012; Collin et al., 1992). 
 
Table 4.7:  Shared proteins between MCF-10A/MCF-7 cells in the NY-BR-1 fraction. 
 
The ATPA protein is present in both cell lines but in just one lane and this protein is involved 
in the respiratory chain. The two keratin proteins (K2C75, KRT34) are once detected in MCF-
7 but twice in the HEK293 cells and are found in hairs and nails. The task of SNX27 is 
endocytosis of plasma membrane receptors and it supports their protein trafficking (Worby 
and Dixon, 2002). This protein is found in both cell lines in two lanes. TBB4B can be seen in 
all three lanes of MCF-7 but just in one of HEK293 (table 4.8). 
 
Table 4.8: Shared proteins between MCF-7/HEK293 cells in the NY-BR-1 fraction. 
 
MCF-10A and HEK293 have only TBB4B in common besides NY-BR-1. TBB4B could be 
detected just in one lane in both cell lines (table 4.9). 
 
 
 
MCF-
10A/MCF-7 
(Shared) 
Gene Name Score 
MCF-10A 
Sign Prot 
Sequences 
MCF-10A 
Score 
MCF-7 
Sign Prot 
Sequences 
MCF-7 
AN30A_HUMAN Ankyrin repeat 
domain-containing 
protein 30A  
2593;1523;1765 42;29;32 787;813;1091 13;16;21 
HS71L_HUMAN Heat shock 70 kDa 
protein 1-like  
225;157 3;2 146;170 2;3 
K22O_HUMAN Keratin, type II 
cytoskeletal 2 oral  
466;458 9;8 380 7 
TBB4B_HUMAN Tubulin beta-4B 
chain  
477 8 266;484;462 4;7;7 
MCF-7/HEK293 
(Shared) 
Gene Name Score 
MCF-7 
Sign Prot 
Sequences 
MCF-7 
Score 
HEK293 
Sign Prot 
Sequences 
HEK293 
AN30A_HUMAN Ankyrin repeat 
domain-containing 
protein 30A  
787;813;1091 13;16;21 2717;2799;2836 47;40;43 
ATPA_HUMAN ATP synthase subunit 
alpha, mitochondrial  
135 3 181 5 
K2C75_HUMAN Keratin, type II 
cytoskeletal 75  
676 10 705;649 10;11 
KRT34_HUMAN Keratin, type I 
cuticular Ha4  
649 11 214;301 4;5 
SNX27_HUMAN Sorting nexin-27  162;182 3;4 1076;1096 19;18 
TBB4B_HUMAN Tubulin beta-4B chain  266;484;462 4;7;7 273 5 
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Table 4.9: Shared proteins between MCF-10A/HEK293 cells in the NY-BR-1 fraction. 
 
TBB4B is the only protein shared by all three cell lines. This protein is the major component 
of microtubules. Microtubules form the cytoskeleton of each cell and are involved in many 
cellular processes such as chromosome separation during mitosis/meiosis and cellular 
trafficking (Vicente and Wordeman, 2015). 
 
4.5 Is NY-BR-1 a progenitor cell marker? 
Stem or progenitor cells are important to maintain tissues and to replace lost cells during 
normal attrition and injuries. They are present in every tissue. The mammary progenitor cells 
help to shape the mammary glands during puberty, pregnancy, and lactation. Different subsets 
of progenitor cells in the mammary gland are known as described in the introduction (see 
1.4). 
The proliferation assay showed that NY-BR-1 positive cells do not proliferate but also not 
going into an increased apoptosis compared to NY-BR-1 negative cells. The analysis of the 
cell cycle revealed that more NY-BR-1 positive cells accumulate in the G1 phase compared to 
the non-transfected and NY-BR-1 negative cell population. As described in chapter 4.1.1 the 
mosaic-like expression pattern of the NY-BR-1 protein suggests that the NY-BR-1 positive 
cells form a functionally different cell population in the mammary gland. The NY-BR-1 
expression pattern in breast tumours depends on the molecular subtype ( figure 4.44). If the 
theory is considered that the different subtypes in breast cancer are due to the different 
progenitor population it can be probable that NY-BR-1 is a marker for a certain progenitor 
cell population in the mammary gland. 
 
4.5.1 Generation and analysis of mammospheres  
Several years ago an in vitro cultivation system was developed to generate non-adherent 
mammospheres from human mammary epithelial cells. The characteristic feature of these 
cells is that they are undifferentiated due to the fact that they can proliferate in suspension. 
Additionally, it was shown that these mammospheres have the ability to differentiate along 
the mammary epithelial lineages (Dontu et al., 2003).  
MCF-
10A/HEK293 
(Shared) 
Gene Name Score 
MCF-10A 
Sign Prot 
Sequences 
MCF-10A 
Score 
HEK293 
Sign Prot 
Sequences 
HEK293 
AN30A_HUMAN Ankyrin repeat 
domain-containing 
protein 30A  
2593;1523;1765 42;29;32 2717;2799;2836 47;40;43 
TBB4B_HUMAN Tubulin beta-4B chain  477 8 273 5 
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Thus, in theory only undifferentiated cells have the ability to form mammospheres in ultra-
low binding plates. After seven to nine days of culturing, primary spheres can be harvested, 
after two weeks secondary and after three weeks tertiary. They are analysed via fluorescence 
staining and qPCR. In figure 4.34 primary, secondary and tertiary mammospheres of patient 
HD-T-311 are shown prior to analysis. The isolated epithelial cells were isolated from healthy 
breast tissue. 
Figure 4.34: Primary, secondary and tertiary mammospheres of isolated healthy epithelial cells from 
patient HD-T-311. The arrows indicate spheres. 
 
4.5.2 qPCR analysis of mammospheres 
To analyse the expression of NY-BR-1 and other lineage markers, the spheres were harvested, 
RNA was isolated and a qPCR was performed. First, the NY-BR-1 expression in four patients 
was tested (figure 4.35A). The NY-BR-1 expression in the primary mammospheres of 
patients HD-T-263 (CP: 25) and HD-T-311 (CP: 28) is higher compared to the patients HD-T-
283 (lowest expression profile) (CP: 31) and HD-T-292 (CP: 28). All samples were normalized 
against the housekeeping gene ß-Actin (CP: 13-19). 
It was possible to generate enough spheres from patient HD-T-311 to dissociate the primary 
ones to generate secondary and at the end even tertiary spheres. The results show that NY-
BR-1 expression in the spheres is lost during longer culturing periods (figure 4.35B) with CP 
values starting with 28 and decreasing to 35.  
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Figure 4.35: NY-BR-1 expression in mammospheres derived from isolated healthy epithelial cells 
assessed by qPCR. A: Primary mammospheres of four different patients were tested regarding their 
NY-BR-1 expression level. B: NY-BR-1 expression was analysed in primary, secondary and tertiary 
mammospheres of patient HD-T-311.  
 
4.5.3 Fluorescence staining of primary mammospheres 
Fluorescence staining was performed to test whether mammospheres also express NY-BR-1 
on the protein level.  Enough spheres were generated of two different healthy patients (figure 
4.36). The spheres were stained with Hoechst (blue (nucleus), α-NY-BR-1#2 (green) and 
either with cytokeratin18 (CK18) or CK14 antibodies (red). A mammosphere is shown for 
patient HD-T-258 and three spheres for patient HD-T-311. In these two patients it can be 
observed that the NY-BR-1 expression is distributed on the membrane and in the cytosol of a 
cell. CK18 is a luminal cell cytokeratin and is used to discriminate myoepithelial from 
luminal cells. CK14 is a marker used to detect myoepithelial cells. No (HD-T-311) or just 
weak (HD-T-258) CK18 expression can be observed and this indicate that the cells are not 
luminal origin.  
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Figure 4.36: Fluorescence staining of mammospheres of two different patients. (Blue: nucleus, Green: 
NY-BR-1, Red: CK18 (HD-T-258), CK14 (HD-T-311)) 
 
The spheres were further analysed on RNA level to characterize the cell population in more 
detail because the different progenitor cell populations have different kinds of gene 
expression. Therefore, the expression level of HER2, PR and ER were investigated. All 
samples were normalized to the housekeeping gene ß-Actin. The expression levels of ER are 
not shown because in all tested samples a CP value of 35 was detected. Thus, no ER 
expression on RNA level in all tested samples could be observed. The HER2 expression is in 
general higher (CP: between 21 and 28) (figure 4.37A) and PR expression levels (CP: 33 – 35) 
(figure 4.37B). HD-T-311 secondary spheres show the highest HER2 expression but do not 
express the PR. In the HD-T-292 spheres HER2 expression is the lowest and no PR 
expression could be detected at all. 
Figure 4.37: Expression level of Her2 (A) and progesterone receptor (B) in mammospheres of 
different patients analysed by qPCR. (p.s.; primary sphere, s.s.: secondary sphere) 
 
 
The mammospheres were further characterized and the expression level of FOXA1 (also 
known as HNF-3A), GATA-3 and integrin-α 6 (also known as CD49f) were analysed (figure 
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4.38). GATA-3 is a transcription factor and it regulates the differentiation of the luminal cells 
in the mammary gland (Kouros-Mehr et al., 2006). Moreover, GATA-3 is involved in the 
ERα pathway and is considered to be a marker in ER+ and ER-/AR+ cancer (Kouros-Mehr et 
al., 2008). GATA-3 interacts with FOXA1, which is a downstream target of GATA-3 in the 
mammary glands. FOXA1, also known as HNF-3α, is called a pioneer factor for ERα in ERα+ 
breast cancer. These factors have the ability to bind directly on chromatin. Integrin-α 6 is an 
adhesion molecule and characterizes basal and bipopent progenitor cells in the mammary 
gland. 
In all tested spheres, GATA-3 expression levels are higher compared to FOXA1 expression. 
In the secondary andin the tertiary spheres of patient HD-T-311 the GATA-3 expression 
increases. The lowest expression of GATA-3 was observed in patients HD-T-263 and HD-T-
292 (figure 4.38A). The highest level of FOXA1 expression was detected in patient HD-T-
311 primary spheres and it decreases from the primary to the tertiary spheres. The lowest 
expression of this pioneer factor is observed in the primary spheres of patient HD-T-283 and 
HD-T-292 (figure 4.38B). The expression level of integrin-α 6 are comparable between the 
tertiary spheres of patient HD-T-311, and primary spheres of HD-T-283 and HD-T-292. The 
lowest amount can be found in patient HD-T-263 and the highest in the secondary spheres of 
patient HD-T-311 (figure 4.37C).  
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Figure 4.38: Expression profiles of GATA-3 (A), FOXA1 (B) and Integrin-α 6 (C) in the generated 
mammopsheres of all patients. (p.s.; primary sphere, s.s.: secondary sphere, t.s.: tertiary sphere) 
 
4.5.4 IHC staining of ER and NY-BR-1 in serial tissue sections 
Serial FFPE tissue sections of healthy patients were generated to analyse the co-localization 
of NY-BR-1 with ERα. The different progenitor subsets in the mammary gland can be ER+ as 
well as ER
-
 as described in chaper 1.4. 
The ERα (left) and the NY-BR-1 staining (right) of patient HD-T-292 and HD-T-311 are 
shown exemplary in figure 4.39. The mammary gland cells of patient HD-T-292 can be ER
-
/NY-BR-1
+
 (indicated with black arrows) as well as ER
+
/NY-BR-1
+
 (indicated with blue 
arrows). The cells of patient HD-T-311 consist of ER
-
/NY-BR-1
+
 cells. 
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Figure 4.39: IHC staining of 4 µM FFPE tissue sections derived from healthy patients. The nucleus 
is stained blue (haematoxylin) and the brown stained cells are ER (left) and NY-BR-1 positive (right). 
The tissue derived from breast reduction. The magnification is 20 fold. The blue arrows indicate 
ER
+
/NY-BR-1
+
 cells, the black arrows ER
-
/NY-BR-1
+
. 
 
In summary, a mosaic like NY-BR-1 expression pattern is observed in healthy patients. In 
breast carcinoma patient the expression pattern depends most likely on the molecular subtype 
ranging from no to a homogenous expression pattern. NY-BR-1 expression can be detected on 
RNA level for a specific time period in mammospheres but it becomes less after two weeks of 
culturing.  Moreover, the expression level varies from patient to patient also depending on the 
progenitor subset. Co-expression with integrin-α6, HER2, GATA-3 and FOXA1 could be 
observed but not with ER and PR. The IHC staining revealed that NY-BR-1 positive cells are 
not always ER or PR positive. 
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4.6 In silico analysis 
Integrative functional analyses involving genomics, transcriptomics and epigenomics were 
performed to explore the transcriptional regulation and expression pattern of NY-BR-1. For in 
silico analyses, data from publicly available resources such as dbSNP, ICGC, TCGA, 
ENCODE, and NCBI SRA were used. More information about the SNP analysis within the 
NY-BR-1 gene is depicted in the manuscript (page 168). 
 
4.6.1 SNP analysis of the promoter region and gene body 
SNPs in the promoter region can alter transcription factor binding and thus prevent or enhance 
transcription initiation. The SNPs, located in the promoter region of NY-BR-1 up to 2000 bp 
upstream from the transcription start site, are summarized in table 4.10. Additionally, the 
transcription factors are shown, predicted by the Alibaba 2.0 tool. Interestingly, SNPs exist in 
the predicted binding sites of GR, TBP, SP1, HNF-3, C/EBPα, YY1, c-Fos, c-Jun and AP-1. 
These factors are either involved in the ERα pathway or in transcription initiation or are 
known as proto-oncogenes.  
 
Table 4.10: Overview of all SNPs, located in the promoter region of NY-BR-1. Their position is 
upstream of the transcription start site. Additionally, the predicted transcription factors are shown for 
specific SNP positions.  
Variation 
Name 
Position Position in promotor 
upstream 
Variant Alleles Predicted transcription factors 
rs184032975 37412790 1995 C/T   
rs12221253 37412799 1986 C/T   
rs370025586 37412814 1971 G/A   
rs77426826 37412816 1969 A/G   
rs189011172 37412850 1935 C/T   
rs371244298 37412860 1925 C/T   
rs368433595 37412889 1896 G/A   
rs374206891 37412903 1882 A/C GR 
rs371968048 37412937 1848 A/G   
rs113089428 37412967 1818 -/A TBP, GATA-1, HB 
rs191763434 37412968 1817 A/T TBP, GATA-1, HB 
rs199569240 37412968 1817 -/T TBP, GATA-1, HB 
rs182715277 37413056 1729 G/A SP1 
rs187045318 37413113 1672 G/A   
rs58721264 37413117 1668 C/T SP1 
rs377674377 37413121 1664 G/T SP1 
rs12357251 37413138 1647 A/G HNF-3 
rs7908887 37413139 1646 G/A HNF-3 
rs57894012 37413139 1646 -
/AAAAAAAAAAA 
HNF-3 
rs12357252 37413144 1641 A/G   
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rs191538949 37413189 1596 T/C   
rs11011043 37413218 1567 G/A SP1 
rs183689800 37413302 1483 C/T SP1 
rs187716252 37413346 1439 G/T SP1, C/EBPα, AP-2α, E1, MyoD 
rs11011044 37413352 1433 G/A E1, MyoD 
rs2944452 37413403 1382 T/C   
rs74772832 37413441 1344 C/A SP1 
rs71297788 37413453 1332 -/A   
rs192694302 37413498 1287 T/A   
rs150975043 37413524 1261 C/A GR 
rs115317596 37413572 1213 A/C   
rs147929641 37413593 1192 G/- SP1, WT1, Krox-20 
rs369399202 37413677 1108 G/A SP1 
rs117975813 37413682 1103 C/T SP1, E4, myogenin 
rs185741129 37413706 1079 G/C/T   
rs190448522 37413715 1070 C/T SP1 
rs145899299 37413763 1022 G/T SP1 
rs370828102 37413885 900 G/- C/EBPα, HNF-3, TBP, HOXA4 
rs78349175 37413887 898 A/T C/EBPα, HNF-3, TBP, HOXA4 
rs375624717 37413888 897 -/T C/EBPα, HNF-3, TBP, HOXA4 
rs74669586 37413889 896 T/A C/EBPα, HNF-3, TBP, HOXA4 
rs71007621 37413907 878 T/- MEB-1, HNF-3 
rs181762978 37413912 873 G/A   
rs200897330 37414007 778 TT/-   
rs147795150 37414033 752 G/A   
rs114832447 37414163 622 C/A SP1, NF-1 
rs35660139 37414241 544 G/A Krox-20, RAP1, SP1, YY1 
rs184411029 37414312 473 G/C SP1 
rs11011045 37414433 352 G/A c-Jun, c-Fos, C/EBPα, AP-1 
rs370351587 37414541 244 G/A   
rs376482133 37414558 227 C/G SP1 
rs141172730 37414582 203 A/G   
rs115377424 37414625 160 G/A   
rs61866716 37414661 124 T/C SP1 
rs61866717 37414679 106 G/C ETF 
rs371009767 37414774 11 C/T SP1 
 
Figure 4.40 summarizes the analysis of the spectrum of SNPs on the nucleotide level in the 
promoter region of NY-BR-1. It shows a conserved profile with A>T/T>A transitions being 
the most frequent changes followed by A>G/T>C. Several insertions and deletions are 
occurring. Less frequently the G>A/C>T and G>C/C>G transitions can be observed.  
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Figure 4.40: Graphical representation of the spectrum of nucleotide variations in the NY-BR-1 
promoter. 
 
Not only SNPs in a promoter region are important but also SNPs in the gene body because 
they can influence the splicing machinery. Thus, they might be responsible for new transcripts 
and proteins, which can have different structures and functions.  
In the Ensembl BioMart database, 2898 SNPs are recorded for the ANKRD30A transcript 
ENST00000611781. 2880 of these were imported from dbSNP and 18 from NHLBI ESP. 
1832 SNPs have been validated by independent submissions or frequency/genotype data. 
However, the clinical significance has not been determined yet for any of the SNPs. Out of all 
2898 SNPs, 65 (2.07 %) were synonymous (sSNPs,) 191 (6.09 %) were non-synonymous 
(nsSNPs), and 2430 (77.48 %) occurred in intronic regions (figure 4.41A). nsSNPs were 
selected for further investigation. 69 nsSNPs were predicted to be damaging/deleterious by at 
least two of the used tools (PROVEAN, SIFT or PolyPhen). Analysis of the spectrum of 
nsSNPs on the nucleotide level showed a conserved profile with A>T/T>A transitions being 
the most frequent changes (figure 4.41B) The spectrum of amino acid changes was analysed, 
too. It could be observed that hydrophile>hydrophile transitions occur most frequently and 
hydrophobe>hydrophobe transitions second frequently (figure 4.41C). The nsSNPs 
rs200639888 and rs367841401, which were predicted to be highly damaging by all three 
tools, have an amino acid change from leucine to proline which are hydrophobe amino acids. 
The third damaging nsSNP predicted by all three tools, rs377750885, has a change from 
glutamic acid (hydrophile) to (hydrophobe) valine. 
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Figure 4.41: A: Graphical representation of distribution of intronic SNPs, non-synoymous SNPs 
(nsSNPs), synonymous SNPs (sSNPs), and SNPs at splicing sites for the NY-BR-1 gene, based on the 
dbSNP and NHLBI ESP databases. B+C: Graphical representation of spectrum of damaging nsSNPs 
variation. B) nucleotide variations, C) amino acid variations. 
 
191 nsSNPs were analysed and the results varied between the used tools: SIFT predicted 79 
damaging nsSNPs, Provean 28 nsSNPs, and PolyPhen2 102 nsSNPs. 16 nsSNPs were 
predicted to be damaging by all three tools, and a total of 69 nsSNPs were predicted 
damaging by at least two of the used tools. SIFT and PolyPhen2 have the biggest overlap with 
63 common predictions. This may be due to the common step of assessing the degree of 
conservation by utilizing a multiple sequence alignment of homologous sequences. 36 
damaging nsSNPs were only predicted by PolyPhen2 because PolyPhen2 is the only tool that 
takes functional relevant sites into account. The location of the 69 damaging SNP within the 
ANKRD30A gene is shown in figure 4.42A. It is noteworthy that a lot of the damaging SNPs 
are located in the longest exons 7 and 34. Between exon 19 and 24 no damaging nsSNPs are 
found and this can be observed in exon 35 and 36 as well. In dbSNP, 39 of the NY-BR-1 
SNPs are annotated to be in splicing sites, located at donor or acceptor sites (figure 4.42B). 
These SNPs have the potential to influence the splicing process and new transcripts can be 
generated. The predicted splicing SNPs do not accumulate in exon 7 or 34 but more around 
exon 8, between exon 13 and 18, and between exon 25 and 31. A characteristic feature 
between the exons 10 and 30 is that the exons have a recurrent bp length (29, 73, 62, and 91) 
and contain repetitive elements. 
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Figure 4.42: Location of the damaging SNPs (A) and splicing SNPs (B) within the gene of NY-BR-1 
consisting of 36 exons. The length of exons is not true to scale. 
 
4.6.2 NY-BR-1 expression in molecular subtypes of breast cancer 
The molecular subtype classification is important in breast cancer to choose the best therapy 
strategy, which can differ significantly between hormone sensitive or insensitive tumours. 
This division depends on the receptor status (ER
+/-
, PR
+/-
, HER2
+/-
). By using the publicly 
available RNA-Seq dataset published by Varley et al. which includes 28 samples of breast 
cancer cell lines, 42 samples of triple negative breast cancer (TNBC), 42 samples of ER
+
 
breast cancer and 56 non-malignant breast tissue samples, it was possible to perform several 
analyses (Varley et al., 2014).  
The first analysis included the NY-BR-1 gene expression in all samples. In few of the breast 
cell lines (BT-474, MDA-MB-134, DY30T2, MDA-MB-361, ZR-75-30, MDA-MB-453) a 
weak NY-BR-1 gene expression was detected. The highest gene expression can be observed 
in ER
+
 tumour samples but in all other samples (triple negative, uninvolved ER
+
, healthy and 
uninvolved triple negative) a weak or no gene expression of NY-BR-1 can be seen (figure 
4.43). 
 
4 Results 
 
- 119 - 
 
 
Figure 4.43: Gene expression analysis of NY-BR-1 in breast cell lines, ER
+
 and triple negative tumors, 
uninvolved tissue of ER
+
 and triple negative tumors and in healthy samples. This data set was 
published from Varley et al. (2014). 
 
Within this data set the NY-BR-1 expression was compared in two contrary breast cancer 
subtypes (ER
+
 and TNBC). Also the adjacent tissue was analysed. The results in figure 4.44 
show that NY-BR-1 is significantly over-expressed in ER
+
 compared to TN breast cancer 
samples. Moreover, NY-BR-1 is significantly over-expressed in ER
+
 breast cancer 
(p=0.00003341) compared to the ER
+
 adjacent healthy tissue. Between TNBC and its 
uninvolved tissue no significant difference in NY-BR-1 expression can be observed.  
 
 
 
 
 
 
 
 
 
Figure 4.44: NY-BR-1 expression analysis in breast cancer subtypes and corresponding uninvolved 
tissue using the public available Varley data set. (TNBC: triple negative breast cancer) 
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Additionally an exon coverage analysis was performed. As mentioned before NY-BR-1 
consists of 36 exons and it is likely that with such a high number of exons different transcripts 
might exist. Therefore, an exon coverage analysis was done with the Varley data set. Figure 
4.45 shows that the first exons (one-nine) are rarely expressed in ER
+
 breast cancer. The latter 
exons (26-36) have a higher expression profile in ER
+
 breast cancer. In all other samples the 
exon coverage is in general very weak but it is striking that in ER
+
 and TN uninvolved 
samples the latter exons are mainly expressed to a low extent. Thus, a part of NY-BR-1 is 
expressed on RNA level even in healthy tissue. In TN breast cancer samples no exon is highly 
expressed.  
 
 
Figure 4.45: Exon coverage analysis of NY-BR-1 in ER
+
 and TN breast cancer, ER
+
 and TN 
uninvolved tissue samples. 
 
Another analysis of the Varley et al. data set includes the genes, which are down-regulated in 
TNBC compared to ER
+ 
cancers.  The more negative the fold change the more down-
regulation of a gene takes place. The strongest down-regulated genes are on top and in table 
4.11 the 50 most down-regulated genes in TNBC are shown. Interestingly, NY-BR-1 (rank 
30) is more down-regulated than ESR1 (rank 37) but less than PGR (rank 24). 
 
Table 4.11: Overview of 50 most down-regulated genes in TNBC of the Varley et al. data set. 
Rank Gene   Mean ER+ Mean TN log2FoldChange 
1 CLEC3A C-type lectin domain family 3, member A 1.308378e+03 8.1556323 -7.325767 
2 SERPINA6 serpin peptidase inhibitor, clade A, member 6 1.499204e+03 10.7746594 -7.120410 
3 DSCAM-AS1 DSCAM antisense RNA 1 1.664696e+03 12.0825480 -7.106190 
4 CDC20B cell division cycle 20B 4.160569e+02 3.5834650 -6.859282 
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5 CYP2B7P1 cytochrome P450, family 2, subfamily B, 
polypeptide 7 pseudogene 1 
7.126869e+03 79.3743597 -6.488452 
6 GPR139 G protein-coupled receptor 139 1.386844e+01 0.1685781 -6.362244 
7 CST9 cystatin 9 (testatin) 2.438800e+02 3.1042927 -6.295763 
8 IL20 interleukin 20 4.106654e+02 5.9158212 -6.117241 
9 CST5 cystatin D 9.000948e+01 1.5902817 -5.822723 
10 POTEKP POTE ankyrin domain family, member K, 
pseudogene 
1.674666e+03 35.6991742 -5.551839 
11 LINC01016 long intergenic non-protein coding RNA 1016 3.637712e+02 8.3872786 -5.438685 
12 AGR3 anterior gradient 3 3.861895e+03 96.6420863 -5.320514 
13 ABCC8 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 8 
5.678362e+03 156.1320543 -5.184636 
14 TFF1 trefoil factor 1 4.883072e+03 135.5756561 -5.170619 
15 TPM3_1 TPM3_1 6.820731e+01 1.9560138 -5.123938 
16 KCNC2 potassium voltage-gated channel, Shaw-related 
subfamily, member 2 
5.952804e+02 17.4759734 -5.090125 
17 GRPR gastrin-releasing peptide receptor 6.604642e+02 19.4249135 -5.087500 
18 DEFB132 defensin, beta 132 5.315296e+01 1.6424929 -5.016191 
19 CXorf27 chromosome X open reading frame 27 1.732960e+01 0.5483333 -4.982042 
20 C1orf64 chromosome 1 open reading frame 64 1.148827e+03 38.1890170 -4.910859 
21 KCNU1 potassium channel, subfamily U, member 1 2.547165e+01 0.8498496 -4.905541 
22 TFF3 trefoil factor 3 (intestinal) 8.619518e+03 289.2790123 -4.897074 
23 RIMS4 regulating synaptic membrane exocytosis 4 2.958008e+03 103.6255306 -4.835175 
24 PGR progesterone receptor 5.767404e+03 234.8600123 -4.618049 
25 TPRG1-AS2 TPRG1 antisense RNA 2 3.033012e+02 12.4025144 -4.612047 
26 FAM47A family with sequence similarity 47, member A 1.122428e+01 0.4594130 -4.610687 
27 AREG_1 AREG_1 1.031969e+02 4.4602995 -4.532116 
28 NAT1 N-acetyltransferase 1 (arylamine N-
acetyltransferase) 
5.289695e+03 229.1042127 -4.529109 
29 EEF1A2 eukaryotic translation elongation factor 1 alpha 
2 
1.759765e+04 792.7481463 -4.472377 
30 ANKRD30A ankyrin repeat domain 30A 1.456245e+05 7024.3568743 -4.373743 
31 MIR548F2 microRNA 548f-2 9.005343e+00 0.4397379 -4.356065 
32 CT62 cancer/testis antigen 62 3.205531e+02 15.7743010 -4.344915 
33 LINC00993 LINC00993 1.183818e+04 586.0805833 -4.336204 
34 GRIK3 glutamate receptor, ionotropic, kainate 3 4.330880e+03 219.3444329 -4.303390 
35 LOC100131320 LOC100131320 5.768424e+02 29.4592284 -4.291386 
36 NKAIN1 Na+/K+ transporting ATPase interacting 1 3.117204e+03 159.8424201 -4.285530 
37 ESR1 estrogen receptor 1 1.347108e+04 695.0266169 -4.276654 
38 C10orf82 chromosome 10 open reading frame 82 2.039416e+02 11.0623994 -4.204420 
39 KLHDC7A kelch domain containing 7A 1.411618e+03 76.8824712 -4.198551 
40 CYP4B1 cytochrome P450, family 4, subfamily B, 
polypeptide 1 
3.321585e+03 182.1837529 -4.188406 
41 KCNK15 potassium channel, subfamily K, member 15 2.669967e+03 148.0443570 -4.172721 
42 TPRG1 tumor protein p63 regulated 1 1.644171e+03 91.7290773 -4.163838 
43 MAGEB17 melanoma antigen family B, 17 1.555129e+02 8.6969135 -4.160387 
44 SPPL2C signal peptide peptidase like 2C 5.785534e+01 3.2471110 -4.155222 
45 CST9L cystatin 9-like 1.520535e+01 0.8700051 -4.127411 
46 CLIC6 chloride intracellular channel 6 5.775863e+03 332.9907089 -4.116483 
47 LOC389033 placenta-specific 9 pseudogene 1.156680e+02 6.6923381 -4.111336 
48 SYTL5 synaptotagmin-like 5 7.027512e+02 40.9525252 -4.100990 
49 TNRC18P1 TNRC18P1 1.163228e+03 68.2845151 -4.090431 
50 SYT9 synaptotagmin IX 5.237676e+02 30.8791238 -4.084223 
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4.6.3 Correlation of NY-BR-1 expression with other genes 
To get a hint, which genes are up- or down-regulated while NY-BR-1 is expressed or not, an 
analysis of different data sets was performed. Analysis of the breast cancer ER ChIP-Seq 
dataset from Ross-Innes et al. revealed several ER binding sites in the genomic region of NY-
BR-1 (figure 4.46) (Ross-Innes et al., 2012). It is striking that these binding sites are present 
from the beginning of the gene until intron 21. No binding sites are present from exon 23 until 
the end of the NY-BR-1 gene. The ER binding site between exon eight and nine exists in all 
three samples. 
 
Figure 4.46: NY-BR-1 ER-binding peaks in three tumor samples detected with ER ChIP-seq. 
 
Using the RNA-seq data from Varley et al. a gene expression profiling of the genes GATA-3, 
FOXA1, CK19, integrin-α 6, Elf5 and epithelial cell adhesion molecule (EpCAM) could be 
performed (Varley et al., 2014). CK19 expression can be detected in almost all samples with 
small exceptions in cell lines, triple negative, uninvolved ER
+
 and triple negative samples. In 
different cell lines and ER
+
 probes the CK19 gene expression is high and in the last three 
sample groups low (figure 4.47A). The gene expression of integrin-α 6 shows a different 
pattern: the expression is weaker compared to CK19 and it is mainly expressed in some cell 
lines, uninvolved ER
+
 tissue as well as in healthy and uninvolved triple negative tissue (figure 
4.47B). Another interesting marker is Elf5, which is expressed in mammary luminal 
progenitor cells. This protein is involved in alveolar progression (Oakes et al., 2008)(Oakes et 
al., 2008). In the analysed data set Elf5 gene expression is even weaker than integrin-α 6 
expression. It is almost not expressed in ER
+
 samples but in TN, uninvolved ER
+
, healthy and 
uninvolved TN tissues. Few cell lines do express Elf5 but on a very weak level (figure 
4.47C). EpCAM is involved in cell signalling, differentiation and migration processes and due 
to its potential to up-regulate c-myc it is categorized as oncogenic. It is expressed in several 
carcinomas, therefore functions as a tumour marker, and in progenitor cells. EpCAM is highly 
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expressed in almost all cell lines and TN samples, weakly expressed in the other tested 
samples figure 4.47D). GATA-3 expression is very high in the ER
+
 tumour samples but weak 
in TN, healthy and uninvolved TN samples. Few cell lines express GATA-3 as well some 
uninvolved ER
+
 samples (figure 4.47E). In contrast to GATA-3 is FOXA1 expression in 
general weaker. The FOXA1 expression is mainly in breast cell lines and ER
+
 samples 
observed. A decreased gene expression is found in uninvolved ER
+
 and TN and healthy 
samples. The TN samples have no or a very low expression of FOXA1 (figure 4.47F). 
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Figure 4.47: Gene expression analysis of A: CK19, B: integrin-α 6, C: Elf5, D: EpCAM, E: GATA-3, 
F: FOXA1 in breast cell lines, healthy, ER
+
 and TN samples as well as the adjacent tissues of ER
+
 and 
TN samples using the RNA-seq data of Varley et al. 
 
4 Results 
 
- 125 - 
 
4.6.4 In silico analysis of NY-BR-1 methylation status  
As described before methylation can have an impact on transcription initiation and therefore 
on gene expression. By using the TCGA database the methylation pattern of the twelve single 
fragments in the NY-BR-1 promoter region and gene body were analysed in the different 
molecular subtypes of breast cancer. The location of the fragments is shown in figure 4.48. 
One fragment (cg20211778) is located within the gene body; all other fragments are located 
before the transcription start site. 
 
 
 
 
 
 
 
 
 
 
Figure 4.48: Overview of the location of the fragments used in the methylation analysis. Orange: 
methylated (score >= 600), Purple: partially methylated (200 < score < 600) 
 
It is noticeable that fragment cg06872272, fragment cg06644844 and fragment cg15023313 
are highly methylated nearly throughout all samples. The fragment cg20211778 is highly 
demethylated in HER2, luminal A and B samples. In normal samples this fragment seems to 
be hyper-methylated (figure 4.49). 
 
 
Figure 4.49: Clusterheatmap of the methylation analysis of single fragments located in the promoter 
region and gene body of NY-BR-1 in the different molecular subtypes of breast cancer. (Colourkey: 
light yellow: highly methylated, dark blue: highly demethylated) 
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Due to in silico analyses it was possible to identify 69 damaging and 39 splicing SNPs. 
Moreover, it was shown that NY-BR-1 is mainly expressed in ER
+
 breast cancer and less in 
TN. NY-BR-1 belongs to the top 50 genes beside PGR and ER, which are down-regulated in 
TNBC. Another analysis with Chip-Seq data revealed that several ER binding sites are 
present within the NY-BR-1 gene. Gene expression analysis with RNA–Seq data showed that 
specific genes are expressed in ER
+
 breast cancer as well. Additionally, no uniform 
methylation pattern of NY-BR-1 in the different molecular subtypes could be observed. 
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5 Discussion 
The breast cancer associated antigen NY-BR-1 was discovered by a SEREX screening. NY-
BR-1 has restricted expression pattern in breast, prostate and testis, it is over-expressed in the 
majority (>70 %) of breast cancer patients, humoral and cellular immune response were 
detected and it has a subcellular localization to the cytoplasm and plasma-membrane. 
Therefore, it represents a promising target protein for cancer immunotherapy, e.g. antibody-
based or CAR therapies or for vaccination because CD4 and CD8 T-cell epitopes were 
identified (Gardyan et al., 2015; Jäger et al., 2005). 
However up to date, the biological function of NY-BR-1 in normal and tumorigenic breast 
tissues, its interaction partners and how it is transcriptionally regulated are unknown. 
Therefore the aims of this project were to reveal the transcriptional regulation, the effect of 
NY-BR-1 over-expression on cellular processes (e.g. proliferation, apoptosis) and protein 
interaction partner by combining wet lab techniques with in silico analyses. 
 
5.1 Transcriptional regulation of NY-BR-1 
The transcriptional regulation of gene expression is a complex process including chromatin 
remodelling, transcription factors, methylation in the promoter region or in the gene itself, and 
specific promoter elements (e.g. TATA box, enhancer, insulator, silencer, and activators).    
To understand how NY-BR-1 is transcriptionally regulated in normal breast tissue and breast 
tumours, a bioinformatic analysis of the predicted promoter region was performed. With the 
Alibaba 2.0 tool transcription factor binding sites as well as CpG islands (figure 4.6) were 
predicted in the assumed promoter region of the ANKRD30A gene (Grabe, 2002). The 
prediction included binding sites for the nuclear receptors ER, GR, PR, RXR/RAR and T3R 
but no binding sites were predicted for androgen receptor (AR). AR belongs to the nuclear 
receptor family and can be activated by binding of the ligand testosterone (Roy et al., 1999). 
The AR is related to the PR and can be blocked by high dosages of progestins (Bardin et al., 
1983). This shows that the actions of the single nuclear receptor are intertwined with each 
other. 
The breast tissue is a dynamic tissue and hormonal regulated underlying the hormonal 
changes during the menstrual cycle, pregnancy or menopause. Therefore it is supposable that 
NY-BR-1 expression is regulated by hormones and their receptors acting as TFs. As 
published by Theurillat et al. (2007), NY-BR-1 expression was compared with ER, HER2 
status, EGFR, prognosis and HLA class I antigen expression. 1.444 primary breast cancer 
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samples, 88 recurrence samples, 525 lymph nodes and 91 distant metastases were analysed by 
tissue microarrays. The results of the study showed that NY-BR-1 and ER expression can be 
correlated to each other (P < 0.0001) but not NY-BR-1 to HER2 status or EGFR. The co-
expression of NY-BR-1 and HLA class I antigen in 15 % of the primary breast tumours and in 
6 % of the distant metastases emphasizes once more that NY-BR-1 is a suitable target for 
cancer immunotherapy. The outcome for breast cancer patients was better when NY-BR-1 
was expressed (Theurillat et al., 2007). It is noteworthy to mention that in this study no 
discrimination between the single molecular subtypes of breast cancer was done but the 
results indicate that ER influences NY-BR-1 expression. 
 
As numerous binding sites for nuclear hormone receptors were identified, established cell 
lines were treated with different hormones and analysed for NY-BR-1 expression. For these 
experiments, NY-BR-1 negative as well as weakly NY-BR-1 positive normal breast and 
breast cancer cell lines were selected to investigate whether the respective treatment leads to 
the induction of NY-BR-1 transcription. As shown exemplary for MCF-7 and ZR-75-1 cells, 
these previous stimulation studies did not lead to an up-regulation of NY-BR-1 (figure 4.7). 
The measured copy numbers were low and no significant changes in NY-BR-1 expression 
levels were detectable. Many breast cell lines were analysed regarding their endogenous NY-
BR-1 expression but with the available tools no NY-BR-1 expression could be detected on 
protein level by Western blot analysis. The immortalized cell lines have the advantage to 
overcome the state of senescence and divide continuously with the right culture conditions 
compared to the primary cells. But due to the high turn over rate of cell divison during 
culturing the cells acquire mutations which can impair important cell signalling pathways. 
However, the ex vivo primary material enables to examine the natural state under controlled 
conditions for a certain time period. The microenvironment in primary tissues is preserved as 
well as in pleural effusions because the latter were cultured with conditioned medium, 
containing the cleared supernatant of the effusion including cytokines, chemokines, hormones 
and growth factors.  
Because no suitable cell culture system was available the transcriptional regulation of 
endogenous NY-BR-1 was investigated in primary cells, normal breast tissues, isolated 
epithelial cells derived from normal breast tissues and tumour cells from pleural effusions.  
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5.1.1 Transcriptional regulation of NY-BR-1 in normal breast tissue 
To study the transcriptional regulation in normal breast tissue, tissue pieces derived from 
breast reductions of healthy patients were used and stimulated with different hormones and 
agents. Before the stimulation experiments could start, the tissues needed to be dissected to 
purge the glandular tissue from fat and connective tissue. A challenge was to differentiate 
between connective tissue (in breast a high amount is present) and glandular tissue by eye. 
This led to a high heterogeneity between the single tissue pieces and thus also between the 
amount of NY-BR-1 expressing cells. As shown in figure 4.4 the NY-BR-1 expression in 
normal breast tissue is mosaic-like. Using IHC staining of the stimulated cryo-preserved 
tissues the heterogeneity of the tissues could have been resolved and the effects of stimulation 
would have been visible on protein level. But due to technical problems (difficulties to get the 
tissue section on a slide due to fat and connective tissue, tissue section was disrupted after 
staining) it was not possible to generate stained tissue sections of the stimulated samples. 
 
Two controls were chosen: tissue pieces without any stimulation cultured as long as the 
stimulated samples and never cultured tissue pieces. The stimulation within the tissue pieces 
showed that, in most of the cases, the non-cultured cells have a higher NY-BR-1 expression 
on mRNA level compared to the tissues/cells being in culture but have never been stimulated 
(figure 4.8). It seems that the NY-BR-1 expression is lost during the culturing process due to 
the absence of specific substances.  
The tissue pieces were stimulated with specific agents alone or in combination. The function 
of the used agents is summarized in table 3.4. The results of the stimulated tissue cells showed 
that none of the tested substances has the ability to have consistently the same effect on NY-
BR-1 expression (figure 4.9A). An exception is the stimulation with VitD3 because it 
suppresses NY-BR-1 expression in all tissue pieces. VitD3 binds to the vitamin D receptor 
(VDR), which belongs to the superfamily of nuclear receptors regulating the synthesis of 
many genes, by acting as a ligand-activated transcription factor (Evans, 1988). During 
puberty, pregnancy and lactation the VDR expression is the highest and is exclusively 
expressed in the differentiated luminal epithelial cells. It does not co-localize with Ki-67 
positive cells suggesting that VDR positive cells are differentiated cells with no proliferative 
functions (Narvaez et al., 2014; Santagata et al., 2014; Zinser et al., 2002). Moreover, there is 
a connection between ER and VDR: ER
+
 cells have higher VDR expression levels compared 
to ER
-
 cells and after application of oestrogen VDR is up-regulated in breast cancer cell lines 
(Buras et al., 1994; Byrne et al., 2000). As shown by IHC staining NY-BR-1
+
 cells can be 
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ER
+
 as well as ER
-
 in normal tissues (figure 4.39). It needs to be analysed how the VDR 
expression level conduct in the different stimulated samples because VitD3 stimulation blocks 
NY-BR-1 expression in the stimulated tissue pieces whereas E2 stimulation has opposed 
effects. Due to the complexity of VitD3 processing it is difficult to study the VDR effects in 
the in vivo situation of human mammary epithelial cells. In combination with 5’Aza VitD3 
stimulation shows conflicting results on NY-BR-1 expression. This might be due to the 
heterogeneity of the tissue and the different amount of ER
+
 cells and this can influence the 
NY-BR-1 expression. The analysis of the VDR levels in the samples can give information 
about how diverse its expression pattern is and whether this needs to be considered.  
Two patients were also stimulated with other agents (progesterone, retinoic acid, TSA) (figure 
4.10). In both analysed patients (HD-T-203/HD-T-258) retinoic acid stimulation decreases 
NY-BR-1 expression compared to the control whereas the combination with 5’Aza has 
opposed effects. The retinoic acid receptor (RAR) and retinoic X receptor belong to the 
nuclear receptor superfamily of ligand-dependent transcription factors (Chambon, 1996). 
After binding of retinoic acid (9-cis) to RAR a conformational change is induced affecting 
other proteins, leading to repression or induction of transcriptional activation (Evans and 
Mangelsdorf, 2014). Further analyses are necessary to reveal the molecular consequences of 
retinoic acid stimulation. The analysis of the methylation status shows whether different 
methylation settings in the promoter region of NY-BR-1 are influences the effects of retinoic 
acid actions on NY-BR-1 expression.  
The progesterone stimulated tissue pieces of HD-T-203 and HD-T-258 show that NY-BR-1 
expression is down-regulated whereas the combination Aza/Progesterone leads to an up-
regulation of NY-BR-1 (figure 4.10). Progesterone is a steroid hormone and is involved in 
many biological processes such as mammary gland development and reproduction (Macias 
and Hinck, 2012). The isoform of the progesterone receptor (PR) PR-B drives mammary 
gland development and expansion (Conneely et al., 2001). The actions and involvements of 
progesterone and its receptor are manifold: Via paracrine signalling progesterone can induce 
proliferation to steroid receptor negative cells but it needs to be considered that the PR is 
expressed just on 10-15 % of the luminal cells (Brisken et al., 1998). Furthermore, it is known 
that progesterone is a key driver for mammary gland stem cell expansion and maintenance 
(Brisken, 2013) through the PR-RANKL pathway (Tanos et al., 2013). The PR can bind to 
progesterone response elements located in the DNA to initiate and alter transcription by 
recruiting cofactors (Cicatiello et al., 2004; Diep et al., 2015). Moreover, the actions of PR are 
depending on ER and it is able to “sense” the cell context of presence or absence of activated 
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pathways (Diep et al., 2015). Thus the interplay between ER and PR is an important aspect to 
understand a part of the hormonal regulation in the female breast. It seems that for NY-BR-1 
expression and regulation both hormones and their receptors are necessary but how this might 
work in detail needs to be analysed. To test the effect of ER and PR on NY-BR-1 expression 
an experimental set up can be the stimulation of tissue pieces with E2 and progesterone, E2 
and RU-486 (an progesterone receptor antagonist), Tamoxifen and progesterone and control 
tissues (not stimulated). The NY-BR-1 expression can be analysed on mRNA level via qPCR 
and on protein level either via IHC staining or Western blot analysis.  
In general it was observed that older patients (~ 45+ years) have more NY-BR-1 expression 
compared to the younger ones (18-30 years). An explanation is that the breast tissue is a 
dynamic tissue and the genetic profile of specific cell populations are changing due to 
different hormone levels appearing within a woman’s life time such as menstrual cycle, none, 
one or more pregnancies, breast feeding and menopause (Medina, 2005). These processes 
force cells to change their normal behaviour because new structures (alveogenesis) need to 
emerge but also to regress when hormonal changes occur.  
 
To receive a more homogenous cell population the next step was to isolate and culture 
epithelial cells derived from breast reductions. This cell population consists mainly of 
myoepithelial and luminal cells. The same controls as with the tissue pieces were taken and 
analysed regarding their NY-BR-1 expression. The same effect, that NY-BR-1 expression is 
higher in the non-cultured cells than in the cultured ones, was observed in both analysed 
patients (figure 4.11). With the isolated epithelial cell populations different effects of certain 
stimulation agents could be detected compared to the cultured tissue pieces. Patient HD-T-
292 and 311 show an increase of NY-BR-1 expression after progesterone stimulation. The 
same was observed after retinoic acid and TSA were applied. In one patient (HD-T-292) a 
clear down-regulation of NY-BR-1 was observed with Tamoxifen and Aza/Tamoxifen 
compared to the control. The second patient (HD-T-311) showed a down-regulation with the 
combination Aza/Tamoxifen but not with Tamoxifen alone (figure 4.12). Tamoxifen is an ER 
antagonist and while binding to the ligand-binding domain of ERα a conformational change is 
induced. Thereby, corepressors are recruited and oestrogen is not able to bind to its receptor 
anymore leading to a non-proliferative effect (Hayes and Lewis-Wambi, 2015). The 
conflicting results of Tamoxifen on NY-BR-1 expression could be explained with the 
observation that depending on the cell type and the present promoter settings 4-
hydroxytamoxifen, which functions as antagonists at EREs, can behave as agonists through 
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indirect pathways (ligand-dependent activation, recruitment of co-factors). Moreover, it has 
been shown that ERβ can oppose the actions of Tamoxifen on an AP-1 reporter gene or on the 
SP1 pathway (Kushner et al., 2000; Paech et al., 1997; Saville et al., 2000). AP-1 and SP1 
have both predicted binding sites in the promoter region of NY-BR-1 (table 4.1). The 
stimulation with oestrogen alone or in combination with 5’Aza has conflicting effects. It can 
be observed that the ER related stimulations (E2, Tamoxifen alone or in combination with 
5’Aza) have opposed effects on the NY-BR-1 expression in the two analysed patients. To 
confirm whether oestrogen and Tamoxifen have a general impact on NY-BR-1 expression in 
healthy isolated epithelial cells more patients need to be stimulated and analysed.  
 
5.1.2 Transcriptional regulation of NY-BR-1 in pleural effusion cells 
Due to early detection methods (mammography) and new therapy strategies (neoadjuvant 
therapy) breast carcinomas are smaller in size and thus less tumor tissue is available. 
Therefore, pleural effusions represent a good source to study NY-BR-1 expression in primary 
tumour cells because the effusions contain tumour cells, immune cells like macrophages and 
lymphocytes as well as cytokines, chemokines, and growth factors. The diagnosis of the 
primary tumour is shown in table 4.3. It must be pointed out that the molecular subtype forms 
another aspect that is important regarding NY-BR-1 expression. Considering the in silico 
analysis NY-BR-1 is mainly expressed in ER
+
 breast carcinomas and less in triple negative 
(figure 4.43). Pleural effusion cells were tested regarding their HER2, EpCAM, CK19 and 
intra- and extra-cellular NY-BR-1 expression by FACS analysis (figure 4.17). Additionally 
the mRNA levels of ER, PR and HER2 expression were tested (figure 4.18). The results show 
that the receptor status of the obtained pleural effusion cells can have changed compared to 
the one of the primary tumour. This indicates that due to therapy and selection pressure the 
gene expression profile is changing and this can have consequences on NY-BR-1 expression 
with either repressing or enhancing it. It needs to be considered that the patients of the 
obtained pleural effusions differ in therapy status and treatment.  
The two controls were also analysed separately (figure 4.13). As opposed to normal breast 
tissue and isolated normal epithelial cells, the NY-BR-1 expression in NY-BR-1
+
 pleural 
effusions could be maintained for several weeks when cultured with the specific conditioned 
supernatant (figure 4.19). The NY-BR-1 expression decreases from day zero to day eleven but 
after this status quo is achieved the NY-BR-1 expression is detectable on mRNA level at least 
until day 28. The decrease of NY-BR-1
+
 cells can be due to that these cells do not proliferate 
and are going into a senescence state and are therefore overgrown of NY-BR-1- cells. 
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These observations lead to the conclusion that the NY-BR-1 expression might depend on 
certain substances existing in the medium. A systematic cytokine and chemokine analysis 
would help to compare the supernatants of NY-BR-1 negative vs. NY-BR-1 postive, e.g. a 
multiplex assay containing 50 different cytokines/chemokines. Additionally, the supernatants 
of NY-BR-1
+
 and NY-BR-1
-
 pleural effusions can be analysed by using 2D gelelectrophoresis 
or mass spectrometry. 
 
The pleural effusion cells of four patients were additionally stimulated with VPA, Tamoxifen 
and both in combination with 5’Aza (figure 4.15). Tamoxifen and Aza/Tamoxifen up-regulate 
NY-BR-1 in two patients (HD-A-73, -78) but in HD-A-88 a down-regulation is seen 
compared to the control cells. This shows again that NY-BR-1 regulation/expression is 
intertwined somehow with ER. In three patients (HD-A-73, -78, -88) a down-regulation of 
NY-BR-1 could be observed by VPA stimulation and in two patients (HD-A-73, -88) in lesser 
content by Aza/VPA as well. The down-regulation by VPA was unexpected because the 
HDAC inhibitor VPA is responsible to open the chromatin structure to make a gene more 
accessible. One of the latest stimulation experiments with TSA and VPA was a time kinetic to 
see whether the effects of VPA or TSA are changing over time (figure 4.16). The pleural 
effusion cells were obtained from the same patients known as HD-A-88. The results show that 
E2, progesterone, VitD3, retinoic acid and VPA up-regulate NY-BR-1 expression compared 
to the controls. This finding is a contrast to the stimulation of the HD-A-88 pleural effusion 
cells because the stimulation with the indicated hormones promoted a NY-BR-1 down-
regulation. An explanation is that the cells of HD-A-88 were cultured and stimulated over a 
longer time period (up to six days), whereas the cells of HD-A-90 were cultured for one day 
and stimulated for twelve hours. TSA alone has not the ability to up-regulate NY-BR-1 in 
such content as the other substances. At the 8 and 10 h time point TSA/E2 and VPA/TSA/E2 
even down-regulate NY-BR-1 expression. Also the other combinations TSA with 
progesterone, VitD3, retinoic acid and VPA show less NY-BR-1 up-regulation compared to 
the control and VPA in combination with the mentioned substances. Thus it seems that 
proteins such as TFs are blocked or repressed by TSA or VPA stimulation that affects NY-
BR-1 expression. TSA and VPA inhibit class I and II deacetylases. It is known that HDACs 
are not just affecting the acetylation status of histones but also non-histone effector proteins 
such as transcription factors and signal transduction mediators to alter, enhance or repress 
transcription initiation (Drummond et al., 2005). The following non-histone proteins are 
influenced by HDAC inhibitors because they increase the acetylation status: GATA-1 (Boyes 
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et al., 1998), ERα (Wang et al., 2001), androgen receptor (AR) (Fu et al., 2003), YY1 (Yao et 
al., 2001) and MyoD (Sartorelli et al., 1999). Almost all of these proteins have predicted 
binding sites in the promoter region of NY-BR-1 (table 4.1). Additionally, tumour associated 
proteins are influenced by HDAC inhibitors. HER2/neu is down-regulated (Scott et al., 2002) 
but c-myc (Sasakawa et al., 2003) and ERα (Yang et al., 2000) are up-regulated after applying 
HDAC inhibitors. In contrast to Yang et al., who also took the methylation status of the DNA 
into account, the group of Reid found out that ERα expression is blocked in MCF-7 cells after 
incubation with TSA and VPA due to a reduction of mRNA encoding for ERα.  Additionally, 
they detected a reversible promoter shutoff of ERα, pS2 and cyclin D1 (Reid et al., 2005). It 
might depend on the context that VPA and TSA have the ability to up- or down regulate NY-
BR-1 expression. It needs to be testified whether the influence on acetylation on the before 
described proteins can be mediated by VPA and TSA as well. But if these named proteins are 
regulated by acetylation it might be possible that they are able to affect NY-BR-1 expression. 
This needs to be clarified by a systemic analysis of the TFs, hormone receptor expression and 
control genes to ensure that the appropriate pathways are functional. 
 
In HD-A-66, -68, and -86 NY-BR-1 expression is extremely low. The explanation for this 
finding can be that these cells had no NY-BR-1 expression at all due to a molecular subtype, 
which is not known for NY-BR-1 expression, or the therapy application represses NY-BR-1 
expression. The receptor status of the pleural effusion cells of these three patients is as 
followed: HD-A-66/-68 are triple negative and HD-A-86 is weakly HER2
+
 but ER
-
/PR
-
. 
These results confirm the in silico analysis of the Varley et al. data set, where NY-BR-1 is 
expressed in ER
+
 breast cancer but not in triple negative (Varley et al., 2014). With the 
applied stimulation setting it was not possible to force NY-BR-1 expression in any 
measurable way. If it turns out to be true that NY-BR-1 is expressed on specific progenitor 
subsets in the mammary gland than the analysed pleural effusion cells of the patients HD-A-
66, -68, and -86 had lost the characteristic features of certain cancer progenitor cells. Maybe 
when NY-BR-1 negative cells get back into stem/progenitor cell character they would start to 
express NY-BR-1 in a more frequent manner. 
For the future settings several points need to be addressed: 
1. Stimulation of tissue pieces and isolated epithelial cells from the same patient to 
analyse the effect on NY-BR-1 expression. 
2. Culturing of tissue pieces and isolated epithelial cells with conditioned medium to 
maintain NY-BR-1 expression over a longer culture period. 
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3. Longer stimulation time period (applying the stimulation agents every day for up to 
three to six days). 
4. Other combinations like e.g. E2/progesterone, TSA/E2/progesterone, E2/RU-486, 
Tamoxifen/progesterone and VPA/E2/progesterone can be tested to detect the 
influence on NY-BR-1 expression in normal and tumourigenic tissues. 
5. A detailed phenotypic characterization of the cells (receptor, TFs) on mRNA and 
protein level by qPCR and Western blot. 
6. Another trial could include the concomitant inhibition of HDACs and DNA 
methyltransferases (DNMT) to see whether NY-BR-1 can be up-or down-regulated as 
it is observed with the RARβ2 (Mongan and Gudas, 2005). 
7. Using Chip-Seq technology to fish specific TFs and analysing their binding activity in 
the NY-BR-1 promoter. 
 
5.1.3 Epigentic regulatory mechanisms 
Transcriptional regulation not only occurs on histone level but also on the DNA self by de- or 
hypermethylation in specific promoter regions. From some of the stimulated probes (isolated 
epithelial and pleural effusion cells) DNA was isolated to analyse the influence of stimulation 
agents on the methylation status and whether the methylation status can be correlated to NY-
BR-1 expression (figure 4.21). Unfortunately, the NY-BR-1 promoter region and the gene 
body right after transcription start site contain a lot of repetitive elements, which makes it 
difficult to obtain clear results and to study all interesting regions. This is the reason why it 
was only possible to analyse the promoter region up to approximately 1.300 bp of 
transcription start site and to have just two amplicons (number 57, 58) located within the 
gene. 
Considering these results it shows that the differences in methylation status might occur 
randomly and might not influence NY-BR-1 expression at first sight. It is interesting that in 
some amplicon areas an increased methylation pattern can be detected but that does not seem 
to influence the NY-BR-1 expression at this point. To verify these findings more stimulated 
samples need to be analysed. It is worth to mention that 5-Aza-2´Deoxycytidine, a 
demethylation agent, functions as a positive control and should result in hypo-methylation of 
proliferating cells. As the primary cultured cells do not proliferate or proliferate very slowly, 
Aza treatment may not have had the desired effect and has thus no impact on NY-BR-1 
expression. Moreover, it would be interesting to investigate the methylation within the gene to 
see whether a specific pattern can be observed between stimulated tumour cells and healthy 
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breast cells. A detailed database analysis of the methylation status of various fragments in the 
promoter region and gene body of NY-BR-1 is described in chapter V in silico analysis. A 
detailed database analysis of TCGA samples showed that also no uniform methylation pattern 
of the promoter region of NY-BR-1 can be connected to NY-BR-1 expression in the different 
molecular subtypes of breast cancer. 
 
Nevertheless, from these results the conclusion can be drawn that NY-BR-1 expression is not 
mainly regulated by the methylation status in the promoter region. The transcriptional 
regulation of NY-BR-1 can be influenced by ER and PR but that needs to be confirmed with 
further experiments. The effects of VPA and TSA stimulation suggest that transcription 
initiation of NY-BR-1 occurs on histone level and through factors regulated or affected by 
acetylation.  
Considering the limitation of patient samples and obtained material it is difficult to analyse 
systematically a complex process such as the transcriptional regulation of a protein. It 
becomes important that many factors (microenvironment of normal and tumourigenic tissue, 
molcecular subtypes, interplay between TFs, epigenetic modifications) influence the 
transcriptional initiation of a protein. If further material is acquired the experiments as 
mentioned before will be performed. 
 
5.2 Functional analysis of NY-BR-1 
One major task during this project was to determine the function of NY-BR-1 in normal 
breast tissue as well as in breast cancer. Knowing the biological function of the tumour-
associated antigen NY-BR-1 is important to understand its role in cellular processes. As NY-
BR-1 is over-expressed in the majority of breast cancers, the effect of NY-BR-1 over-
expression on proliferation, apoptosis and the cell cycle was investigated in transiently 
transfected normal HEK293 and MCF10A cells, the cancer cell line MCF-7 and transformed 
HEK293T cells. A challenge was that the transfection efficacy varies strongly between the 
cell lines and in transiently transfected cells NY-BR-1 expression decreases rapidly after three 
to four days after transfection (HEK293: 11.6 – 0.397 %, MCF-7: 16.7 – 1-89 %) (figure 
4.24). By using FACS analysis it was still possible to analyse low amounts of NY-BR-1
+
 cell 
populations. The compensation of the single used colours was difficult to adjust because the 
expressed GFP in the pc3 GFP transfected cells (control cells) was too strong and beamed 
into the other channels. Therefore, the amount of the pc3 GFP plasmid was reduced for 
transfection. 
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The proliferation assay revealed that NY-BR-1
+
 cells do not proliferate as indicated by the 
PKH26 labelling and do not go into apoptosis on an increased level (Annexin/7-AAD 
staining) compared to the non-transfected cells, pc3 GFP transfected cells and NY-BR-1
-
 cell 
population (figure 4.22-4.28).  
The effect of NY-BR-1 over-expression in transfected cell lines was analysed in more detail 
by performing cell cycle analyses. The cell cycle analysis of pc3 NY-BR-1 transfected cells 
from day one to day three showed that NY-BR-1
+
 cells arrest more in the G1 phase than the 
non-transfected cells and the NY-BR-1
-
 population cells (figure 4.28-4.31). These results 
indicate that NY-BR-1 is responsible to slow down the cell cycle and prevents the cells going 
from G1 to S phase.  
It is known that the retinoblastoma (rb), p107 and p130 repressors bind to the E2F 
transcription factor and thereby preventing the transition. Several cell cycle checkpoints are 
present. The G1 phase checkpoint is necessary to sense any type of DNA damage. If the 
decision is made to go into the S phase the level of cyclin D rises and forms complex with 
diverse proteins. Translocation of the E2F4 and E2F5 repressors is taking place as well as 
transcriptional activation of downstream targets to promote the G1 to S transition (Skotheim 
et al., 2008). In the case that NY-BR-1 promotes G1 phase arrest a detailed analysis of the 
different phosphorylated Rb proteins and cyclin D1 is necessary. Ki-67, a proliferation 
marker, could also be an indicator. If NY-BR-1 positive cells are in G1 arrest they should be 
Ki-67 negative because this protein is absent in resting cells. IHC staining of normal 
mammary gland tissue showed that NY-BR-1
+ 
cells are Ki-67
-
 indicating that the NY-BR-1
+
 
cells are in a quiescent state. 
One major problem was that the cells quickly loose the NY-BR-1 expression. A reason for 
this phenomenon can be that the cells digest the plasmid and remove the already expressed 
NY-BR-1 because it slows down the proliferation. It was tried to generate stable transfected 
cell lines but the cells proliferate very slowly and after two months of cultivation the cells lost 
NY-BR-1 expression on RNA and protein level. A way to circumvent this problem is to 
generate viral transduced cells stably expressing NY-BR-1 and repeat the proliferation assay 
and cell cycle analysis. Another explanation of the G1 phase arrest of NY-BR-1
+
 cells is the 
assumption that NY-BR-1 is expressed in stem/progenitor cells of the mammary gland. This 
kind of cells is in a quiescent state and they start proliferation after a certain stimulus. This 
will be illustrated in detail in the stem/progenitor chapter (chapter 5.4). 
To analyse the differences between NY-BR-1 positive vs. NY-BR-1 negative cells laser micro 
dissection (LMD) is a useful tool. That tool enables to cut out single cells or tissue areas 
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positive or negative for NY-BR-1. The drawback of this method is that enough material needs 
to be obtained which can be difficult due to low amount of tissues. Moreover for RNA-Seq 
analysis the RNA quality is poor because the laser cutting is performed at room temperature. 
Nevertheless, with the obtained material it is possible to do proteomics or DNA analysis.  
 
5.3 Identification of NY-BR-1 protein interaction partner 
Protein-protein interactions are regulated by a particular stimulus or signal and depend on 
cell-type, developmental stage of the cell, cell cycle phase and the presence of other proteins. 
The identification of NY-BR-1 protein interaction partner helps to understand the role of NY-
BR-1 in cellular processes (proliferation, cell cycle etc.) in a given cellular environment since 
execution of a particular protein function will be strongly dependent on contact with surfaces 
of neighboring proteins (Ngounou Wetie et al., 2014).  
To find specific interaction partners of NY-BR-1 a Co-IP with a following mass spectrometry 
analysis was performed with three transiently pc3 NY-BR-1 transfected cell lines (HEK293, 
MCF-7, MCF-10A). Co-IPs of lysates from primary cells were also done with α-NY-BR-1 
(C-18) and α-NY-BR-1#2 to analyse the interaction partners of NY-BR-1 in a natural setting 
but after silver - or coomassie blue staining no NY-BR-1 at the appropriate height in the SDS-
PAGE gels could be detected.  
For analysis the unique proteins in the NY-BR-1 transfected cells were taken and compared 
with each other in all cell lines. Differences between the NY-BR-1 scores/significant protein 
sequences between the three cell lines could be observed and this can be due to a difference in 
transfection efficacy resulting in different protein expression levels and thus the scores are 
varying. Furthermore, the differences of efficiency in immunoprecipitation need to be 
considered although all samples were treated the same way. As stated by Ngounou Wetie et 
al. this biochemical method for protein-interaction detection has some weaknesses: the used 
polyclonal antibody (α-NY-BR-1 (C-18)) can lack high specificity and avidity and therefore a 
risk is of detecting non-specific interactions, due to the presence of highly abundant 
contaminating proteins, exists. The monoclonal antibody α-NY-BR-1#2 was used to perform 
Co-IPs of either pc3 NY-BR-1 transfected cell lines or of lysates derived from primary 
material but after silver staining no NY-BR-1 band could be detected at the appropriate 
height. However, the analysis of large molecular weight complexes can be a problem.  In 
some cases genetic modifications prior to the biochemical analysis need to be performed as 
well as the destruction of the native cellular environment (Ngounou Wetie et al., 2014). 
Although this method has some disadvantages, it can give hints for potential interaction 
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partner in short time, is cost-effective, ease-of-use, and is compatible with other downstream 
methods. 
Tubulin beta-4B chain (TBB4) is the only protein shared between all cell lines and this 
protein is a major component of microtubules, which are involved in chromosome separation 
during mitosis/meiosis and cell trafficking. Moreover, microtubules are a component of the 
cytoskeleton of every cell and of the mitotic spindles (Vicente and Wordeman, 2015). The 
protein K220, also known as KRT76, belongs to the type II keratin family and could be 
detected in MCF-10A and MCF-7 cells. This protein constitutes the intermediate filaments of 
the cytoskeleton and help to maintain cell function and structure. The third interesting protein 
is SNX27, which belongs to the sorting nexin family. Proteins of this family are involved in 
endocytosis of plasma membrane receptors and it supports their protein trafficking. SNX27 
protein contains a PX domain (phospholipid-binding motif) and a PDZ domain (protein-
protein interaction domain that is often found in the postsynaptic density of neuronal 
excitatory synapses). This domain combination is unique to SNX27 (Wang et al., 2014; 
Worby and Dixon, 2002). The HS71L protein could be detected in two lanes of the MCF-10A 
and MCF-7 cell lines. This heatshock protein is involved to maintain the right folding of a 
newly synthetized protein (chaperone character) and to prevent aggregation of existing 
proteins. The identified proteins, which might be potential interaction partner of NY-BR-1, 
can be clustered as components of the cytoskeleton, and regulation of protein trafficking and 
folding. 
It is known that NY-BR-1 localizes in the cytoplasm and plasma-membrane (Seil et al., 
2007). The translation of mRNA into a protein takes place in the cytosol of a cell or across the 
membrane of the endoplasmatic reticulum. The synthesized peptide is stored in the 
endoplasmatic reticulum until it gets packed into a vesicle and transported to its final 
location(Reece et al., 2014). Therefore it is not unlikely that NY-BR-1 interacts with proteins 
involved in trafficking and folding. Further analyses by western blot or a Co-IP against TBB4 
and K220 can help to understand how these two proteins are influenced by NY-BR-1 
expression.  
 
5.4 NY-BR-1 expression in stem/progenitor cells in the mammary gland 
As described in the stem cell chapter 1.5 many different stem/progenitor cell populations are 
known to be present in the mammary gland. They fulfil specific functions depending on the 
developmental state of the breast (puberty, pregnancy, breast feeding, and menopause). 
Although many questions about stem/progenitor cells in the breast remain unclear it is 
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assumed that the different molecular subtypes of breast cancer arise due to these different 
stem/progenitor cell populations. The theory describes that due to mutations occurring in the 
normal different stem/progenitor cell populations the subtypes emerge (Reya et al., 2001). 
The evidence for this theory is that breast cancer stem cells (BCSC) share similarities with 
normal stem cells regarding their self-renewal and differentiation (Ginestier et al., 2007; Ponti 
et al., 2005). A second theory assumes that BCSCs arise from epithelial-mesenchymal 
transition (EMT) because the cells, undergone EMT, have an increased ability to form 
mammospheres and they express many genes associated with that process (Mani et al., 2008; 
Velasco-Velázquez et al., 2012). As described in chapter 1.5 the different molecular subtypes 
of breast cancer are prognostic and require unique therapy strategies and thus it is important 
to characterize the cells as detailed as possible.  
The NY-BR-1 expression pattern in the normal breast is very mosaic-like and only single 
cells per gland express this protein as assessed by IHC staining of various normal breast tissue 
sections (figure 4.4). The NY-BR-1 expression in breast cancer depends on the molecular 
subtype and mainly ER
+
 specimens express NY-BR-1 (figure 4.49). Moreover, the 
proliferation assay and the cell cycle analyses revealed that NY-BR-1 over-expressing cells 
do not proliferate, do not show increased apoptosis and accumulate in the G1 phase. All these 
results led to the assumption that NY-BR-1 might be a potential stem/progenitor cell marker 
in the mammary gland. 
As proposed by Dontu et al., mammary gland progenitor cells can form non-adherent 
mammospheres with the ability to differentiate along all three mammary epithelial lineages 
(myoepithelial cells that form the basal layer of ducts and alveoli, ductal epithelial cells that 
line the lumen of ducts, and alveolar epithelial cells that synthesize milk proteins). Secondary 
and tertiary mammospheres are more enriched with a 100 % of multilineage progenitors 
compared to the primary spheres containing these progenitor cells to a lesser content (Dontu 
et al., 2003). 
Mammospheres from four different healthy patients were generated with isolated epithelial 
cellsfrom reduction mammoplastiesaccording to the protocol of Dontu et al. A lot of cells are 
needed to generate enough spheres to do all analyses including immunofluorescence and IHC 
staining, Western blot, qPCR and to generate secondary and tertiary spheres. That is the 
reason why not all analyses were carried out with all patients. Nevertheless, it was possible to 
generate primary, secondary and tertiary spheres of one patient and the qPCR results show 
that NY-BR-1 is expressed in the mammospheres, but expression is lost over the culturing 
time period suggesting that beside growth factors (basic fibroblast growth factor (FGF), EGF) 
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other factors (e.g. E2, progesterone) are needed to regulate and maintain NY-BR-1 expression 
in culture.  
Compared to the mammospheres NY-BR-1 expression can be maintained over a period of 
several weeks in pleural effusion cells if incubated with the conditioned medium but the 
expression decreases until it is diminished completely (figure 4.19). It is important to 
characterize the substances (cytokines, chemokines, hormones), which are implied in the 
supernatant of the pleural effusion because it is very likely that they help to maintain NY-BR-
1 expression under the requirement that the cells of the patients are NY-BR-1 positive. If 
these substances can be identified by e.g. a bioplex analysis and applied to the spheres it 
might be possible to maintain NY-BR-1 expression even over a longer culture period, which 
would improve the analysis of the gene expression profile. The NY-BR-1 expression on 
mRNA level varies between the four patients and this can be due to different kinds of 
stem/progenitor cell subsets or difference in the amount of progenitor cells (figure 4.35). To 
get a better impression, which proteins are up- or down-regulated while NY-BR-1 is 
expressed or not, HER2, ER, PR, GATA-3, FOXA1, and integrin-α 6 expressions were 
analysed via qPCR. Results of other groups showed that specific progenitor cells in the 
mammary gland are ER and PR negative and this could be confirmed by the four analysed 
patients (Lim et al., 2009; Visvader and Stingl, 2014). Strikingly, the HER2 expression was 
high compared to the other tested receptors/proteins. It belongs to the epidermal growth factor 
family besides HER1, HER3 and HER4 and is a transmembrane protein. HER2 has no own 
ligand and becomes activated after HER2/HER3 dimerization (Koutras and Evans, 2008). 
HER2 is known for enhancing cell proliferation and repressing apoptosis (Olayioye, 2001) 
and shows thus opposed effects compared to NY-BR-1 expression. But it is noteworthy that 
the HER2 expression was analysed in primary cells and the NY-BR-1 over-expression effect 
occurred in transfected cell lines.  
As shown by Theurillat et al. NY-BR-1 expression could not be linked to HER2 status in 
breast cancer samples (Theurillat et al., 2007). Now it is necessary to test whether the HER2 
expression on mRNA level is translated to protein level in the mammospheres and whether 
they correlate with NY-BR-1 expression. It needs to be considered that this HER2 expression 
can be a coincidence because HER2 and HER3 are needed for mammary gland development 
at different stages e.g. for alveogenesis (Stern, 2003). Due to missing information it is not 
known whether the tested patients were pregnant and had breast feeding.  
However, NY-BR-1 expression is not associated with other progenitor cell marker, such as 
GATA-3, FOXA1, and integrin-α 6. Dontu et al. did a transcriptional profiling of 
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mammosphere derived cells and their analysis revealed that GATA-3 expression is only 
occurring in differentiated cells (Dontu et al., 2003). It is suggested that the transcription 
factors GATA-3 and FOXA1 interact with each other and that they are also known to be 
regulators of ERα expression. GATA-3 is involved in the formation of terminal end buds at 
puberty and luminal cell differentiation (Kouros-Mehr et al., 2006). It is a driver of breast 
oncogenesis and low GATA-3 expression is described for ER/PR negative, HER2 over-
expressing breast cancer (Mehra et al., 2005). FOXA1 binds to specific promoters of genes 
associated with regulating signalling pathways and the cell cycle (Carlsson and Mahlapuu, 
2002). By binding to cis-regulatory regions of heterochromatin it enhances the binding 
between ERα and chromatin (Laganière et al., 2005). The interplay between GATA-3, 
FOXA1 and ER are thought to be needed for normal mammary gland development, 
particularly the differentiation of mammary stem/ progenitor cells to the ER-positive lineage 
(Hisamatsu et al., 2014). Due to the absence of ER in all tested NY-BR-1 expressing 
mammospheres and a weak GATA-3/FOXA1 expression it is likely that NY-BR-1 is 
expressed in an undifferentiated stem/progenitor cell subset in the mammary gland.  
Integrin-α 6 (CD49f) is used for the characterization of the myoepithelial lineage in the 
mammary gland (Shackleton et al., 2006; Stingl et al., 2006). In the tested mammospheres 
integrin-α 6 is expressed but it cannot be connected to a specific NY-BR-1 expression profile 
suggesting it is not the best link to NY-BR-1 expression. This assumption is confirmed by the 
gene expression profile of integrin-α 6 of the RNA-Seq data set published by Varley et al. It 
shows that integrin-α 6 is rather expressed in certain breast cell lines, healthy samples and in 
ER
+
 and TN adjacent breast tissue but not in ER
+
 and TN breast cancer tissues while NY-BR-
1 is mainly expressed in ER
+
 breast cancer samples (figure 4.43) (Varley et al., 2014). 
The immunofluorescent staining of mammospheres of two different patients shows that the 
spheres are NY-BR-1
+
. The spheres of one patient (HD-T-258) were stained with CK14 
(myoepithelial cell marker) and the spheres of the other patient (HD-T-311) stained with 
CK18 (luminal cell marker). But the expression of both markers is very weak until negative 
suggesting that progenitor cells expressing NY-BR-1 belong to a much undifferentiated 
subset of stem/progenitor cells in the healthy mammary gland. In contrast to the 
mammaospheres the gene expression analysis of the Varley et al. data set demonstrates that 
CK19 expression is increased in ER
+
 breast cancer samples compared to TN, healthy, ER
+
 
and TN uninvolved tissues. These results show that one has to distinguish between 
mammospheres and tumorigenic tissue and that NY-BR-1 expression occurs in luminal 
epithelial cells in breast cancer samples. 
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To characterize the gene expression profile of NY-BR-1 positive mammospheres a microarray 
could help to understand the up- or down-regulation of certain genes when NY-BR-1 is 
expressed to get more details which progenitor cell population expresses NY-BR-1. Another 
option can be the culturing of potential progenitor cells derived from mammospheres on 
collagen or matrigel and analysing if mammary gland structures are develop after adding of 
e.g. prolactin (Dontu et al., 2003). If so they could be tested on NY-BR-1 expression and 
maybe the function of NY-BR-1 becomes clearer.  
Co-localization of NY-BR-1 with ER in serial tissue sections of normal mammary gland 
tissues, analysed by IHC staining (figure 4.39), show that NY-BR-1
+
 cells can be either ER
+
 
as well as ER
-
. From these data it can be concluded that NY-BR-1 is expressed in 
mammospheres but it seems that it must be an early undifferentiated subset with ER
+
/ER
-
 
negative status. Furthermore, a detailed gene expression profile is necessary of NY-BR-1 
positive vs NY-BR-1 negative cells using e.g. the LMD method. In the case that enough cells 
are available a FACS sort with additionally RNA-Seq analysis can be performed. Another 
option is the analysis of co-localization of NY-BR-1 with PR, CD49f, EpCAM, and integrin-α 
6 via IHC staining in healthy and tumorigenic breast tissues. The results can give information 
about the expression profile and can provide evidence of the specific progenitor subset.  
 
5.5 In silico analysis of NY-BR-1 
Computational analysis becomes increasingly important to understand complex settings such 
as interactions between proteins, to understand and analyse large data sets (sequencing data) 
and to find differences in the gene profile of cells in normal but also in tumorigenic tissue. 
Here, several different analyses were performed regarding the in silico characterization of 
NY-BR-1.  
 
5.5.1 Molecular subtypes  
As described before breast cancer is classified according to the different receptor status of ER, 
PR and HER2. This classifications needs to be done to evaluate the best therapy strategy for 
the patient. However, the highest NY-BR-1 expression could be detected in ER
+
 breast cancer 
(figure 4.44) but here it was not possible to discriminate the ER
+
 breast cancer samples further 
into luminal A or B. This would have been helpful to see whether the ER
+
 breast cancer 
samples are also HER2
+
, thus a kind of luminal B because then it could be comparable with 
the gene expression profile of the mammospheres. These additional data could offer valuable 
clues to analyse whether NY-BR-1 expression in normal breast samples is correlated to HER2 
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expression but not to ER/PR. And these findings could be compared to tumorigenic breast 
where it seems to be the other way around. As described in the mammosphere chapter GATA-
3, FOXA1 and ER are tight together to regulate transcription of specific genes. The gene 
expression profile of GATA-3 and FOXA1 of the Varley et al. data set shows that these two 
factors are mainly expressed in ER
+
 breast cancer samples (Varley et al., 2014). Compared to 
TN breast cancer NY-BR-1 was significantly over-expressed in ER
+
 samples indicating that 
the receptor status is important and a marker for NY-BR-1 expression (figure 4.44). 
Moreover, NY-BR-1 belongs to the top 50 genes down-regulated in TN breast cancer (table 
4.11). It is even more down-regulated than ER encouraging that NY-BR-1 has important 
functions in the mammary gland and is regulated by at least ER.  
The methylation pattern of the stimulated samples, described in chapter 5.1, could not be 
correlated to a specific NY-BR-1 expression pattern. But here it needs to be considered that 
just a small number of samples could be analysed. Therefore, the information of the TCGA 
database was consulted because the data sets contain larger sample numbers. As described 
earlier the NY-BR-1 expression differs in the different molecular subtypes of breast cancer. 
The breast cancer samples in the TCGA database were grouped according to the known 
subtypes but a specific methylation pattern of the analysed fragments to NY-BR-1 expression 
in a specific subtype could not be linked. This result suggests that another regulation 
mechanism is responsible for NY-BR-1 expression, e.g. on histone level or by ER and PR. To 
look into a regulation mechanism on histone level Chip-Seq can be used with antibodies 
against common histone modifications (acetylation, methylation) to see whether differences 
exist between NY-BR-1 positive and negative cells.  
 
5.5.2 SNP analysis 
One of the main analyses included a detailed look at SNPs in the assumed promoter region 
and within the gene of NY-BR-1. SNPs are the most common type of genetic variation and 
they contribute to every human disease, conferring susceptibility or resistance or influencing 
interaction with environmental factors (Li et al., 2014). Genome-wide association studies 
(GWAS) focus more on SNPs in coding sequences but the non-coding SNPs, found 
augmented in promoters, enhancers and on 3’ ends, can affect the expression of neighbouring 
genes and can be responsible for specific disease phenotypes (Molineris et al., 2013). 56 
SNPs are located in the NY-BR-1 promoter up to 2000 bp upstream of the transcription start 
site and few are located in predicted binding sites of different TFs (table 4.10). Of great 
interest are the SNPs located in the GR, HNF-3 (also known as FOXA1/2/3), TBP, SP1, 
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C/EBPα, YY1, c-Fos, c-Jun and AP-1 predicted binding sites. The functions of the encoded 
proteins are shown in table 5.1. These TFs are known to be proto-oncogenes or are involved 
in different cellular processes. If NY-BR-1 is also involved in regulating cellular processes it 
needs to be evaluated whether certain SNPs have an influence on the binding affinity of 
specific TFs and if yes which consequences this might have on the transcription initiation of 
NY-BR-1 and for the cell self. Another important issue is to analyse if specific SNPs are 
present in breast cancer patients and can be correlated to NY-BR-1 expression and thus also 
with disease progression. From different studies it is known that SNPs can have impact on 
patient prognosis, outcome and course of the disease (Chirilă et al., 2014; Yamamoto-Ibusuki 
et al., 2014). 
 
Table 5.1: Specific TFs affected by SNPs with predicted binding sites in the promoter region of NY-
BR-1. Information of the TFs are from www.genecards.org  
Transcription 
factor 
Function 
AP-1 (activator 
protein 1) 
 A heterodimeric protein composed of proteins belonging to the c-Fos, c-Jun, ATF 
and JDP families. 
 Regulation of gene expression in response to a variety of stimuli (cytokines, growth 
factors, stress, and bacterial and viral infections). 
 It controls a number of cellular processes (differentiation, proliferation, and 
apoptosis). 
 AP-1 upregulates transcription of genes containing the TPA DNA response element. 
C/EBPα 
(CCAAT/enhancer-
binding proteins) 
 Critical transcription factor in adipogenesis, growth control and differentiation of 
various tissues. 
 The protein encoded is a bZIP transcription factor binding as a homodimer to certain 
promoters and enhancers. 
 It forms heterodimers with the related proteins CEBP-beta and CEBP-gamma. 
 The protein can interact with CDK2 and CDK4, thereby inhibiting these kinases and 
causing growth arrest in cultured cells.  
c-Fos  Is a proto-oncogene. 
 Protein forms heterodimer with c-jun  resulting in the formation of AP-1 complex 
which binds DNA at AP-1 specific sites at the promoter and enhancer regions of 
target genes and converts extracellular signals into changes of gene expression (cell 
proliferation, differentiation and survival; genes associated with hypoxia; and 
angiogenesis). 
 It induces a loss of cell polarity and epithelial-mesenchymal transition, leading to 
invasive and metastatic growth in mammary epithelial cells. 
c-Jun  In combination with c-Fos, forms the AP-1 early response transcription factor. 
 It is activated through double phosphorylation by the JNK pathway but has also a 
phosphorylation-independent function. 
 Overexpression of c-jun in MCF-7 cells  increased aggressiveness, as shown by 
increased cellular motility, increased expression of a matrix degrading enzyme 
MMP-9, increased in vitro chemo-invasion and tumour formation in nude mice in the 
absence of exogenous estrogens. 
 The MCF-7 cells with c-jun overexpression became unresponsive to estrogen and 
tamoxifen  c-jun overexpression is proposed to lead to an estrogen-independent 
phenotype in breast cancer cells.  
GR (Glucocorticoid 
receptor) 
 The receptor to which cortisol and other glucocorticoids bind, regulates genes 
controlling the development, metabolism, and immune response. 
HNF-3 (also known 
as FOXA1/2/3) 
 FOXA1 (HNF-3α) and FOXA2 (HNF-3β) belong to the forkhead/winged helix DNA 
binding domain family. 
 Function of FOXA1 is further described in the text (see 5.4). 
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SP1 (Specificity 
protein 1) 
 The encoded protein is involved in cell differentiation, cell growth, apoptosis, 
immune responses, response to DNA damage, and chromatin remodeling. 
 Post-translational modifications such as phosphorylation, acetylation, glycosylation, 
and proteolytic processing significantly affect the activity of this protein, which can 
be an activator or a repressor.  
TBP (TATA box 
binding protein) 
 General transcription factor that binds specifically to a DNA sequence called the 
TATA box.  
 It helps position RNA polymerase II over the transcription start site of the gene. 
YY1 (ying-yang 1)  YY1 is a ubiquitously distributed transcription factor belonging to the GLI-Kruppel 
class of zinc finger proteins.  
 It may direct histone deacetylases and histone acetyltransferases to a promoter in 
order to activate or repress the promoter. 
 YY1 has been shown to interact with Histone deacetylase 2, FKBP3, ATF6, Myc, 
SAP30, EP300, HDAC3, NOTCH1 and RYBP. 
 
Most of the SNPs found in the gene body of NY-BR-1 are located in introns (figure 4.41). 
Introns are non-coding regions and are removed during the splicing process but this process 
can be influenced by intronic SNPs. 39 of the downloaded SNPs are annotated as splice 
region variants in dbSNP (figure 4.42). If SNPs are located at a donor or acceptor site they 
can affect the splicing machinery and new transcripts can be produced translated into a 
protein or it leads to a break off and no protein can be translated (Lewandowska, 2013).  
The publicly available data contains only the somatic mutations. The TCGA data base offers 
the possibility, after an application is requested, to analyse the raw data, such as exome 
sequences to look at germline mutations. It is of note that it would be interesting to analyse 
whether certain damaging/splicing SNPs in the NY-BR-1 gene can be correlated with clinical 
data such as presence in specific molecular subtypes of breast cancer, age, and ethnicity or if 
they can be related to different transcripts of NY-BR-1.   
 
5.5.3 Splice Variants 
An analysis of the RNA-Seq data set from Varley et al showed that in ER
+
, TN uninvolved 
and ER
+
 uninvolved tissue the latter exons (exon 20, 26-36) of NY-BR-1 are highly expressed 
compared to the first ones. The highest coverage can be found in the ER
+
 breast cancer 
samples. In TN breast cancer no difference can be observed between the coverage of all 
exons-they are all low (figure 4.45) (Varley et al., 2014). These findings suggest that different 
transcripts exist. In further analysis it needs to be validated if these transcripts are translated 
into protein or if they have another function or will be degraded with the consequence that no 
NY-BR-1 is expressed. To identify splice variants a DNA microarray could help. The exon 
coverage confirms the results of Theurillat et al. They performed an in situ hybridization of 
exon 4-7 and 30-33 and observed that the latter are signiﬁcantly stronger expressed and more 
frequently detected on mRNA level (70 % vs. 35 %, p < 0.0001). They draw the conclusion 
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that alternative splice variants that lack 5-prime sequences of NY-BR-1 are present, which 
also could be observed in the normal breast epithelium (Theurillat et al., 2008). For the qPCR 
analysis a primer pair was used with binding sites in the latter exons (see figure 6.1). It was 
tried to design appropriate primer for the 5’ end but many repetitive elements are existing in 
the 5’ area and due to the existing NY-BR-1.1 isoform it was difficult to get specific primer. 
To test whether splice variants are existing and whether they have different functions within 
cellular processes deletion constructs could be used. The cell lines (MCF-7, MCF-10A, 
HEK293, and HEK293T) could be transiently transfected and analysed by FACS 
measurements to analyse their effect on proliferation and cell cycle.  
 
5.5.4 Gene analysis of different transcription factors 
By refining the characterization of the breast cancer samples a better profile for NY-BR-1 
expression is possible. That ER might be crucial for NY-BR-1 expression is also shown by 
predicted binding sites in the promoter region (table 4.1) and a Chip-Seq analysis where 
several ER binding sites are present in the NY-BR-1 gene (figure 4.46). These binding sites 
are all found up to intron 21 and none later suggesting that ER might be involved in the 
expression of NY-BR-1 and also which exons are expressed. ER regulates biological 
processes by affecting gene expression. After oestrogen-ligand binding to ER they are able to 
bind directly to oestrogen response elements (EREs) in promoters of target genes to attract co-
regulators to the receptor to change chromatin structure and to promote RNA polymerase II 
binding. Another way to regulate genes by ER is that ER interacts with other TF complexes 
like Fos/Jun (AP-1 responsive elements) or SP1 in promoters without EREs. Thus, in general 
the ER action depends on the composition of co-regulatory proteins present in a cell, which 
binding elements are existing in a promoter and the hormones because they can modulate 
transcription and signalling pathways (Heldring et al., 2007; Katzenellenbogen et al., 1996; 
Nilsson et al., 2001). Considering all these data ER seems to be involved in the regulation of 
NY-BR-1 expression but how this finally works needs to be sorted out with further 
experiments. 
 
5.5.5 Progenitor marker 
The limitation of RNA-Seq data is that it does not give evidence whether the mRNA is also 
translated into a protein. Nevertheless, it can be used to get an impression what is transcribed 
into mRNA. 
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Several progenitor marker in the mammary gland were chosen. Elf5, belongs to the luminal 
lineage in the adult mammary gland, is mainly expressed in TN breast cancer and to a lower 
extent in healthy, ER
+
 and TN uninvolved tissues suggesting that Elf5 is down-regulated in 
luminal originated ER
+
 breast cancer. Elf5 also does not play a role to be co-expressed with 
NY-BR-1 in certain breast cancer types but it needs to be tested whether it can be linked to 
NY-BR-1 expression in normal mammary gland samples. Beside Elf5 integrin-α 6 is a 
progenitor marker for the myoepithelial lineage. The expression pattern of integrin-α 6 is 
comparable with Elf5 because just a weak expression can be found in ER
+
 breast cancer 
samples (figure 4.37) (Varley et al., 2014). The expression pattern of Elf5 and integrin-α 6 
underline that NY-BR-1+ cells are originate from luminal epithelial cells in breast cancer.  
In silico analysis supports the NY-BR-1 data/results generated by wet lab techniques. Now it 
is necessary to look into new data sets to confirm the previous findings and to characterize the 
regulation and co-expressing genes of NY-BR-1 in more detail. 
 
 
To summarize the results, NY-BR-1 is expressed mainly in well differentiated hormone 
sensitive estrogen receptor positive breast cancer subtypes and it is likely that NY-BR-1 
expression is influenced by ERα and/or PR expression, but the association of NY- BR-1 
expression and ER signaling still needs to be elucidated. Furthermore, transiently NY-BR-1 
expressing cells show an inhibited proliferation rate and accumulate in the G1 phase. In vivo, 
endogenous NY-BR-1 is expressed in non proliferating (Ki-67 negative) cells in normal 
breast tissue. The protein potentially interacts with the tubulin beta-4B chain suggesting a 
crucial role during mitosis. Moreover, NY-BR-1 was shown to be expressed in progenitor 
cells of the mammary gland. The phenotypic characterization of these progenitor cells and the 
question whether the protein is also expressed in cancer stem cells is part of ongoing studies.  
 
6 Appendix 
 
- 149 - 
 
6 Appendix 
 
Figure 6.1: A section of the NY-BR-1 sequence showing the binding sites of the primer pairs 60/59 and 
100/80. The latter were used for qPCR analysis.  
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DAB-BOND staining protocol 
For general IHC stainings the automated BOND system from Leica was used. In the 
following a general staining protocol for epitope retrieval 1 is described. 
 
Table 6.1: BOND staining protocol for ER 1. (* Cryo preserved tissue start here; ** Variable dilution 
medium; ***Polymeramplifier) 
Program Time Temperature 
BOND Dewax Solution 30 sec 72°C 
BOND Dewax Solution  72°C 
BOND Dewax Solution  RT 
3 x 99 % EtOH  RT 
2 x BOND Wash solution  RT 
BOND wash solution 5 min RT 
2 x BOND ER Solution 1 (Citratpuffer 6.0)  RT 
BOND ER Solution 1 (Citratpuffer 6.0) 20 min 100°C 
BOND ER Solution 1 (Citratpuffer 6.0) 12 min RT 
3 x BOND wash solution  37°C 
BOND wash solution* 3 min RT 
Peroxide Block 10 min RT 
3 x BOND wash solution  RT 
Serumblock (10 %  goatserum in PBS) 10 min RT 
3 x BOND wash solution  RT 
Primary antibody in TBS/10 % FBS** 30 min RT 
3 x BOND wash solution  RT 
Post primary (secondary antibody, rabbit α-mouse IgG) 8 min RT 
3 x BOND wash solution 2 min RT 
Polymer (secondary antibody, poly***-HRP α-rabbit IgG) 8 min RT 
2 x BOND wash solution 2 min RT 
Deionized water  RT 
Mixed DAB Refine  RT 
Mixed DAB Refine 5 min RT 
3 x Deionized water  RT 
Haematoxylin 5 min RT 
3 x Deionized water  RT 
BOND Wash solution 5 min RT 
Deionized water ~ RT 
  
6 Appendix 
 
- 151 - 
 
Vector cards 
 
The pcDNA3.1 NY-BR-1 plasmid contains the full length NY-BR-1 sequence and was used 
for several applications and is shown exemplary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: pcDNA3.1 NY-BR-1 plasmid used for transfection.  
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Proliferation Assay 
 
Figure 6.3: Overview of the proliferation assay of MCF-10A non-transfected cells. A: The chosen cell 
population for further analysis leaving the cell junk out. B: The cell population divided into GFP 
positive/negative for further analysis. C: Proliferation analysis of the GFP negative cell population 
from day one to day six. D: Cell population staining with 7-AAD and Annexin V to discriminate 
between living/dead and apoptotic cells. 
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Figure 6.4: Results of the proliferation assay of MCF-10A pc3 NY-BR-1 GFP transfected cells. A: The 
chosen cell population for further analysis leaving the cell junk out. B: The cell population divided 
into GFP positive/negative for further analysis. C: Proliferation analysis of the GFP negative cell 
population versus the GFP positive from day one to day six. D: Cell population staining with 7-AAD 
and Annexin V to discriminate between living/dead and apoptotic cells.  
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Figure 6.5: Overview of the proliferation assay of HEK293T non-transfected cells. A: The chosen cell 
population for further analysis leaving the cell junk out. B: The cell population divided into GFP 
positive/negative for further analysis. C: Proliferation analysis of the GFP negative cell population 
from day one to day six. D: Cell population staining with 7-AAD and Annexin V to discriminate 
between living/dead and apoptotic cells. 
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Figure 6.6: Results of the proliferation assay of HEK293T pc3 NY-BR-1 GFP transfected cells. A: The 
chosen cell population for further analysis leaving the cell junk out. B: The cell population divided 
into GFP positive/negative for further analysis. C: Proliferation analysis of the GFP negative cell 
population versus the GFP positive from day one to day six. D: Cell population staining with 7-AAD 
and Annexin V to discriminate between living/dead and apoptotic cells.  
  
6 Appendix 
 
- 156 - 
 
Cell cycle analysis 
 
Figure 6.7: Results of the cell cycle analysis of MCF-10A non-transfected cells. A: Showing the cell 
population for further analysis taking all cells into account. B: The cell population divided into GFP 
positive/negative for further analysis. C: Gates set to leave the duplets and cell junk out. D: Cell cycle 
analysis dividing the cells into subG1, G1, S, and G2 phase after PI staining. 
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Figure 6.8: Results of the cell cycle analysis of MCF-10A NY-BR-1 GFP transfected cells. A: Showing 
the cell population for further analysis taking all cells into account. B: The cell population divided 
into GFP positive/negative for further analysis. C: Gates set to leave the duplets and cell junk out in 
either NY-BR-1 GFP negative or NY-BR-1 GFP positive cell population. D: Cell cycle analysis 
dividing the cells into subG1, G1, S, and G2 phase after PI staining. 
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Figure 6.9: Results of the cell cycle analysis of HEK293T non-transfected cells. A: Showing the cell 
population for further analysis taking all cells into account. B: The cell population divided into GFP 
positive/negative for further analysis. C: Gates set to leave the duplets and cell junk out. D: Cell cycle 
analysis dividing the cells into subG1, G1, S, and G2 phase after PI staining. 
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Figure 6.10: Results of the cell cycle analysis of HEK293T NY-BR-1 GFP transfected cells. A: 
Showing the cell population for further analysis taking all cells into account. B: The cell population 
divided into GFP positive/negative for further analysis. C: Gates set to leave the duplets and cell junk 
out in either NY-BR-1 GFP negative or NY-BR-1 GFP positive cell population. D: Cell cycle analysis 
dividing the cells into subG1, G1, S, and G2 phase after PI staining. 
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Abstract 
Breast cancer is one of the most common malignancies with increasing incidences every year 
and a leading cause of death among women. Although early stage breast cancer can be 
effectively treated, there are limited numbers of treatment options available for patients with 
advanced and metastatic disease. The novel breast cancer associated antigen NY-BR-1 was 
identified by SEREX analysis and is expressed in the majority (>70 %) of breast tumors as 
well as metastases, in normal breast tissue, in testis and occasionally in prostate tissue. The 
biological function and regulation of NY-BR-1 is up to date unknown. Therefore, we 
performed an in silico analysis on the genetic variations of the NY-BR-1 gene using data 
available in public SNP databases and several computer programs. 
Over 2800 SNPs are recorded in the dbSNP and NHLBI ESP databases for the NY-BR-1 
gene. Of these, 65 (2.07 %) are synonymous SNPs, 191 (6.09 %) are non-synoymous SNPs, 
and 2430 (77.48 %) are noncoding intronic SNPs. We analyzed the 191 non-synonymous 
SNPs using the tools SIFT, Polyphen and Provean to find possible functional SNPs. As a 
result, 69 non-synoymous SNPs were predicted to be damaging by at least two, and 16 SNPs 
were predicted as damaging by all three of the used tools. The SNPs rs200639888, 
rs367841401 and rs377750885 were categorized as highly damaging by all three tools. Eight 
damaging SNPs are located in the ankyrin repeat domain (ANK), a domain known for its 
frequent involvement in protein-protein interactions. Considering these results we expect to 
gain more insights into the variations of the NY-BR-1 gene and their possible impact on 
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giving rise to splice variants and therefore influence the function of NY-BR-1 in healthy 
tissue as well as in breast cancer. 
 
Introduction 
Breast cancer is one of the most common malignancies and a leading cause of death among 
women. Although early stage breast cancer can be effectively treated, there are limited 
numbers of treatment options available for patients with advanced and metastatic disease. 
Therefore new targets and strategies need to be developed. A novel breast cancer 
differentiation antigen, designated as New York-Breast-1 (NY-BR-1), was identified by a 
serological cloning strategy (SEREX) [1, 2] and could be a possible target for immunotherapy 
for breast cancer patients [3]. NY-BR-1, also known as ANKRD30A, is located on 
chromosome 10p11-p12. There are several transcripts existing, which contain between 36 and 
42 exons. Although computational analyses have identified NY-BR-1 as being a potential 
transcription factor, the functional aspects of this 158.9 kDa protein are still unknown. NY-
BR-1 protein was shown to be expressed in normal breast epithelia cells and in a majority of 
primary breast cancers [4, 5], while NY-BR-1 mRNA was detected predominantly in breast 
cancers [6, 7]. NY-BR-1 is overexpressed in over 70 % of primary breast tumors and 
metastases [1] and additional details on the involvement of NY-BR-1 in breast cancer will 
lead to a better understanding of the underlying processes.  
Information on genetic variation can provide a valuable insight into the functional range and 
critical regions of a gene. In fact, gene function cannot be fully understood without awareness 
of the potential variability within a gene [8]. To further understand the biological function and 
regulation of NY-BR-1 and its potential for therapeutic approaches, we performed an in silico 
analysis on the genetic variations of the NY-BR-1 gene.  
Genetic variation may be diverse in nature, ranging from single nucleotide polymorphisms 
(SNPs), tandem repeats, small insertions or deletions (indels) to large copy number variations. 
Among these, SNPs are the most common form of human variation and it has been estimated 
that one SNP exists every 290 base-pairs in the human genome [9]. Evidences show that 
through SNPs a wide range of human diseases such as cancer or autoimmunity can be 
triggered. SNPs also might affect the pharmacokinetics and pharmacodynamics of certain 
drugs in cancer therapy [10]. The transcriptional regulation of a protein, its structure and its 
function can be affected by a single base substitution, deletion or insertion. Two groups of 
SNPs are known: synonymous (sSNP) and non- synonymous SNPs (nsSNP). The latter 
results in changes of the translated amino acid sequence. SNPs can be located in introns 
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(affecting gene expression) and exons (altering protein structure or function) of a gene, and 
also in untranslated regions (UTRs) resulting in an altered stability of the mRNA [11].  
The growing number of known SNPs combined with the growing functional annotation of the 
human genome enabled the analysis of links between genetic and phenotypic variation in a 
genome-wide manner. Genome-wide association studies (GWAS) aim to detect links between 
genetic variants (i.e. SNPs) and the appearance of certain phenotypes (i.e. complex diseases). 
A number of studies have shown associations between one or few SNPs and complex 
diseases, but until today it is not entirely clear how much impact SNPs have on certain traits 
in different populations. 
With the steadily increasing number of known human nsSNPs, there is also growing interest 
in identification of the subset that may affect protein function. Various types of features can 
be used to predict the functional impact of nsSNPs: physical and chemical properties of the 
affected amino acids, structural properties of the encoded protein, and evolutionary properties, 
which can be inferred from sequence alignments of homologous proteins [12]. SIFT (Sorting 
Intolerant from Tolerant) [13], PROVEAN (Protein Variation Effect Analyzer) [14] and 
PolyPhen-2 (Polymorphism Phenotyping v2) [15] are computational prediction methods 
which take several of these properties into account and calculate a score to predict whether a 
given nsSNP has a functional impact. We obtained all SNPs for the NY-BR-1 gene and 
investigated the nsSNPs for their functional impact by using these three prediction tools. We 
identified a small number of nsSNPs which seem to affect the protein function of NY-BR-1. 
Additionally, we used in house sequencing data to analyze whether certain SNPs are enriched 
in breast cancer patients.   
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Materials and Methods 
SNP Mining 
dbSNP is hosted by the National Center for Biotechnology Information (NCBI) and is the 
largest repository of SNP data with over 140 million submitted variations [16].  
Another source of variation data is provided by the “The National Heart, Lung and Blood 
Institute” (NHLBI). With the aim of discovering novel genes and mechanisms contributing to 
heart, lung and blood disorders, the NHLBI started the Exome Sequencing Project (ESP) and 
a large and well-phenotyped population with over 200,000 individuals was assembled. The 
protein coding regions of each individual genome (i.e. exome) is sequenced and the variation 
data is made publicly available [17]. 
The Ensembl Variation database incorporates variation data from several sources including 
dbSNP and NHLBI ESP. We used the web interface MartWizard 
(http://central.biomart.org/martwizard/) of the BioMart Central Portal which offers access and 
crosslinks a wide array of biological databases.  
The Ensembl transcript ID ENST00000611781 of the ANKRD30A gene was used to retrieve 
all available germline variations together with the corresponding genomic coordinates, the 
variant descriptions, and the validation status. Using the variant descriptions, we filtered 
coding non-synonymous SNPs (nsSNPs), coding synonymous SNPs (sSNPs) and intronic 
SNPs.  
Additionally, we were provided with exome-sequencing data of 55 breast cancer patients 
from an in-house sequencing project. We also analyzed this dataset and looked for SNPs 
which are recorded in dbSNP. 
 
Prediction of the functional impact of coding nsSNPs using SIFT 
The prediction tool SIFT evaluates the functional impact of SNPs based on sequence 
homology. The prediction is based on the degree of conservation of each amino acid residue 
of the query sequence. To assess the degree of conservation, SIFT compiles a dataset of 
functionally related protein sequences by searching the protein databases UniProt and 
TrEMBL using the PSI-BLAST algorithm and builds an alignment of the found sequences 
and the query sequence. In the second step a normalized probability for each substitution at 
each position of the alignment is calculated and is then recorded in a scaled probability 
matrix. This scaled probability is also called the SIFT score and a substitution is considered to 
be tolerated if the score is greater than 0.05; those less than 0.05 are predicted to be 
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deleterious. The SIFT approach assumes that a highly conserved position is intolerant to most 
substitutions, whereas a poorly conserved position can tolerate most substitutions. 
 
Prediction of the functional impact of coding nsSNPs using PROVEAN 
The tool PROVEAN also uses an alignment approach to assesses the functional impact of 
SNPs. PROVEAN consists of two main steps. In the first step, a set of homologous and 
distantly related sequences from the NCBI NR protein database is collected using BLASTP. 
To remove redundancy, the collected sequences are clustered, based on a sequence identity of 
80 %. A so called supporting set of sequences is assembled by adding sequences from clusters 
most similar to the query sequence, until a sufficient number of clusters is reached in the 
supporting set. In the second step, for each sequence in the supporting sequence set, a delta 
score is computed using the BLOSUM62 substitution matrix. For each cluster, an average 
delta score is computed, and the averaged delta scores are again averaged among all clusters. 
This unbiased averaged delta score is the final PROVEAN score.  
The PROVEAN approach assumes that a variation, which reduces similarity of protein A to 
the homologous or distantly related protein B, is more likely to cause a damaging effect. 
Thus, the impact of a variation on protein function can be measured as the change in 
alignment score, the delta score. Low delta scores are interpreted as variations leading to a 
deleterious effect on protein function, while high delta scores are interpreted as variations 
with neutral effect. 
The tools SIFT and PROVEAN are available online at http://provean.jcvi.org/. On the 
website, we used the tool PROVEAN Human Genome Variants, which provides PROVEAN 
and SIFT predictions for a list of human genome variants. We submitted the list of genomic 
coordinates and variants of our filtered 191 nsSNPs, and chose the default threshold of delta 
score <= -2.5 to detect deleterious variations. 
 
Prediction of the functional impact of coding nsSNPs using PolyPhen-2 
PolyPhen-2 combines information on sequence features, multiple alignments with 
homologous proteins, and structural parameters to predict the impact of a SNP on protein 
function. 
For sequence-based assessment, PolyPhen-2 tries to identify the query as an entry in the 
UniProtKB/Swiss-Prot database. Using the feature table of the corresponding entry, 
PolyPhen-2 checks if a given SNP occurs at functional relevant site, e.g. if the SNP lies 
within a transmembrane, signal peptide, or binding region.  
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Similar to SIFT, PolyPhen-2 also assesses the degree of conversation of the position where 
the SNP occurs by utilizing a multiple sequence alignment of homologous sequences. For 
each variant PolyPhen-2 calculates a position-specific independent counts (PSIC) score. The 
PSIC score difference between the two variants describes the impact of a particular amino 
acid substitution: the higher the PSIC score difference, the higher functional impact the 
substitution is likely to have. 
A BLAST query of the query sequence against protein structure databases is carried out to 
identify corresponding 3D protein structures. If corresponding structures are found, they are 
used to assess, whether the SNP is likely to destroy the hydrophobic core, interactions with 
ligands or other important features of the protein. 
Finally, all parameters are taken together and empirical prediction rules are applied to make 
the final decision, whether the SNP is damaging or benign. 
PolyPhen-2 is available online at http://genetics.bwh.harvard.edu/pph2/. We used the option 
‘Batch query’ and submitted the list of genomic coordinates and variants of our filtered 191 
nsSNPs. 
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Results 
SNP Mining 
In the Ensembl BioMart database 2898 SNPs are recorded for the ANKRD30A transcript 
ENST00000611781. 2880 of these were imported from dbSNP and 18 from NHLBI ESP. 
1832 SNPs have been validated by in dependent submissions or frequency/genotype data. 
However, the clinical significance has not been determined yet for any of the SNPs.  
Out of all 2898 SNPs, 65 (2.07 %) were sSNPs, 191 (6.09 %) were nsSNPs, and 2430 (77.48 
%) occurred in intronic regions (Figure 1).  40 of the downloaded SNPs are annotated as 
splice region variants in dbSNP. We selected nsSNPs for our investigation. 
 
Deleterious nsSNPs predicted by SIFT 
Among the 191 analyzed nsSNPs, 79 nsSNPs were identified to be damaging with a tolerance 
index score >= 0.5. Ten nsSNPS showed a highly damaging tolerance index score of 0.00, 
namely rs200639888, rs372199195, rs144539033, rs369532435, rs199571878, rs376821949, 
rs267602482, rs201234943, rs367841401, and rs377750885. Nine nsSNPs had a tolerance 
index score of 0.001, nine nsSNPs had a score of 0.002, and five had a score of 0.003. The 
remaining nsSNPs contained tolerance index scores varying between 0.004 and 0.048. 
Damaging nsSNPs predicted by PROVEAN 
28 nsSNPs out of the analyzed 191 nsSNPs were predicted to be deleterious with a delta score 
of <= -2.5. 10 nsSNPs showed a highly deleterious score of < - 4.00: rs200639888 (-5.962), 
rs61737412(-5.030), rs201943652(-4.758), rs189195791(-6.263), rs367841401 (-4.465), 
rs185294248(-4.366), rs374753521 (-4.184), rs371981371 (-4.603),  rs377750885(-5.87), and 
rs201764363(-4.025). 
20 nsSNPs were predicted as damaging variations by SIFT and PROVEAN.  rs200639888, 
rs367841401, and rs377750885 were predicted to be highly damaging by SIFT with a 
tolerance index score of 0.00 and are also predicted to be highly deleterious by PROVEAN 
with delta scores of -5.962 and -4.465, and -5.87 respectively. 
 
Damaging nsSNPs predicted by PolyPhen 
Out of the 171 nsSNPs submitted to the PolyPhen-2 server, 102 nsSNPs were considered to 
be damaging: 44 nsSNPs were predicted to be ‘probably damaging’ with an PSIC score of 
2.00 or more, and 58 nsSNPs were predicted to be ‘possibly damaging’ with an PSIC score of 
1.40-1.90. The remaining 89 nsSNPs were predicted to be benign. 
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64 of the nsSNPs which were predicted to be damaging by SIFT, were also predicted 
damaging by PolyPhen. rs200639888, rs369532435, rs267602482, rs201234943, and 
rs377750885 were among the nsSNPs predicted to be highly damaging by SIFT with a 
tolerance index score of 0.00. These five nsSNPs also have high PSIC scores predicted by 
PolyPhen (2.439, 2.746, 2.23, 2.373, and 2.46 respectively). 
19 nsSNPs were predicted to be damaging by Provean and PolyPhen, and 16 nsSNPs were 
predicted to be damaging by all three of the used tools (Figure 2). The nsSNPs  rs200639888, 
rs367841401, and rs377750885 were predicted to be highly damaging/deleterious by all three 
tools. 
 
Damaging nsSNPs predicted by at least two tools 
As summarized in Table 1, 69 nsSNPs were predicted to be damaging/deleterious by at least 
two of the used tools. We selected these 69 nsSNPs to perform a more detailed analysis.  
Analysis of the spectrum of nsSNPs on the nucleotide level showed a conserved profile with 
A>T/T>A transitions being the most frequent changes (Figure 3a). We further analyzed the 
spectrum of amino acid changes and found that hydrophile>hydrophile transitions occur most 
frequently and hydrophobe>hydrophobe transitions second frequently (Figure 3b). 
The nsSNPs rs200639888 and rs367841401, which were predicted to be highly damaging by 
all three tools, have an amino acid change from leucine to proline which are hydrophobe 
amino acids. The third damaging nsSNP predicted by all three tools, rs377750885, has a 
change from glutamic acid (hydrophile) to (hydrophobe) valine. 
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Discussion 
Information on genetic variation can provide a valuable insight into the functional range and 
critical regions of a gene. SNPs are the most common form of genetic variations and a link 
between SNPs and complex diseases have been reported for a number of cases. The BRCA-1 
gene for example and some of its interaction partners are associated with breast cancer. SNPs 
in these genes are not just involved in the onset of a disease but they can promote also disease 
progression and outcome [18, 19]. Here, we systematically analyzed SNPs in the NY-BR-1 
gene to identify those SNPs which can modify the functional properties of the protein. 
In the Ensembl BioMart database 2898 SNPs are recorded for the NY-BR-1 transcript 
ENST00000611781. Out of these, 191 (6.01%) were nonsynonymous SNPs (nsSNPs), i.e. 
polymorphisms which translate into an altered amino acid sequence. As these types of SNPs 
are most likely to have an effect on protein function, we chose to analyze only them further. 
Computational approaches use various types of features to predict the functional impact of 
nsSNPs:  physical and chemical properties of the affected amino acids, structural properties of 
the encoded protein, and evolutionary properties, which can be inferred from sequence 
alignments of homologous proteins. We chose three state-of-the-art computational tools 
which can predict the effects of amino acid substitutions on protein function: SIFT, Provean 
and PolyPhen2. 
191 nsSNPs were analyzed and the results varied between the used tools: SIFT predicted 79 
damaging nsSNPs, Provean 28 nsSNPs, and PolyPhen2 102 nsSNPs. 16 nsSNPs were 
predicted damaging by all three tools, and a total of 69 nsSNPs were predicted damaging by 
at least two of the used tools. SIFT and PolyPhen2 have the biggest overlap with 63 common 
predictions. This may be due to the common step of assessing the degree of conversation by 
utilizing a multiple sequence alignment of homologous sequences. 36 damaging nsSNPs were 
only predicted by PolyPhen2 because PolyPhen2 is the only tool that takes functional relevant 
sites into account. The location of the 69 damaging SNPS within the ANKRD30A gene is 
shown in Figure 4a.  
Up to date the structure of NY-BR-1 has not been solved yet and no homology models for the 
entire protein are available. Thus, we unfortunately could not evaluate the location and effect 
of the predicted damaging nsSNPs on the protein structure.  
In the UniProt database six ankyrin (ANK) repeat motifs are documented for NY-BR-1. The 
ANK repeat motif is one of the most common protein-protein interaction motifs in nature and 
occurs in a large number of functionally diverse proteins. The structure of the ANK repeat 
motif is conserved: each repeat typically consists of 30–34 amino acid residues comprising 
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two anti-parallel α-helices and a long loop ending in a β-hairpin [20]. Proteins containing the 
ANK repeat motif are involved in a diverse set of cellular functions, and defects in ANK 
repeat proteins have been associated with a number of human diseases [21, 22]. Hence, a 
variation within such a functional domain is likely to have an impact on protein function. 
Eight of the 69 damaging nsSNPs in NY-BR-1 are located in an ANK repeat motif: 
rs190686350, rs200639888, rs61737412, rs267602477, rs201943652, rs200651327, 
rs369118323, rs373380909. PolyPhen2 predicted all of them as damaging, whereas Provean 
predicted two, and SIFT one of them as not damaging.  
To understand genetic risk factors it is important how SNPs can change protein structure and 
function because different transcripts can lead to a new structure and function or degradation 
of the protein. Alternative splicing is one of the key drivers to regulate the transcriptome. 
There are four major types known of alternative splicing: exon skipping, alternative 3’ or 5’ 
splice site, and intron retention. Genome studies revealed that exon skipping occurs on a 
frequent basis whereas intron retention is observed on a low frequency. It was assumed that 
intron retentions are derived from non-spliced or partially spliced pre-mRNAs [23]. Intron 
retention can result in mRNA accumulation and protein expression [24]. The alternative 
splicing process can be influenced and controlled by SNPs. If SNPs are located at a donor or 
acceptor site they can affect the splicing machinery. In dbSNP, 39 of the NY-BR-1 SNPs are 
annotated to be splicing, located at donor or acceptor sites (Figure 4b). These SNPs have the 
potential to influence the splicing process and new transcripts can be generated. 
An unknown fraction of SNPs submitted to the public databases may not be true 
polymorphisms, but examples of sequencing errors. Therefore it is important to consider the 
validation status of each SNP. A polymorphism can be validated by independent submissions 
or frequency/genotype data. In our dataset 1832 out of 2898 SNPs have been validated. 
Considering the 69 damaging nsSNPs, 16 have not been validated yet. As these nsSNPs seem 
to have an impact on protein function, validation of them should especially be considered. 
We also analyzed in house exome-sequencing data of 55 breast cancer patients, and found 11 
SNPs in the NY-BR-1 gene in this patient cohort. Seven SNPs occur in more than 10 patients 
and three of these (rs61737412, rs41276130, rs1200875) were predicted damaging by at least 
two of the used tools. This additionally suggests clinical relevance for these three damaging 
SNPs. 
In summary, we have identified 69 damaging nsSNPs within the coding region of the breast 
cancer associated NY-BR-1 gene.  Moreover, we found 39 potential splicing SNPs which can 
affect the alternative splicing process. Our analysis gives an overview on the SNP landscape 
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of NYBR1 and now provides the basis to further study the association of SNPs and the 
molecular breast cancer subtypes “Her2”, “Luminal A/B” and “Triple negative” as well as 
clinical data, such as treatment response, relapse rate and overall survival.   
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Table 1: Summary of all 69 nsSNPs predicted to be damaging/deleterious by at least two of the 
used tools. 
ID chromLoc protLoc nt_var prot_var sift_entry provean_entry polyphen_entry aa_ch in_ank 
rs190686350 37419160 122 G/A A/T Damaging(0.012) Deleterious(-3.27)  probably damaging(0.997) hydrophobe>hydrophile Yes 
rs200639888 37419170 125 T/C L/P Damaging(0) Deleterious(-5.96)  probably damaging(0.997) hydrophobe>hydrophobe Yes 
rs61737412 37419218 141 C/T T/M Damaging(0.035) Deleterious(-5.03)  possibly damaging(0.951) hydrophile>hydrophobe Yes 
rs267602477 37419220 142 G/A A/T Damaging(0.016) Deleterious(-3.41)  probably damaging(0.997) hydrophobe>hydrophile Yes 
rs201943652 37421175 173 T/C L/P Damaging(0.011) Deleterious(-4.76)  probably damaging(0.995) hydrophobe>hydrophobe Yes 
rs373997768 37505217 993 A/C K/T Damaging(0.003) Deleterious(-2.76)  probably damaging(0.963) hydrophile>hydrophile   
rs140013037 37505242 1001 G/C K/N Damaging(0.016) Deleterious(-3.58)  probably damaging(0.963) hydrophile>hydrophile   
rs200399695 37506718 1060 G/C R/T Damaging(0.029) Deleterious(-2.91)             benign(0.013) hydrophile>hydrophile   
rs267602485 37507968 1110 G/A E/K Damaging(0.021) Deleterious(-3.34)  probably damaging(0.98) hydrophile>hydrophile   
rs367841401 37508002 1121 T/C L/P Damaging(0) Deleterious(-4.47)  probably damaging(0.969) hydrophobe>hydrophobe   
rs185294248 37508038 1133 T/C F/S Damaging(0.012) Deleterious(-4.37)             benign(0.006) hydrophobe>hydrophile   
rs373377344 37508379 1247 G/A E/K Damaging(0.048) Deleterious(-2.78)  possibly damaging(0.898) hydrophile>hydrophile   
rs374753521 37508446 1269 A/C Y/S Damaging(0.031) Deleterious(-4.18)             benign(0.347) hydrophile>hydrophile   
rs199841724 37508538 1300 C/A H/N Damaging(0.032) Deleterious(-3.11)             benign(0.03) hydrophile>hydrophile   
rs371878855 37508548 1303 A/G Q/R Damaging(0.012) Deleterious(-2.52)  possibly damaging(0.808) hydrophile>hydrophile   
rs369099906 37508651 1337 A/T L/F Damaging(0.001) Deleterious(-3.22)  probably damaging(0.999) hydrophobe>hydrophobe   
rs371981371 37508671 1344 C/A A/D Damaging(0.003) Deleterious(-4.6)  probably damaging(0.989) hydrophobe>hydrophile   
rs200929491 37508788 1383 G/A R/H Damaging(0.002) Deleterious(-3.55)  probably damaging(0.987) hydrophile>hydrophile   
rs377750885 37508803 1388 A/T E/V Damaging(0) Deleterious(-5.87)  probably damaging(0.997) hydrophile>hydrophobe   
rs201764363 37508814 1392 G/C A/P Damaging(0.002) Deleterious(-4.03)  probably damaging(0.969) hydrophobe>hydrophobe   
rs200651327 37418912 105 G/A E/K Tolerated(0.081) Deleterious(-3.37)  probably damaging(0.999) hydrophile>hydrophile Yes 
rs377744149 37508352 1238 G/A D/N Tolerated(0.083) Deleterious(-3.19)  probably damaging(0.971) hydrophile>hydrophile   
rs201858051 37508539 1300 A/G H/R Tolerated(0.108) Deleterious(-3.06)  possibly damaging(0.651) hydrophile>hydrophile   
rs369118323 37422851 209 C/T L/F Damaging(0.01) Neutral(-1.52)  probably damaging(0.993) hydrophobe>hydrophobe Yes 
rs373380909 37422972 249 G/T G/V Damaging(0.003) Neutral(-2.41)  probably damaging(0.999) hydrophobe>hydrophobe Yes 
rs202090351 37430699 292 C/A P/T Damaging(0.001) Neutral(-1.91)  probably damaging(0.998) hydrophobe>hydrophile   
rs377740138 37430720 299 G/A V/M Damaging(0.002) Neutral(-0.39)  possibly damaging(0.845) hydrophobe>hydrophobe   
rs200845385 37430796 324 C/T T/I Damaging(0.002) Neutral(-0.78)  possibly damaging(0.898) hydrophile>hydrophobe   
rs372199195 37430803 326 T/G D/E Damaging(0) Neutral(-0.13)  possibly damaging(0.643) hydrophile>hydrophile   
rs371384886 37430859 345 C/T A/V Damaging(0.001) Neutral(-0.56)  probably damaging(0.997) hydrophobe>hydrophobe   
rs202098264 37430875 350 C/G F/L Damaging(0.003) Neutral(-1.01)  probably damaging(0.965) hydrophobe>hydrophobe   
rs372420008 37430922 366 A/G K/R Damaging(0.007) Neutral(-0.62)  possibly damaging(0.956) hydrophile>hydrophile   
rs374024060 37430943 373 C/T T/M Damaging(0.011) Neutral(-0.76)  probably damaging(0.975) hydrophile>hydrophobe   
rs144539033 37430978 385 T/C W/R Damaging(0) Neutral(-1.04)  possibly damaging(0.943) hydrophobe>hydrophile   
rs371443557 37431010 395 T/G I/M Damaging(0.004) Neutral(-0.28)  possibly damaging(0.676) hydrophobe>hydrophobe   
rs200264724 37431045 407 C/T T/M Damaging(0.001) Neutral(0.55)  probably damaging(0.989) hydrophile>hydrophobe   
rs369532435 37438591 519 A/T K/M Damaging(0) Neutral(-1.13)  probably damaging(0.996) hydrophile>hydrophobe   
rs267602481 37438727 532 C/T S/F Damaging(0.001) Neutral(-1.27)  possibly damaging(0.842) hydrophile>hydrophobe   
rs199571878 37438753 541 A/C K/Q Damaging(0) Neutral(-0.47)  possibly damaging(0.947) hydrophile>hydrophile   
rs376821949 37438772 547 G/A R/K Damaging(0) Neutral(0.04)  possibly damaging(0.643) hydrophile>hydrophile   
rs45515098 37440991 550 C/T P/L Damaging(0.028) Neutral(-1.27)  possibly damaging(0.581) hydrophobe>hydrophobe   
rs377410013 37440994 551 T/C M/T Damaging(0.045) Neutral(-0.42)  possibly damaging(0.717) hydrophobe>hydrophile   
rs267602482 37441009 556 C/T S/F Damaging(0) Neutral(-1.66)  probably damaging(0.99) hydrophile>hydrophobe   
rs374037740 37441038 566 T/G W/G Damaging(0.009) Neutral(-1.82)  possibly damaging(0.826) hydrophobe>hydrophobe   
rs372878721 37442530 580 G/A V/M Damaging(0.013) Neutral(-0.77)  probably damaging(0.976) hydrophobe>hydrophobe   
rs368660392 37442552 587 A/G H/R Damaging(0.003) Neutral(-1.4)  possibly damaging(0.932) hydrophile>hydrophile   
rs201669885 37447325 602 C/G P/A Damaging(0.012) Neutral(-1.66)  possibly damaging(0.924) hydrophobe>hydrophobe   
rs201976592 37447446 611 C/A T/N Damaging(0.002) Neutral(-1.14)  possibly damaging(0.851) hydrophile>hydrophile   
rs113525905 37447451 613 G/A G/R Damaging(0.013) Neutral(-1.25)  probably damaging(0.998) hydrophobe>hydrophile   
rs201234943 37447491 626 A/T K/M Damaging(0) Neutral(-1.29)  probably damaging(0.98) hydrophile>hydrophobe   
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rs371253665 37451583 636 C/T P/L Damaging(0.001) Neutral(-0.77)  probably damaging(0.994) hydrophobe>hydrophobe   
rs199874591 37451705 644 C/A P/H Damaging(0.001) Neutral(-1.11)  probably damaging(0.997) hydrophobe>hydrophile   
rs201885728 37451744 657 T/C L/S Damaging(0.01) Neutral(-0.08)  possibly damaging(0.932) hydrophobe>hydrophile   
rs183760470 37451752 660 A/C K/Q Damaging(0.002) Neutral(-0.78)  possibly damaging(0.851) hydrophile>hydrophile   
rs41276130 37451768 665 T/G L/W Damaging(0.002) Neutral(-0.98)  probably damaging(0.983) hydrophobe>hydrophobe   
rs202200263 37454055 679 A/G D/G Damaging(0.001) Neutral(-1.04)  possibly damaging(0.924) hydrophile>hydrophobe   
rs374739457 37454063 682 G/C E/Q Damaging(0.018) Neutral(-0.76)  possibly damaging(0.851) hydrophile>hydrophile   
rs17606645 37470263 723 A/T K/N Damaging(0.004) Neutral(-0.44)  possibly damaging(0.851) hydrophile>hydrophile   
rs17590850 37470375 730 A/C N/H Damaging(0.002) Neutral(-0.35)  possibly damaging(0.94) hydrophile>hydrophile   
rs200331751 37478422 817 G/A D/N Damaging(0.028) Neutral(-0.12)  possibly damaging(0.818) hydrophile>hydrophile   
rs201628233 37478440 823 G/T A/S Damaging(0.022) Neutral(-0.44)  possibly damaging(0.841) hydrophobe>hydrophile   
rs184702413 37481992 838 A/G E/G Damaging(0.017) Neutral(-1.16)  possibly damaging(0.851) hydrophile>hydrophobe   
rs200114350 37486388 899 A/G N/S Damaging(0.006) Neutral(-1.64)  possibly damaging(0.713) hydrophile>hydrophile   
rs199691521 37488715 926 A/T E/V Damaging(0.02) Neutral(-1.16)  probably damaging(0.994) hydrophile>hydrophobe   
rs376116213 37505157 973 G/A R/K Damaging(0.004) Neutral(-2.23)  probably damaging(0.976) hydrophile>hydrophile   
rs1200875 37505192 985 C/T R/C Damaging(0.001) Neutral(0.32)  possibly damaging(0.762) hydrophile>hydrophile   
rs375945698 37505306 1023 G/C E/Q Damaging(0.018) Neutral(-2.17)  probably damaging(0.999) hydrophile>hydrophile   
rs368559588 37508121 1161 G/A A/T Damaging(0.04) Neutral(-0.75)  possibly damaging(0.618) hydrophobe>hydrophile   
rs199795040 37508139 1167 C/A Q/K Damaging(0.002) Neutral(-2.3)  possibly damaging(0.886) hydrophile>hydrophile   
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Figure 1  Graphical representation of distribution of intronic SNPs, non-synoymous SNPs (nsSNPs), synonymous 
SNPs (sSNPs), and SNPs at splicing sites for the NY-BR-1 gene, based on the dbSNP and NHLBI ESP databases. 
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Figure 2 Venn diagram showing the overlap of the predictions made by the three tools PolyPhen, PROVEAN and 
SIFT. 
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Figure 3 Graphical representation of spectrum of damaging nsSNPs variation. a) nucleotide variations, b) amino acid 
variations. 
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Figure 4 Graphical representation of location of NY-BR-1 SNPs. a) damaging SNPs, b) splicing SNP. 
 
 
